<SEC-DOCUMENT>0001193125-25-277503.txt : 20251112
<SEC-HEADER>0001193125-25-277503.hdr.sgml : 20251112
<ACCEPTANCE-DATETIME>20251112160309
ACCESSION NUMBER:		0001193125-25-277503
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		20
FILED AS OF DATE:		20251112
DATE AS OF CHANGE:		20251112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cogent Biosciences, Inc.
		CENTRAL INDEX KEY:			0001622229
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				465308248
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-291384
		FILM NUMBER:		251472504

	BUSINESS ADDRESS:	
		STREET 1:		275 WYMAN STREET
		STREET 2:		3RD FLOOR
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		617-945-5576

	MAIL ADDRESS:	
		STREET 1:		275 WYMAN STREET
		STREET 2:		3RD FLOOR
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Unum Therapeutics Inc.
		DATE OF NAME CHANGE:	20180402

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Unum Therapeutics, Inc.
		DATE OF NAME CHANGE:	20141014
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d159388d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">Filed Pursuant to Rule 424(b)(5)<BR>Registration Statement No. 333-291384 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">(To Prospectus dated November 7, 2025) </P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>$200,000,000 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g159388g01n01.jpg" ALT="LOGO" STYLE="width:1.63459in;height:0.720633in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:20pt; font-family:ARIAL" ALIGN="center"><B>Cogent Biosciences, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>1.625% Convertible Senior Notes due 2031 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We are offering
$200,000,000 aggregate principal amount of our 1.625% convertible senior notes due 2031 (the &#8220;notes&#8221;). In addition, we have granted the underwriters an option to purchase, exercisable for 30 days from the date of this prospectus
supplement, up to an additional $30,000,000 aggregate principal amount of notes, solely to cover over-allotments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Maturity; Interest </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We will pay interest on the notes at an annual rate of 1.625%, payable semi-annually in arrears on May 15 and November&nbsp;15 of each year, beginning on May&nbsp;15,
2026. The notes will mature on November&nbsp;15, 2031, unless earlier converted, redeemed or repurchased by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Conversion </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Noteholders may convert their notes at their option only in the following circumstances: (1)&nbsp;during any calendar quarter (and only during such calendar quarter)
commencing after the calendar quarter ending on March&nbsp;31, 2026, if the last reported sale price per share of our common stock, $0.001 par value per share (the &#8220;common stock&#8221;), exceeds 130% of the conversion price for each of at
least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2)&nbsp;during the five consecutive business days immediately
after any 10 consecutive trading day period (such 10 consecutive trading day period, the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than
98% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3)&nbsp;upon the occurrence of certain corporate events or distributions on our common stock, as
described in this prospectus supplement; (4)&nbsp;if we call such notes for redemption; and (5)&nbsp;at any time from, and including, August&nbsp;15, 2031 until the close of business on the scheduled trading day immediately before the maturity date.
We will settle conversions by paying or delivering, as applicable, cash, shares of our common stock or a combination of cash and shares of our common stock, at our election, based on the applicable conversion rate(s). The initial conversion rate is
22.2469 shares of common stock per $1,000 principal amount of notes, which represents an initial conversion price of approximately $44.95 per share, and is subject to adjustment as described in this prospectus supplement. If a &#8220;make-whole
fundamental change&#8221; (as defined in this prospectus supplement) occurs, then we will in certain circumstances increase the conversion rate for a specified period of time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Redemption and Repurchase </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The notes will be redeemable, in whole or in part
(subject to certain limitations described in this prospectus supplement), at our option at any time, and from time to time, on a redemption date on or after November&nbsp;20, 2029 and on or before the 26th scheduled trading day immediately before
the maturity date, at a cash redemption price equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date, but only if the last reported sale price per share of our
common </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
stock exceeds 130% of the conversion price on (1)&nbsp;each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading
day immediately before the date we send the related redemption notice; and (2)&nbsp;the trading day immediately before the date we send such notice. In addition, calling any note for redemption will constitute a make-whole fundamental change with
respect to that note, in which case the conversion rate applicable to the conversion of that note will be increased in certain circumstances if it is converted after it is called for redemption. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">If a &#8220;fundamental change&#8221; (as defined in this prospectus supplement) occurs, then, except as described in this prospectus supplement, noteholders may
require us to repurchase their notes at a cash repurchase price equal to the principal amount of the notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Ranking </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The notes will be our general, unsecured, senior obligations and
will be senior in right of payment to our future indebtedness that is expressly subordinated in right of payment to the notes, equal in right of payment with our existing and future indebtedness that is not expressly subordinated to the notes and
effectively subordinated to our existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness. The notes will be structurally subordinated to all existing and future indebtedness and other
liabilities, including trade payables, and (to the extent we are not a holder thereof) preferred equity, if any, of our current or future subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Listing;
Common Stock </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">No public market currently exists for the notes, and we do not intend to apply to list the notes on any securities exchange or for quotation on any
inter-dealer quotation system. Our common stock is traded on the Nasdaq Global Select Market under the symbol &#8220;COGT.&#8221; On November&nbsp;11, 2025, the last reported sale price per share of our common stock was $33.42. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Concurrent Transaction </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Concurrently with this offering, we are conducting a
public offering (the &#8220;Concurrent Equity Offering&#8221;) of 9,677,420 shares of our common stock (or up to 11,129,033 shares of our common stock if the underwriters in the Concurrent Equity Offering exercise their option to purchase additional
shares of common stock in full). Neither this offering nor the Concurrent Equity Offering is conditioned upon the completion of the other, so it is possible that this offering occurs and the Concurrent Equity Offering does not occur, or vice versa.
We cannot assure you that the Concurrent Equity Offering will be completed on the terms described herein, on significantly different terms, or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The
Concurrent Equity Offering is being made pursuant to a separate prospectus supplement, and nothing contained herein shall constitute an offer to sell or the solicitation of an offer to buy our common stock to be issued in the Concurrent Equity
Offering. See &#8220;Prospectus Supplement Summary&#8212;Recent Developments,&#8221; &#8220;Use of Proceeds&#8221; and &#8220;Description of the Concurrent Equity Offering.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Investing in our notes involves a high degree of risk. You should carefully consider the risks and uncertainties described under the heading &#8220;<A HREF="#supptoc159388_5">Risk&nbsp;Factors</A>&#8221; on page <FONT STYLE="white-space:nowrap">S-11</FONT> of this prospectus supplement and in the accompanying prospectus, as well as those contained in the other documents that are incorporated by reference into this prospectus supplement
and any related free writing prospectus. You should carefully read this entire prospectus supplement and the accompanying prospectus, including any information incorporated by reference hereto and thereto, before deciding whether to purchase the
notes. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PER&nbsp;NOTE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Public offering price<SUP STYLE="font-size:75%; vertical-align:top"> (1) </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">200,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Underwriting discounts and commissions<SUP STYLE="font-size:75%; vertical-align:top"> (2) </SUP></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds to Cogent Biosciences, Inc., before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">194,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Plus accrued interest, if any, from November 18, 2025. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See &#8220;Underwriting&#8221; beginning on page <FONT STYLE="white-space:nowrap">S-79</FONT> of this prospectus supplement for additional information regarding underwriting compensation. </TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The underwriters may also exercise their over-allotment option to purchase up to an additional $30,000,000 aggregate
principal amount of notes from us, at the public offering price, less the underwriting discounts and commissions, for 30 days after the date of this prospectus supplement. If the underwriters exercise the option in full, the total underwriting
discounts and commissions payable by us will be $6,900,000, and the total proceeds to us, before expenses, will be $223,100,000. See &#8220;Underwriting&#8221; for more information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Neither the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy
or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We expect to deliver the
notes in book-entry form through the facilities of The Depository Trust Company (&#8220;DTC&#8221;) on or about November 18, 2025, which will be the fourth business day following the initial trade date for the notes (this settlement cycle being
referred to as &#8220;T+4&#8221;). Under Rule <FONT STYLE="white-space:nowrap">15c6-1</FONT> under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), trades in the secondary market generally are required to settle in
one business day, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade notes prior to the business day preceding the settlement date will be required, by virtue of the fact that the notes
initially will settle T+4, to specify an alternate settlement cycle at the time of any such trade to prevent a failed settlement. Purchasers of the notes who wish to trade the notes prior to the business day preceding the settlement date should
consult their own advisors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Joint <FONT STYLE="white-space:nowrap">Book-Running</FONT> Managers </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="51%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:16pt">
<TD VALIGN="top"><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>J.P.&nbsp;Morgan</B></TD></TR>
</TABLE> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Prospectus Supplement dated November 11, 2025. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc159388_1">ABOUT THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc159388_2">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-2</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc159388_3">PROSPECTUS SUPPLEMENT SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-4</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc159388_4">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-7</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc159388_5">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-11</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc159388_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-21</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc159388_7">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-22</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc159388_8">DESCRIPTION OF NOTES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-23</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc159388_9">DESCRIPTION OF THE CONCURRENT EQUITY OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-66</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc159388_10">DESCRIPTION OF OTHER INDEBTEDNESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-67</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc159388_11">MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-68</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc159388_12">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-79</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc159388_13">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-90</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc159388_14">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-90</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc159388_15">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-90</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc159388_16">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-91</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>PROSPECTUS </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc159388_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc159388_2">CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc159388_3">THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc159388_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc159388_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc159388_6">SECURITIES WE MAY OFFER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc159388_7">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc159388_8">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc159388_9">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc159388_10">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc159388_11">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc159388_12">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc159388_13">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc159388_14">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc159388_15">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are responsible for the information contained and incorporated by reference in this prospectus supplement, the
accompanying prospectus and in any free writing prospectus that we have authorized for use in connection with this offering. We have not authorized anyone to give you any other information, and we take no responsibility for any other information
that others may give you. We are not making offers to sell the securities in any jurisdiction in which an offer or solicitation is not authorized or permitted or in which the person making such offer or solicitation is not qualified to do so or to
anyone to whom it is unlawful to make an offer or solicitation. The information contained and incorporated by reference in this prospectus supplement, the accompanying prospectus and any free writing prospectus that we have authorized for use in
connection with this offering speaks only as of the date of this document, unless the information specifically indicates that another date applies. Neither the delivery of this prospectus supplement, the accompanying prospectus or any free writing
prospectus that we have authorized for use in connection with this offering, nor any sale of securities made under these documents, will, under any circumstances, create any implication that there has been no change in our affairs since the date of
this prospectus supplement, the accompanying prospectus or any free writing prospectus that we have authorized for use in connection with this offering, nor that the information contained or incorporated by reference is correct as of any time
subsequent to the date of such information. You should assume that the information contained and incorporated by reference in this prospectus supplement, the accompanying prospectus and in any free writing prospectus that we have authorized for use
in connection with this offering is accurate only as of the date of the documents containing the information, unless the information specifically indicates that another date applies. Our business, financial condition, results of operations and
prospects may have changed since those dates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="supptoc159388_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus supplement and the accompanying prospectus form part of an automatic shelf registration statement on Form <FONT STYLE="white-space:nowrap">S-3ASR</FONT>
that we filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on November&nbsp;7, 2025, which became automatically effective upon filing, as a &#8220;well-known seasoned issuer&#8221; as defined in Rule 405 under the
Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), using an automatic &#8220;shelf&#8221; registration process. This document contains two parts. The first part consists of this prospectus supplement, which provides you with
specific information about this offering. The second part consists of the accompanying prospectus, which provides more general information, some of which may not apply to this offering. Generally, when we refer only to the &#8220;prospectus,&#8221;
we are referring to both parts combined. This prospectus supplement may add, update or change information contained in the accompanying prospectus. To the extent that any statement we make in this prospectus supplement is inconsistent with
statements made in the accompanying prospectus, or any documents incorporated by reference, the statements made in this prospectus supplement will be deemed to modify or supersede those made in the accompanying prospectus, including the documents
incorporated by reference therein. Information in any document we subsequently file that is incorporated by reference shall modify or supersede the information in this prospectus supplement, the accompanying prospectus and documents incorporated by
reference prior to such subsequent filing. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have not authorized, and the underwriters have not authorized, anyone to provide you with information that is
different from that contained or incorporated by reference in this prospectus supplement or the accompanying prospectus. The information contained in this prospectus supplement or the accompanying prospectus, or incorporated by reference herein, is
accurate only as of the respective dates thereof, regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or of any sale of our securities. It is important for you to read and consider all information
contained in this prospectus supplement and the accompanying prospectus, including the documents incorporated by reference herein and therein, in making your investment decision. You should also read and consider the information in the documents to
which we have referred you in the sections entitled &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation of Certain Information by Reference&#8221; in this prospectus supplement and in the sections entitled &#8220;Where You Can
Find More Information&#8221; and &#8220;Incorporation of Certain Information by Reference&#8221; in the accompanying prospectus, respectively. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are offering to
sell, and seeking offers to buy, our securities only in jurisdictions where offers and sales are permitted. The distribution of this prospectus supplement and the accompanying prospectus and the offering of the securities in certain jurisdictions
may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement and the accompanying prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities
and the distribution of this prospectus supplement and the accompanying prospectus outside the United States. This prospectus supplement and the accompanying prospectus do not constitute, and may not be used in connection with, an offer to sell, or
a solicitation of an offer to buy, any securities offered by this prospectus supplement and the accompanying prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Unless otherwise mentioned or unless the context requires otherwise, throughout this prospectus supplement, the words &#8220;Cogent,&#8221; &#8220;we,&#8221;
&#8220;us,&#8221; &#8220;our&#8221; or the &#8220;Company&#8221; refer to Cogent Biosciences, Inc., and the term &#8220;securities&#8221; refers to the notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="supptoc159388_2"></A>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus supplement contains forward-looking statements, which reflect our current views with respect to, among other things, our operations and financial
performance. All statements other than statements of historical facts contained in this prospectus supplement, including, but not limited to, statements regarding our strategy, future operations, future financial position, future revenue, projected
costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that may cause our actual results, performance
or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In some
cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;might,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;could,&#8221; &#8220;intends,&#8221;
&#8220;target,&#8221; &#8220;projects,&#8221; &#8220;contemplates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;seek,&#8221; &#8220;would&#8221; or &#8220;continue,&#8221; or the
negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial
condition and results of operations. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances
reflected in the forward-looking statements will be achieved or occur. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-
looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking
statements. Some of the key factors that could cause actual results to differ from our expectations include, but are not limited to, the following: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the potential impacts of raising additional capital, including dilution to our existing stockholders, restrictions on our
operations or requirements that we relinquish rights to our technologies or product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the success, cost, and duration of our product development activities and clinical trials, including the enrollment rates
in our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the timing of our planned regulatory submissions to the U.S. Food and Drug Administration for our bezuclastinib product
candidate and any other product candidates we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to obtain and maintain regulatory approval for our bezuclastinib product candidate and any other product
candidates we may develop, and any related restrictions, limitations, and/or warnings in the label of an approved product candidate; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the potential for our identified research priorities to advance our bezuclastinib product candidate or for our teams to
discover and develop additional product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the ability to license additional intellectual property rights relating to our bezuclastinib product candidate or future
product candidates from third parties and to comply with our existing or future license agreements and/or collaboration agreements; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to commercialize our bezuclastinib product candidate and future product candidates in light of the intellectual
property rights of others; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to obtain funding for our operations, including funding necessary to complete further discovery, development
and commercialization of our existing and future product candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the scalability and commercial viability of our manufacturing methods and processes; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the commercialization of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to attract collaborators with development, regulatory, and commercialization expertise; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">future agreements with third parties in connection with the commercialization of our product candidates and any other
approved product; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the size and growth potential of the markets for our product candidates, and our ability to serve those markets;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the rate and degree of market acceptance of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the pricing and reimbursement of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">regulatory developments in the United States and foreign countries, including pharmaceutical and biological product
marketing regulation; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the impact of adverse business and economic conditions including inflationary pressures, general economic slowdown or a
recession, high interest rates, changes in monetary policy, banking institution instability, changes in trade policies, including tariffs or other trade restrictions or the threat of such actions, and the prospect of a, or any then ongoing, shutdown
of the U.S. federal government; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the development and success of competing therapies that are or may be under development in clinical trials or become
available commercially; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to attract and retain key scientific and management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to satisfy the conditions, covenants, and obligations under our loan and security agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the accuracy of our estimates regarding expenses, future revenue, capital requirements, and needs for additional financing;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our expectations regarding our use of the proceeds from any private placements, debt issuances, sales of our preferred
stock and public offerings of our common stock that we may conduct from time to time; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the fact that interim clinical data may not be indicative of future results; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our expectations regarding our ability to obtain and maintain intellectual property protection for our bezuclastinib
product candidate and future product candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our expectations regarding the completion of, and use of proceeds from, this offering and the Concurrent Equity Offering.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in
this prospectus supplement, the accompanying prospectus, information incorporated by reference herein or therein, and any related free-writing prospectus. The forward-looking statements contained in this prospectus supplement are made as of the date
of this prospectus supplement, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="supptoc159388_3"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following summary of our business highlights certain of the information contained elsewhere in, or incorporated by reference into, this prospectus supplement and the
accompanying prospectus. This summary does not contain all of the information that may be important to you. You should carefully read this entire prospectus supplement and the accompanying prospectus, including any information incorporated by
reference, which are described under the headings &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation of Certain Information by Reference&#8221; herein and therein. In particular, you should carefully consider the risks and
uncertainties described under the heading &#8220;Risk Factors&#8221; in this prospectus supplement and in the accompanying prospectus, as well as those contained in the other documents incorporated by reference herein and therein and any related
free writing prospectus. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Company Overview </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are a clinical-stage
biotechnology company focused on developing precision therapies for genetically defined diseases. Our approach is to design rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Our most advanced
program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is
responsible for driving Systemic Mastocytosis, a serious and rare disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (&#8220;GIST&#8221;), a type of
cancer with strong dependence on oncogenic KIT signaling. Bezuclastinib is a highly selective and potent KIT inhibitor with the potential to provide a new treatment option for these patient populations. We are developing bezuclastinib to treat
patients living with <FONT STYLE="white-space:nowrap">Non-Advanced</FONT> Systemic Mastocytosis (&#8220;NonAdvSM&#8221;), Advanced Systemic Mastocytosis (&#8220;AdvSM&#8221;) and GIST. We also have an ongoing Phase 1 study of our novel internally
developed FGFR2 inhibitor. In addition to bezuclastinib, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in ErbB2, PI3K,
KRAS, and JAK2. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For more information about our business, please see our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as
supplemented and updated by subsequent Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> that we have filed or will file with the SEC, and in other
documents which are incorporated by reference into this prospectus supplement and the accompanying prospectus. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Recent Developments </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Clinical Data </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On November 10, 2025, the Company announced positive
results from its bezuclastinib PEAK Phase 3 Trial in GIST. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><U>PEAK Phase 3 Trial Results </U></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">PEAK is a&nbsp;global,&nbsp;randomized Phase 3 clinical trial evaluating&nbsp;bezuclastinib&nbsp;in combination with sunitinib&nbsp;vs. sunitinib monotherapy in patients
with imatinib-resistant or intolerant GIST.&nbsp;In&nbsp;the top-line results, as of the cutoff date,&nbsp;September&nbsp;30, 2025, the bezuclastinib combination demonstrated a substantial and highly statistically significant clinical benefit on the
primary endpoint of progression free survival, reducing risk of </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
disease progression or death compared to the current standard of care by 50% (hazard ratio of 0.50, 95% CI:&nbsp;0.39&#8212;0.65). Median progression free survival, as assessed by blinded
independent central review, was 16.5&nbsp;months for the bezuclastinib combination vs. 9.2 months for sunitinib monotherapy. Additionally, the bezuclastinib combination demonstrated an unprecedented objective response rate in imatinib-resistant
patients, with 46% of patients treated with the bezuclastinib combination achieving an objective response compared to 26% of patients treated with sunitinib. At the time of this analysis, data for overall survival remains immature. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Based on these data, and the number of ongoing patients receiving treatment on the bezuclastinib arm, the estimated mean duration of treatment for the bezuclastinib
combination is projected to exceed 19 months. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><U>Safety Data </U></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of
the data cutoff, the bezuclastinib combination was generally well&nbsp;tolerated,&nbsp;and no unique risks were observed with the novel combination when compared to the known safety profile of&nbsp;sunitinib.&nbsp;The most commonly reported Grade
3&#043; treatment emergent adverse events in either arm (bezuclastinib combination&nbsp;vs.&nbsp;sunitinib) included: Hypertension (29.4% vs. 27.4%), Neutropenia (15.2% vs. 15.4%), ALT/AST increased (10.8% vs. 1.4%), Anemia (9.3% vs. 4.8%) and
Diarrhea (7.8% vs. 7.2%). 7.4% of patients on the bezuclastinib combination and 3.8% of patients on sunitinib monotherapy discontinued study treatment(s) due to treatment related adverse events. Hepatic adverse events were predominantly transient
and manageable lab abnormalities; the majority of which were low grade, non-serious, reversible and asymptomatic. In the combination arm, ALT/AST elevations led to bezuclastinib dose reductions in 12.7% of patients with only 3&nbsp;subjects (1.5%)
discontinuing bezuclastinib for ALT/AST elevations. All Grade 3 ALT/AST elevations resolved, and no Grade 4 elevations were reported across the study.</P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><U>Potential Commercial Opportunity </U></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company believes bezuclastinib
represents a significant commercial opportunity across multiple indications. Based on internal analyses and external market research, the Company estimates a global annual market opportunity of over $4 billion for bezuclastinib in combination with
sunitinib as a potential second-line treatment for patients with imatinib-resistant or intolerant GIST, approximately $3 billion for the treatment of patients with NonAdvSM, and approximately $500 million for the treatment of patients with AdvSM.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Complete analysis of the Phase 3 PEAK data is ongoing, and the Company plans to present detailed results at a major medical conference in the first half of
2026.</P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><U>Anticipated Upcoming Milestones </U></B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Announce top-line results from the pivotal APEX trial in December 2025. APEX is a registration-directed, global, open-label
trial in patients with AdvSM </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Present multiple bezuclastinib presentations at the 67th&nbsp;Annual Meeting of the American Society of Hematology
(&#8220;ASH&#8221;), including two oral presentations from the pivotal SUMMIT trial in NonAdvSM patients </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Present initial data from the Company&#8217;s novel JAK2 V617F inhibitor at ASH, showcasing its best-in-class potential
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Submit the Company&#8217;s first new drug application (&#8220;NDA&#8221;) for bezuclastinib in NonAdvSM patients by the end
of 2025 </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Submit NDA for bezuclastinib in imatinib-resistant or intolerant GIST patients in the first half of 2026
</P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Concurrent Equity Offering </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Concurrently with
this offering, we are conducting the Concurrent Equity Offering of 9,677,420 shares of our common stock (or up to 11,129,033 shares of our common stock if the underwriters in the Concurrent Equity Offering exercise in full their option to purchase
additional shares of common stock). The Concurrent Equity Offering is being made pursuant to a separate prospectus supplement. Nothing contained herein shall constitute an offer to sell or the solicitation of an offer to buy shares of common stock
in the Concurrent Equity Offering. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Neither this offering nor the Concurrent Equity Offering is conditioned upon the completion of the other, so it is possible that
this offering occurs and the Concurrent Equity Offering does not occur, or vice versa. We cannot assure you that the Concurrent Equity Offering will be completed on the terms described herein, on significantly different terms, or at all. See
&#8220;Description of the Concurrent Equity Offering.&#8221; </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Corporate Information </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We were incorporated in March 2014 under the laws of the State of Delaware. We completed our initial public offering in April 2018, and in July 2020 we completed the
asset acquisition of Kiq Bio LLC (formerly Kiq LLC) and shifted our development to bezuclastinib, a selective tyrosine kinase inhibitor licensed from Plexxikon, Inc. In October 2020, we changed our name to Cogent Biosciences, Inc. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our principal executive office is located at 275 Wyman Street, 3rd Floor, Waltham, Massachusetts 02451, and our telephone number is (617)
<FONT STYLE="white-space:nowrap">945-5576.</FONT> Our corporate website address is www.cogentbio.com. The information contained on our website is not incorporated by reference into this prospectus supplement or the accompanying prospectus, and you
should not consider any information contained on, or that can be accessed through, our website as part of this prospectus supplement or the accompanying prospectus in deciding whether to purchase the notes. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="supptoc159388_4"></A>THE OFFERING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The summary below describes the principal terms of the notes. The terms of the notes described below are subject to important limitations and exceptions that are
described in more detail under the caption &#8220;Description of Notes.&#8221; As used in this section, &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; refer to Cogent Biosciences, Inc. and not to its subsidiaries. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B>Issuer </B></P></TD>
<TD>Cogent Biosciences, Inc. </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B>Notes </B></P></TD>
<TD>$200,000,000 aggregate principal amount of 1.625% convertible senior notes due 2031 (or $230,000,000 aggregate principal amount if the underwriters exercise their over-allotment option in full). </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B>Ranking </B></P></TD>
<TD>The notes will be our general, unsecured, senior obligations and will be: </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="28%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="right">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">senior in right of payment to our future indebtedness that is expressly subordinated in right of payment to the notes;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="28%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="right">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">equal in right of payment with our existing and future indebtedness that is not expressly subordinated to the notes;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="28%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="right">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">effectively subordinated to our existing and future secured indebtedness, to the extent of the value of the collateral
securing that indebtedness; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="28%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="right">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to
the extent we are not a holder thereof) preferred equity, if any, of our current or future subsidiaries. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="28%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">As of September&nbsp;30, 2025, the outstanding principal amount of our consolidated indebtedness for borrowed money was $50&nbsp;million, all of which was senior secured indebtedness consisting of term loans (the
&#8220;Term Loans&#8221;) borrowed under the loan and security agreement, dated June&nbsp;11, 2025, among us, as borrower, certain of our subsidiaries, as guarantors, the lenders party thereto and SLR Investment Corp., as the administrative agent
and collateral agent for itself and the lenders (the &#8220;Credit Facility&#8221;). After giving effect to the issuance of the notes (assuming no exercise of the underwriters&#8217; over-allotment option), and giving effect to the use of proceeds
from this offering to repay the Term Loans in full, as of September&nbsp;30, 2025, the aggregate principal amount of our total indebtedness would have been $200&nbsp;million. </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="28%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The indenture governing the notes will not limit the amount of debt or other liabilities that we or our current or future subsidiaries may incur. </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B>Maturity </B></P></TD>
<TD>November&nbsp;15, 2031, unless earlier converted, redeemed or repurchased. </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B>Interest </B></P></TD>
<TD>1.625% per annum, payable semi-annually in arrears on May&nbsp;15 and November&nbsp;15 of each year, beginning on May&nbsp;15, 2026. In addition, special interest will accrue on the notes in the circumstances described under the caption
&#8220;Description of Notes&#8212;Events of Default&#8212;Special Interest as Sole Remedy for Certain Reporting Defaults.&#8221; </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B>Conversion Rights </B></P></TD>
<TD>Noteholders may convert their notes at their option only in the following circumstances: </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="28%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="right">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">during any calendar quarter (and only during such calendar quarter) commencing after the calendar quarter ending on
March&nbsp;31, 2026, if the last reported sale price per share of our common stock exceeds 130% of the conversion price for each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and
including, the last trading day of the immediately preceding calendar quarter; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="28%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="right">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">during the five consecutive business days immediately after any 10 consecutive trading day period (such 10 consecutive
trading day period, the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of
our common stock on such trading day and the conversion rate on such trading day; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="28%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="right">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">upon the occurrence of certain corporate events or distributions on our common stock, as described in this prospectus
supplement; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="28%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="right">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">if we call such notes for redemption; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="28%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="right">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">at any time from, and including, August&nbsp;15, 2031 until the close of business on the scheduled trading day immediately
before the maturity date. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="28%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We will settle conversions by paying or delivering, as applicable, cash, shares of our common stock or a combination of cash and shares of our common stock, at our election, based on the applicable conversion rate. If
we elect to deliver cash or a combination of cash and shares of our common stock, then the consideration due upon conversion will be determined over an observation period consisting of 25 &#8220;VWAP trading days&#8221; (as defined in this
prospectus supplement). The initial conversion rate is 22.2469 shares of common stock per $1,000 principal amount of notes, which represents an initial conversion price of approximately $44.95 per share, and is subject to adjustment as described in
this prospectus supplement. </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="28%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If a &#8220;make-whole fundamental change&#8221; (as defined in this prospectus supplement) occurs, then we will in certain circumstances increase the conversion rate for a specified period of time. </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="28%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See &#8220;Description of Notes&#8212;Conversion Rights.&#8221; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B>Optional Redemption </B></P></TD>
<TD> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">The notes will be redeemable, in whole or in part (subject to certain limitations described below), at our option at any time, and from time to time, on or after
November&nbsp;20, 2029 and on or before the 26th scheduled trading day immediately before the maturity date, at a cash redemption price equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but
excluding, the redemption date, but only if the last reported sale price per share of our common stock exceeds 130% of the conversion price on (1)&nbsp;each of at least 20 trading days, whether or not consecutive, during the
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="28%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:arial">
30&nbsp;consecutive trading days ending on, and including, the trading day immediately before the date we send the related redemption notice; and (2)&nbsp;the trading day immediately before the
date we send such notice. However, we may not redeem less than all of the outstanding notes unless at least $75.0&nbsp;million aggregate principal amount of notes are outstanding and not called for redemption as of the time we send the related
redemption notice. In addition, calling any note for redemption will constitute a make-whole fundamental change with respect to that note, in which case the conversion rate applicable to the conversion of that note will be increased in certain
circumstances if it is converted after it is called for redemption. See &#8220;Description of Notes&#8212;Optional Redemption.&#8221; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:arial"><B>Repurchase at the Option of the&nbsp;Noteholders After a Fundamental Change </B></P></TD>
<TD>If a &#8220;fundamental change&#8221; (as defined in this prospectus supplement) occurs, then, except as described in this prospectus supplement, noteholders may require us to repurchase their notes at a cash repurchase price equal to the
principal amount of the notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date. See &#8220;Description of Notes&#8212;Fundamental Change Permits Noteholders to Require Us to
Repurchase Notes.&#8221; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:arial"><B>Trustee, Paying Agent and Conversion Agent </B></P></TD>
<TD>U.S. Bank Trust Company, National Association. </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:arial"><B>Concurrent Equity Offering </B></P></TD>
<TD>Concurrently with this offering, we are offering 9,677,420 shares of our common stock (or up to 11,129,033 shares of our common stock if the underwriters in the Concurrent Equity Offering exercise their option to purchase additional shares of
common stock in full). Neither this offering nor the Concurrent Equity Offering is conditioned upon the completion of the other, so it is possible that this offering occurs and the Concurrent Equity Offering does not occur, or vice versa. We cannot
assure you that the Concurrent Equity Offering will be completed on the terms described herein, on significantly different terms, or at all. The Concurrent Equity Offering is being made pursuant to a separate prospectus supplement and an
accompanying prospectus forming part of an effective registration statement, and nothing contained herein shall constitute an offer to sell or the solicitation of an offer to buy our common stock to be issued in the Concurrent Equity Offering. See
&#8220;Use of Proceeds&#8221; and &#8220;Description of the Concurrent Equity Offering.&#8221; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B>No Public Market </B></P></TD>
<TD> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">The notes are a new class of securities for which no established trading market currently exists. We do not intend to apply to list the notes on any securities
exchange or for quotation on any inter-dealer quotation system. Accordingly, a liquid market for the notes may never develop. Certain of the underwriters have advised us that they intend to make a market in the notes. However, they are not
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="28%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:arial">
obligated to do so and may discontinue any market-making activity at any time without notice in their sole discretion. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:arial"><B>Material U.S. Federal Income Tax Considerations </B></P></TD>
<TD>For a description of the material U.S. federal income tax considerations of owning, converting and disposing of the notes and owning and disposing of shares of our common stock into which the notes may be converted, see &#8220;Material U.S.
Federal Income Tax Considerations.&#8221; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B>Use of proceeds </B></P></TD>
<TD>We intend to use the net proceeds from this offering, together with the net proceeds from the Concurrent Equity Offering, to repay $50 million of Term Loans outstanding under the Credit Facility, plus accrued interest and associated fees, and
the remainder for development and regulatory activities relating to bezuclastinib and other product candidates, the anticipated commercial launch and commercialization of bezuclastinib, as well as for working capital and general corporate purposes.
</TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="28%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If the underwriters exercise their over-allotment option, we expect to use the net proceeds from the sale of the additional notes for general corporate purposes. See &#8220;Use of Proceeds&#8221; for additional
information. </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B>Risk factors </B></P></TD>
<TD>You should read and consider the information set forth under the heading &#8220;Risk Factors&#8221; in this prospectus supplement and in the accompanying prospectus, together with the risk factors and cautionary statements described in our
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2024 and subsequent Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> incorporated by reference herein, before
deciding to invest in the notes. </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:arial"><B>Nasdaq Global Select Market Symbol </B></P></TD>
<TD>Our common stock is listed on the Nasdaq Global Select Market under the symbol &#8220;COGT.&#8221; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B>Book-Entry Form </B></P></TD>
<TD>We will initially issue the notes in the form of one or more global notes registered in the name of Cede&nbsp;&amp; Co., as nominee of DTC, without interest coupons, which we will deposit with the trustee as custodian for DTC. Beneficial
interests in global notes will be shown on, and transfers of global notes will be effected only through, the records maintained by DTC. Except in limited circumstances, we will not issue certificated notes. </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="28%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See &#8220;Description of Notes&#8212;Book Entry, Settlement and Clearance.&#8221; </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="supptoc159388_5"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>The following risk factors and other information included in this prospectus supplement should be carefully considered. The risks and uncertainties described below
are not the only ones we face. Additional risks and uncertainties not presently known to us or that we presently deem less significant may also impair our business operations. You should carefully consider the risks described below, as well as those
contained in the other documents incorporated by reference in this prospectus supplement and accompanying prospectus and any free writing prospectus that we have authorized for use in connection with this offering, before deciding whether to invest
in the notes. If any of the following risks occur, our business, financial condition, results of operations and future growth prospects could be materially and adversely affected. In any such case, the trading price of our common stock could
decline, and you could lose all or part of your investment. </I></P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks Relating to this Offering </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The notes will be effectively subordinated to our existing and future secured indebtedness and structurally subordinated to the liabilities of our subsidiaries.
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The notes will be our general, unsecured, senior obligations and will rank senior in right of payment to our future indebtedness that is expressly
subordinated in right of payment to the notes, equal in right of payment with our existing and future indebtedness that is not expressly subordinated to the notes and effectively subordinated to our existing and future secured indebtedness, to the
extent of the value of the collateral securing that indebtedness. In addition, because none of our subsidiaries will guarantee the notes, the notes will be structurally subordinated to all existing and future indebtedness and other liabilities,
including trade payables, and (to the extent we are not a holder thereof) preferred equity, if any, of our current or future subsidiaries. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of September&nbsp;30,
2025, the outstanding principal amount of our consolidated indebtedness for borrowed money was $50&nbsp;million, all of which was senior secured indebtedness consisting of the Term Loans. After giving effect to the issuance of the notes (assuming no
exercise of the underwriters&#8217; over-allotment option), and giving effect to the use of proceeds from this offering to repay the Term Loans, as of September&nbsp;30, 2025, the aggregate principal amount of our total indebtedness would have been
$200&nbsp;million. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If a bankruptcy, liquidation, dissolution, reorganization or similar proceeding occurs with respect to us, then the holders of any of our secured
indebtedness may proceed directly against the assets securing that indebtedness. Accordingly, those assets will not be available to satisfy any outstanding amounts under our unsecured indebtedness, including the notes, unless the secured
indebtedness is first paid in full. The remaining assets, if any, would then be allocated pro rata among the holders of our senior, unsecured indebtedness, including the notes. There may be insufficient assets to pay all amounts then due. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If a bankruptcy, liquidation, dissolution, reorganization or similar proceeding occurs with respect to any of our current or future subsidiaries, then we, as a direct or
indirect common equity owner of any such subsidiary (and, accordingly, holders of our indebtedness, including the notes), will be subject to the prior claims of such subsidiary&#8217;s creditors, including trade creditors and preferred equity
holders. We may never receive any amounts from such subsidiary to satisfy amounts due under the notes. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our indebtedness and liabilities could limit the cash
flow available for our operations, expose us to risks that could adversely affect our business, financial condition and results of operations and impair our ability to satisfy our obligations under the notes. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of September&nbsp;30, 2025, we had $50.0&nbsp;million aggregate principal amount of indebtedness for borrowed money, all of which was senior secured indebtedness
consisting of the Term Loans, which we intend to repay in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
full using the net proceeds of this offering. We will incur $200,000,000 (or, if the underwriters exercise their over-allotment option in full, $230,000,000) principal amount of additional
indebtedness as a result of this offering. Following this offering, we may incur additional indebtedness to meet future financing needs. Our indebtedness could have significant negative consequences for our security holders and our business, results
of operations and financial condition by, among other things: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">increasing our vulnerability to adverse economic and industry conditions; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">limiting our ability to obtain additional financing on acceptable terms or at all; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">requiring the dedication of a substantial portion of our cash flow from operations to service our indebtedness, which will
reduce the amount of cash available for other purposes; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">limiting our flexibility to plan for, or react to, changes in our business; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">diluting the interests of our existing stockholders as a result of issuing shares of our common stock upon conversion of
the notes; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">placing us at a possible competitive disadvantage with competitors that are less leveraged than us or have better access to
capital. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our business may not generate sufficient funds, and we may otherwise be unable to maintain sufficient cash reserves, to pay amounts due
under our indebtedness, including the notes, and our cash needs may increase in the future. In addition, any future indebtedness that we may incur after this offering may contain, financial and other restrictive covenants that limit our ability to
operate our business, raise capital or make payments under our other indebtedness. If we fail to comply with these covenants or to make payments under our indebtedness when due, then we would be in default under that indebtedness, which could, in
turn, result in that and our other indebtedness becoming immediately due and payable in full. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may be unable to raise the funds necessary to repurchase the
notes for cash following a fundamental change or to pay any cash amounts due upon maturity or conversion of the notes, and our other indebtedness may limit our ability to repurchase the notes or to pay any cash amounts due upon their maturity or
conversion. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Noteholders may, subject to a limited exception described in this prospectus supplement, require us to repurchase their notes following a
fundamental change at a cash repurchase price generally equal to the principal amount of the notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date. See &#8220;Description of
Notes&#8212;Fundamental Change Permits Noteholders to Require Us to Repurchase Notes.&#8221; Upon maturity of the notes, we must pay their principal amount and accrued and unpaid interest in cash, unless they have been previously converted, redeemed
or repurchased. In addition, unless we elect to deliver solely shares of our common stock to settle such conversion (other than paying cash in lieu of delivering any fractional share), all conversions of notes will be settled partially or entirely
in cash. We may not have enough available cash or be able to obtain financing at the time we are required to repurchase the notes or pay any cash amounts due upon their maturity or conversion. In addition, applicable law, regulatory authorities and
the agreements governing our other indebtedness may restrict our ability to repurchase the notes or to pay any cash amounts due upon their maturity or conversion. Our failure to repurchase notes or to pay any cash amounts due upon their maturity or
conversion when required will constitute a default under the indenture. A default under the indenture or the fundamental change itself could also lead to a default under agreements governing our other indebtedness, which may result in that other
indebtedness becoming immediately payable in full after any applicable notice or grace periods. We may not have sufficient funds to satisfy all amounts due under the other indebtedness and the notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Not all events that may adversely affect the trading price of the notes and our common stock will result in an
adjustment to the conversion rate. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will adjust the conversion rate of the notes for certain events, including: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">certain stock dividends, splits and combinations; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the issuance of certain rights, options or warrants to holders of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">certain distributions of assets, debt securities, capital stock or other property to holders of our common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">cash dividends on our common stock; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">certain tender or exchange offers. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">See &#8220;Description of Notes&#8212;Conversion Rights&#8212;Conversion Rate Adjustments.&#8221; We are not required to adjust the conversion rate for other events,
such as third-party tender offers or an issuance of our common stock (or securities convertible into, or exercisable or exchangeable for, our common stock) for cash, that may adversely affect the trading price of the notes and our common stock. An
event may occur that adversely affects the noteholders and the trading price of the notes and the underlying shares of our common stock but that does not result in an adjustment to the conversion rate. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Not all significant restructuring transactions will constitute a fundamental change, in which case you will not have the right to require us to repurchase your
notes for cash, or a make-whole fundamental change, in which case you will not be entitled to an increased conversion rate under the make-whole fundamental change provisions of the notes. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If certain corporate events called &#8220;fundamental changes&#8221; occur, then, subject to a limited exception described in this prospectus supplement, you will have
the right to require us to repurchase your notes for cash. See &#8220;Description of Notes&#8212;Fundamental Change Permits Noteholders to Require Us to Repurchase Notes.&#8221; In addition, if a &#8220;make-whole fundamental change&#8221; occurs,
then we will in certain circumstances increase the conversion rate for a specified period of time. See &#8220;Description of Notes&#8212;Conversion Rights&#8212;Increase in Conversion Rate in Connection with a Make-Whole Fundamental Change.&#8221;
However, the definitions of &#8220;fundamental change&#8221; and &#8220;make-whole fundamental change&#8221; are limited to specific corporate events and do not include all events that may adversely affect our financial condition or the trading
price of the notes. For example, a leveraged recapitalization, refinancing, restructuring or acquisition by us may not constitute a fundamental change that would require us to repurchase the notes or a make-whole fundamental change that would result
in an increased conversion rate. Nonetheless, these events could significantly increase the amount of our indebtedness, harm any credit rating that we may have at that time or adversely affect our capital structure and the trading price of the
notes. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The increase to the conversion rate resulting from a make-whole fundamental change may not adequately compensate noteholders for the lost option value
of their notes. In addition, a variety of transactions that do not constitute a make-whole fundamental change may significantly reduce the option value of the notes without a corresponding increase to the conversion rate. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If certain corporate events that constitute a &#8220;make-whole fundamental change&#8221; occur (including conversions of notes that are called or deemed called for
redemption), then we will, in certain circumstances, temporarily increase the conversion rate. See &#8220;Description of Notes&#8212;Conversion Rights&#8212;Increase in Conversion Rate in Connection with a Make-Whole Fundamental Change.&#8221; The
amount of the increase to the conversion rate will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
depend on the date on which the make-whole fundamental change becomes effective and the applicable &#8220;stock price.&#8221; While the increase to the conversion rate is designed to compensate
noteholders for the lost option value of their notes resulting from a make-whole fundamental change (including an optional redemption of their notes), the increase is only an approximation and may not adequately compensate noteholders for the loss
in option value. In addition, if the applicable &#8220;stock price&#8221; is greater than $400.00 per share of common stock or less than $31.00 per share of common stock (in each case, subject to adjustment), then we will not increase the conversion
rate for the make-whole fundamental change. Moreover, we will not increase the conversion rate pursuant to these provisions to an amount that exceeds 32.2580 shares of our common stock per $1,000 principal amount of notes, subject to adjustment.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Furthermore, the definition of make-whole fundamental change is limited to certain specific transactions. Accordingly, the make-whole fundamental change provisions
of the indenture will not protect noteholders from other transactions that could significantly reduce the option value of the notes. For example, a <FONT STYLE="white-space:nowrap">spin-off</FONT> or sale of a subsidiary or business division with
volatile earnings, or a change in our line of business, could significantly affect the trading characteristics of our common stock and reduce the option value of the notes without constituting a make-whole fundamental change that results in a
temporary increase to the conversion rate. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, our obligation to increase the conversion rate in connection with a make-whole fundamental change (including
for notes converted in connection with a redemption) could be considered a penalty, in which case its enforceability would be subject to general principles of reasonableness and equitable remedies. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>There is currently no trading market for the notes. If an active trading market for the notes does not develop, then noteholders may be unable to sell their notes
at desired times or prices, or at all. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The notes are a new class of securities for which no established trading market currently exists. We do not intend to
apply to list the notes on any securities exchange or for quotation on any inter-dealer quotation system. Although certain of the underwriters have advised us that they intend to make a market in the notes, they are not obligated to do so and may
discontinue any market-making activity at any time without notice in their sole discretion. Accordingly, an active market for the notes may never develop, and, even if one develops, it may not be maintained. If an active trading market for the notes
does not develop or is not maintained, then the market price and liquidity of the notes may be adversely affected and noteholders may not be able to sell their notes at desired times or prices, or at all. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The liquidity of the trading market, if any, and future trading prices of the notes will depend on many factors, including, among other things, the trading price and
volatility of our common stock, prevailing interest rates, our dividend yield, financial condition, results of operations, business, prospects and credit quality relative to our competitors, the market for similar securities and the overall
securities market. Many of these factors are beyond our control. Historically, the market for convertible debt has been volatile. Market volatility could significantly harm the market for the notes, regardless of our financial condition, results of
operations, business, prospects or credit quality. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The trading price of our common stock, the condition of the financial markets, prevailing interest rates
and other factors could significantly affect the trading price of the notes. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect that the trading price of our common stock will significantly affect
the trading price of the notes, which could result in greater volatility in the trading price of the notes than would be expected for <FONT STYLE="white-space:nowrap">non-convertible</FONT> securities. The trading price of our common stock will
likely continue to fluctuate in response to the factors described or referred to elsewhere in this section and under the caption &#8220;Cautionary Statement Regarding Forward-Looking Statements,&#8221; among others, many of which are beyond our
control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, the condition of the financial markets and changes in prevailing interest rates can have an adverse
effect on the trading price of the notes. For example, prevailing interest rates have fluctuated in the past and are likely to fluctuate in the future, and we would expect an increase in prevailing interest rates to depress the trading price of the
notes. An increase in short- or long-term interest rates, including as a result of a rise in actual or expected inflation, could cause the trading price of the notes to fall significantly. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The issuance or sale of shares of our common stock, including sales made pursuant to the Concurrent Equity Offering, or rights to acquire shares of our common
stock, could depress the trading price of our common stock and the notes. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may conduct future offerings of common stock, preferred stock or other
securities that are convertible into, or exercisable or exchangeable for, our common stock to finance our operations or fund acquisitions, or for other purposes. In addition, as of September&nbsp;30, 2025, we have (i) 27,499,141 shares of our common
stock subject to stock options with a weighted-average exercise price of $8.80 per share; (ii)&nbsp;up to 3,054,000 shares of our common stock subject to outstanding and unvested performance-based restricted stock units; (iii)&nbsp;1,021,195 shares
of our common stock reserved for future grant or issuance under the 2020 Inducement Plan; and (iv) 1,669,043 shares of our common stock reserved for future grant or issuance under the 2018 Stock Option and Incentive Plan. Concurrently with this
offering, we are offering 9,677,420 shares of our common stock (or up to 11,129,033 shares of our common stock if the underwriters in the Concurrent Equity Offering exercise in full their option to purchase additional shares of common stock) in the
Concurrent Equity Offering. The indenture for the notes will not restrict our ability to issue additional equity securities in the future. If we issue additional shares of our common stock or rights to acquire shares of our common stock, if any of
our existing stockholders sells a substantial amount of our common stock, or if the market perceives that such issuances or sales may occur, then the trading price of our common stock and, accordingly, the notes may significantly decline. In
addition, our issuance of additional shares of common stock will dilute the ownership interests of our existing common stockholders, including noteholders who have received shares of our common stock upon conversion of their notes. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We will make only very limited covenants in the indenture, and these limited covenants may not protect your investment. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Many debt instruments contain provisions that are designed to restrict the borrower&#8217;s activities and operations in a manner that is designed to preserve the
borrower&#8217;s ability to make payments on the related indebtedness when due. These provisions include financial and operating covenants, and restrictions on the payments of dividends, the incurrence of indebtedness or the issuance or repurchase
of securities by the borrower or any of its subsidiaries. The indenture for the notes will not contain any of these covenants or restrictions or otherwise place any meaningful restrictions on our ability to operate our business as management deems
appropriate. As a result, your investment in the notes may not be as protected as an investment in an instrument that contains some or all of these types of covenants and restrictions. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Regulatory actions, changes in market conditions and other events may adversely affect the trading price and liquidity of the notes and the ability of investors
to implement a convertible note arbitrage trading strategy. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect that many investors in the notes, including potential purchasers of the notes from
investors in this offering, will seek to employ a convertible note arbitrage strategy. Under this strategy, investors typically short sell a certain number of shares of our common stock and adjust their short position over time while they continue
to hold the notes. Investors may also implement this type of strategy by entering into swaps on our common stock in lieu of, or in addition to, short selling shares of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The SEC and other regulatory authorities have implemented various rules and taken certain actions, and may in the
future adopt additional rules and take other actions, that may impact those engaging in short selling activity involving equity securities (including our common stock). These rules and actions include Rule 201 of SEC Regulation SHO, the adoption by
the Financial Industry Regulatory Authority, Inc., and the national securities exchanges of a &#8220;limit <FONT STYLE="white-space:nowrap">up-limit</FONT> down&#8221; program, the imposition of market-wide circuit breakers that halt trading of
securities for certain periods following specific market declines, and the implementation of certain regulatory reforms required by the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010. Any governmental or regulatory action that
restricts investors&#8217; ability to effect short sales of our common stock or enter into equity swaps on our common stock could depress the trading price of, and the liquidity of the market for, the notes. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, the liquidity of the market for our common stock and other market conditions could deteriorate, which could reduce, or eliminate entirely, the number of
shares available for lending in connection with short sale transactions and the number of counterparties willing to enter into an equity swap on our common stock with a note investor. These and other market events could make implementing a
convertible note arbitrage strategy prohibitively expensive or infeasible. If investors in this offering or potential purchasers of the notes that seek to employ a convertible note arbitrage strategy are unable to do so on commercial terms, or at
all, then the trading price of, and the liquidity of the market for, the notes may significantly decline. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>You may be subject to tax if we adjust, or fail to
adjust, the conversion rate of the notes, even though you do not receive a corresponding cash or property distribution. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The conversion rate of the notes is
subject to adjustment in certain circumstances, including the payment of cash dividends on our common stock. If the conversion rate is adjusted as a result of a distribution that is taxable to our common stockholders, such as a distribution of money
or other property, you generally will be deemed, for U.S. federal income tax purposes, to have received a distribution, which may be treated as a taxable dividend to the extent of our current or accumulated earnings and profits, without the receipt
of any cash. In addition, a failure to adjust (or to adjust adequately) the conversion rate after an event that increases your proportionate interest in us could be treated as a deemed taxable dividend to you. If a make-whole fundamental change
occurs prior to the maturity date, under some circumstances, we will increase the conversion rate for notes converted in connection with that make-whole fundamental change. Such increase may also be treated as a distribution subject to U.S. federal
income tax as a dividend. See &#8220;Material U.S. Federal Income Tax Considerations&#8212;Consequences to U.S. Holders&#8212;Constructive Distributions.&#8221; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If
you are a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder (as defined in &#8220;Material U.S. Federal Income Tax Considerations&#8221;), any deemed dividend would generally be subject to U.S. federal withholding tax at a 30% rate, or such
lower rate as may be specified by an applicable income tax treaty. Any U.S. federal withholding tax or backup withholding may be withheld from or set off against payments on the notes (or, in certain circumstances, from the issuance of shares of
common stock upon a conversion of the notes) or our common stock owned by you or from any proceeds of any subsequent sale, exchange or other disposition of such note (including the retirement of such note) or such common stock by you or from your
other funds or assets. See &#8220;Material U.S. Federal Income Tax Considerations&#8212;Consequences to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders&#8212;Dividends and Constructive Distributions.&#8221; </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>A rating agency may not rate the notes or may assign a rating that is lower than expected. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We do not intend to seek to have the notes rated by any rating agency. However, if one or more rating agencies rate the notes and assign a rating that is lower than the
rating that investors expect, or reduce their rating in the future, then the trading price of our common stock and the notes could significantly decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, market perceptions of our creditworthiness will directly affect the trading price of the notes.
Accordingly, if a ratings agency rates any of our indebtedness in the future or downgrades or withdraws the rating, or puts us on credit watch, then the trading price of the notes will likely decline. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Provisions in the indenture could delay or prevent an otherwise beneficial takeover of us. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Certain provisions in the notes and the indenture could make a third-party attempt to acquire us more difficult or expensive. For example, if a takeover constitutes a
fundamental change, then, except as described in this prospectus supplement, noteholders will have the right to require us to repurchase their notes for cash. In addition, if a takeover constitutes a make-whole fundamental change, then we may be
required to temporarily increase the conversion rate. In either case, and in other cases, our obligations under the notes and the indenture could increase the cost of acquiring us or otherwise discourage a third party from acquiring us or removing
incumbent management, including in a transaction that noteholders or holders of our common stock may view as favorable. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>You may be unable to convert your
notes before August&nbsp;15, 2031, and the trading price of the notes could be less than the value of the consideration into which they could otherwise be converted. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Before August&nbsp;15, 2031, you may convert your notes only if specific conditions are met. If these conditions are not met, then you will not be able to convert your
notes and receive the cash, shares of our common stock or combination of cash and shares, as applicable, into which the notes would otherwise be convertible. As a result, the notes may trade at prices that are less than the value of the
consideration into which they would otherwise be convertible. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The conditional conversion feature of the notes, if triggered, may adversely affect our
financial condition and results of operations. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the event the conditional conversion feature of the notes is triggered, noteholders will be entitled to
convert the notes at any time during specified periods at their option. If one or more noteholders elect to convert their notes, unless we elect to satisfy our conversion obligation by delivering solely shares of our common stock (other than paying
cash in lieu of delivering any fractional share), we would be required to settle a portion or all of our conversion obligation through the payment of cash, which could adversely affect our liquidity. In addition, even if noteholders do not elect to
convert their notes, we could be required under applicable accounting rules to reclassify all or a portion of the outstanding principal of the notes as a current rather than long-term liability, which would result in a material reduction of our net
working capital. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Fluctuations in the trading price of our common stock after you elect to convert your notes may cause you to receive less valuable
consideration than expected. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will generally have the right to settle conversions in cash, shares of our common stock or a combination of cash and shares.
If we elect to settle conversions solely in cash or in a combination of cash and shares, then the consideration due upon conversion of any note will be determined based on the volume-weighted average price of our common stock during the related
&#8220;observation period,&#8221; which is defined under the caption &#8220;Description of Notes&#8212;Definitions&#8221; and will consist of 25 &#8220;VWAP trading days.&#8221; Except in certain circumstances, the observation period will begin
after the related conversion date. Accordingly, a considerable amount of time may lapse between the time you elect to convert your notes and the time you receive the consideration due upon conversion, and if the trading price of our common stock
declines during this time, then you may receive less consideration, or consideration that is less valuable, than expected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Your investment in the notes may be harmed if we redeem the notes. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will have the right to redeem the notes, in whole or in part, in certain circumstances on or after November&nbsp;20, 2029 and on or before the 26th scheduled trading
day immediately before the maturity date. See &#8220;Description of Notes&#8212;Optional Redemption.&#8221; If we redeem your notes, then the cash comprising the redemption price, in the case of a redemption, or the applicable conversion
consideration, in the case of a conversion in connection with a redemption, in either case, may not fully compensate you for any future interest payments that you would have otherwise received or for any other lost time value of your notes. In
addition, if we redeem your notes, you may not be entitled to benefit from potential future appreciation in the trading price of our common stock, and you may be unable to reinvest any proceeds from the redemption in comparable investments at
favorable interest rates. In addition, a redemption of less than all of the outstanding notes will likely harm the liquidity of the market for the unredeemed notes following the redemption. Accordingly, if your notes are not redeemed in a partial
redemption, then you may be unable to sell your notes at the times you desire or at favorable prices, if at all, and the trading price of your notes may decline. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The accounting method for the notes could adversely affect our reported financial condition and results. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The accounting method for reflecting the notes on our balance sheet, accruing interest expense for the notes and reflecting the underlying shares of our common stock in
our reported diluted earnings per share may adversely affect our reported earnings and financial condition. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In accordance with applicable accounting standards, we
expect that the notes we are offering will be reflected as a liability on our balance sheets, with the initial carrying amount equal to the principal amount of the notes, net of issuance costs. The issuance costs will be treated as a debt discount
for accounting purposes, which will be amortized into interest expense over the term of the notes. As a result of this amortization, the interest expense that we expect to recognize for the notes for accounting purposes will be greater than the cash
interest payments we will pay on the notes, which will result in lower reported income. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, we expect that the shares underlying the notes will be
reflected in our diluted earnings per share using the &#8220;if converted&#8221; method. Under that method, if the conversion value of the notes exceeds their principal amount for a reporting period, then we will calculate our diluted earnings per
share assuming that all of the notes were converted at the beginning of the reporting period and that we issued shares of our common stock to settle the excess. The <FONT STYLE="white-space:nowrap">after-tax</FONT> interest expense associated with
the notes will not be added back to the numerator of the diluted earnings per share calculation for these purposes. However, if reflecting the notes in diluted earnings per share in this manner is anti-dilutive, or if the conversion value of the
notes does not exceed their principal amount for a reporting period, then the shares underlying the notes will not be reflected in our diluted earnings per share. The application of the <FONT STYLE="white-space:nowrap">if-converted</FONT> method may
reduce our reported diluted earnings per share, and accounting standards may change in the future in a manner that may adversely affect our diluted earnings per share. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Furthermore, if any of the conditions to the convertibility of the notes is satisfied, then we may be required under applicable accounting standards to reclassify the
liability carrying value of the notes as a current, rather than a long-term, liability. This reclassification could be required even if no noteholders convert their notes and could materially reduce our reported working capital. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have not reached a final determination regarding the accounting treatment for the notes nor the application of the
<FONT STYLE="white-space:nowrap">if-converted</FONT> method, and the description above is preliminary. Accordingly, we may account for the notes and calculate diluted earnings per share in a manner that is significantly different than described
above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The conversion of notes could impair our financial position and liquidity. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Unless we elect to deliver solely shares of our common stock to settle such conversion (other than paying cash in lieu of delivering any fractional share), we must
settle at least a portion of our conversion obligation in cash, and therefore, the conversion of notes could materially and adversely affect our financial position and liquidity. Before August&nbsp;15, 2031, noteholders will have the right to
convert their notes only upon the occurrence of certain events. From and after August&nbsp;15, 2031, noteholders may convert their notes at any time at their election until the close of business on the scheduled trading day immediately before the
maturity date. See &#8220;Description of Notes&#8212;Conversion Rights.&#8221; However, many of the conditions that permit the conversion of notes before August&nbsp;15, 2031 are beyond our control. We could be required to expend a significant
amount of cash to settle conversions, which could significantly harm our financial position and liquidity. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Because the notes will initially be held in
book-entry form, noteholders must rely on DTC&#8217;s procedures to exercise their rights and remedies. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will initially issue the notes in the form of one
or more &#8220;global notes&#8221; registered in the name of Cede&nbsp;&amp; Co, as nominee of DTC. Beneficial interests in global notes will be shown on, and transfers of global notes will be effected only through, the records maintained by DTC.
Except in limited circumstances, we will not issue certificated notes. See &#8220;Description of Notes&#8212;Book Entry, Settlement and Clearance.&#8221; Accordingly, if you own a beneficial interest in a global note, then you will not be considered
an owner or holder of the notes. Instead, DTC or its nominee will be the sole holder of the notes. Payments of principal, interest and other amounts on global notes will be made to the paying agent, who will remit the payments to DTC. We expect that
DTC will then credit those payments to the DTC participant accounts that hold book-entry interests in the global notes and that those participants will credit the payments to indirect DTC participants. Unlike persons who have certificated notes
registered in their names, owners of beneficial interests in global notes will not have the direct right to act on our solicitations for consents or requests for waivers or other actions from noteholders. Instead, those beneficial owners will be
permitted to act only to the extent that they have received appropriate proxies to do so from DTC or, if applicable, a DTC participant. The applicable procedures for the granting of these proxies may not be sufficient to enable owners of beneficial
interests in global notes to vote on any requested actions on a timely basis. In addition, notices and other communications relating to global notes will be sent to DTC. We expect DTC to forward any such communications to DTC participants, which in
turn would forward such communications to indirect DTC participants. However, we can make no assurance that you timely receive any such communications. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Holding notes will not, in itself, confer any rights with respect to our common stock. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Noteholders will generally not be entitled to any rights with respect to our common stock (including voting rights and rights to receive any dividends or other
distributions on our common stock). However, noteholders will be subject to all changes affecting our common stock to the extent the trading price of the notes depends on the market price of our common stock and to the extent they receive shares of
our common stock upon conversion of their notes. For example, if we propose an amendment to our charter documents that requires stockholder approval, then a noteholder will not, as such, be entitled to vote on the amendment, although the noteholder
will be subject to any changes implemented by that amendment in the powers, preferences or special rights of our common stock. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The closing of this offering
is not contingent upon the closing of the Concurrent Equity Offering, and vice versa. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The closing of this offering is not contingent upon the closing of the
Concurrent Equity Offering. Therefore, it is possible that this offering occurs and the Concurrent Equity Offering does not occur, or vice versa, or that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
neither occurs or either offering results in lower net proceeds than we currently estimate. We cannot assure you that the Concurrent Equity Offering will be completed on the terms described
herein, on significantly different terms, or at all. Accordingly, if you decide to purchase the notes, you should be willing to do so whether or not we complete the Concurrent Equity Offering. This prospectus supplement is not an offer to sell or a
solicitation of an offer to buy any of the common stock being offered in the Concurrent Equity Offering. See &#8220;Description of the Concurrent Equity Offering.&#8221; </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We have broad discretion as to the use of proceeds from this offering and may not use the proceeds effectively. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our management will have considerable discretion in the application of the net proceeds, and you will not have the opportunity, as part of your investment decision, to
assess whether the proceeds are being used appropriately. The failure of our management to apply these funds effectively could result in unfavorable returns and uncertainty about our prospects, each of which could cause the price of the notes and
our common stock to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="supptoc159388_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We estimate that we will receive net proceeds from this offering of approximately $193.7&nbsp;million (or approximately $222.8&nbsp;million if the underwriters exercise
their over-allotment option in full), after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We
estimate we will receive net proceeds from the Concurrent Equity Offering, if it is consummated as currently contemplated, of approximately $281.7 million (or approximately $324.0&nbsp;million if the underwriters in the Concurrent Convertible Notes
Offering exercise their option to purchase additional shares of common stock in full), after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We intend to use the net proceeds from this offering, together with the net proceeds from the Concurrent Equity Offering, to repay $50 million of Term Loans under the
Credit Facility, plus accrued interest and associated fees, and the remainder for development and regulatory activities relating to bezuclastinib and other product candidates, the anticipated commercial launch and commercialization of bezuclastinib,
as well as for working capital and general corporate purposes. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Term Loans under the Credit Facility mature on June 1, 2030 and bear interest at an annual rate
equal to 4.75% plus the greater of (i) one-month term Secured Overnight Financing Rate, and (ii) 4.15% per annum. The proceeds of the loans under the existing term loan facility were used for development and regulatory activities relating to
bezuclastinib and other product candidates, the anticipated commercial launch and commercialization of bezuclastinib, as well as for working capital and general corporate purposes. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If the underwriters exercise their over-allotment option, we expect to use the net proceeds from the sale of the additional notes for general corporate purposes. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our expected use of proceeds from this offering represents our current intentions based on our present plans and business condition. As of the date of this prospectus
supplement, we cannot predict with certainty all of the particular uses for the proceeds to be received upon the completion of this offering or the amounts that we will actually spend on the uses set forth above. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Based on our current business plans, we believe that the net proceeds from this offering, together with the net proceeds from the Concurrent Equity Offering and our
existing cash will be sufficient to fund our planned operations into 2028. The amount and timing of our actual expenditures will depend on numerous factors, including the pace and results of our research and development efforts, the timing and
success of clinical trials, the timing and costs associated with the manufacture and supply of product candidates, the timing of regulatory submissions and any unforeseen cash needs. For additional information regarding our potential capital
requirements, including factors that could cause actual costs to vary from the estimates set forth above, see &#8220;Risk Factors&#8221; in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pending the use of the net proceeds, we may invest the proceeds in interest-bearing, investment-grade securities, certificates of deposit or government securities.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="supptoc159388_7"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table presents our cash and cash equivalents and our capitalization as of September&nbsp;30, 2025: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">on an actual basis; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">on an as adjusted basis to give effect to (i)&nbsp;the issuance and sale of $200,000,000 aggregate principal amount of the
notes we are offering (assuming the underwriters do not exercise their over-allotment option), after deducting the underwriting discounts and commissions and our estimated offering expenses but without giving effect to the expected use of proceeds
from this offering, (ii)&nbsp;the completion of the Concurrent Equity Offering (assuming no exercise of the option of the underwriters to purchase additional shares of our common stock) at a public offering price of $31.00 per share, and (iii) the
repayment of $50 million of Term Loans under the Credit Facility, plus accrued interest and associated fees. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This table should be read in
conjunction with the other information included or incorporated by reference in this prospectus supplement, including our condensed financial statements and related notes. Because the completion of this offering is not contingent on the completion
of the Concurrent Equity Offering, you should not assume that the Concurrent Equity Offering, as reflected in the as adjusted column in the table below, will take place. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000;">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of September&nbsp;30, 2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000;"><FONT STYLE="font-size:8pt"><B>(in thousands, except share and per&nbsp;share&nbsp;data)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000;"><B>Actual</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000;"><B>As&nbsp;adjusted</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">125,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">545,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Long-term debt:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Credit Facility<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">1.625% Convertible Senior Notes due 2031 offered
hereby<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Stockholders&#8217; equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Preferred stock, $0.001 par value; 8,979,420 shares authorized; no shares issued or outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series A <FONT STYLE="white-space:nowrap">non-voting</FONT> convertible preferred stock, $0.001 par value;
1,000,000 shares authorized; 67,414 shares issued and outstanding at September&nbsp;30, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series B <FONT STYLE="white-space:nowrap">non-voting</FONT> convertible preferred stock, $0.001 par value;
20,580&nbsp;shares authorized; 6,868 shares issued and outstanding at September&nbsp;30,&nbsp;2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Common stock, $0.001 par value; 300,000,000 shares authorized; 139,827,662 shares issued and outstanding at
September&nbsp;30, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital<SUP
STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,280,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,561,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,085,928)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,085,928)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total stockholders&#8217; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">302,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">583,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">352,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">783,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#8220;Actual&#8221; reflects outstanding borrowings under the Credit Facility, without deduction for debt discounts or issuance costs, and does not reflect the additional $350.0&nbsp;million available to be drawn by us
under the Loan and Security Agreement upon the achievement of certain milestones and the satisfaction of certain financial covenants. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts shown in the table above for the notes we are offering represent their principal amount. However, we expect that the initial liability carrying amount of the notes for accounting purposes will be recorded
net of issuance costs, which will be treated as a debt discount for accounting purposes and amortized into interest expense over the term of the notes. As a result of this amortization, the interest expense that we expect to recognize for the notes
for accounting purposes will be greater than the cash interest payments we will pay on the notes, which will result in lower reported net income or larger reported net loss. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="supptoc159388_8"></A>DESCRIPTION OF NOTES </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will issue the notes under an indenture (the &#8220;base indenture&#8221;), to be dated as of the initial closing date of this offering, between us and U.S. Bank
Trust Company, National Association, as trustee (the &#8220;trustee&#8221;), as supplemented by a supplemental indenture (the base indenture, as so supplemented, the &#8220;indenture&#8221;), to be dated as of the initial closing date of this
offering, between us and the trustee. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following is a summary of certain provisions of the notes and the indenture. It is only a summary and is not complete. We
qualify this summary by referring you to the indenture and the notes, because they, and not this summary, define your rights as a holder of the notes. We will provide you with a copy of the indenture, which includes the form of the notes, as
provided under the caption &#8220;Where You Can Find Additional Information.&#8221; In addition, the indenture and the notes will be deemed to include certain terms that are made a part of the indenture and the notes pursuant to the Trust Indenture
Act of 1939, as amended (the &#8220;Trust Indenture Act&#8221;). </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This &#8220;Description of Notes&#8221; section supplements and, to the extent inconsistent
therewith, supersedes the information in the accompanying prospectus under the caption &#8220;Description of Debt Securities.&#8221; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Certain terms used in this
summary are defined below under the caption &#8220;&#8212;Definitions.&#8221; Certain other terms used in this summary are defined in the indenture. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In this
section, references to (i) &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Cogent Biosciences, Inc. only and not to any of its subsidiaries; and (ii)&nbsp;any &#8220;note&#8221; refers to any authorized denomination of a note,
unless the context requires otherwise. For purposes of the description below, the term &#8220;including&#8221; means &#8220;including without limitation.&#8221; </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Generally </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The notes will: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">be our general unsecured, senior obligations; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">initially be limited to an aggregate principal amount of $200,000,000 (or $230,000,000, if the underwriters&#8217;
over-allotment option is exercised in full); </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">bear cash interest from, and including, November 18, 2025, at an annual rate of 1.625%, payable semi-annually in arrears on
May&nbsp;15 and November&nbsp;15 of each year, beginning on November&nbsp;15, 2026; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">bear special interest in the circumstances described below under the caption &#8220;&#8212;Events of Default&#8212;Special
Interest as Sole Remedy for Certain Reporting Defaults&#8221;; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">mature on November&nbsp;15, 2031, unless earlier converted, redeemed or repurchased; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">be redeemable, in whole or in part (subject to certain limitations), at our option, at any time, and from time to time, on
or after November&nbsp;20, 2029 and on or before the 26th scheduled trading day immediately before the maturity date, at a cash redemption price equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but
excluding, the redemption date (subject to the right of noteholders on a &#8220;regular record date&#8221; (as defined below under the caption &#8220;&#8212;Interest&#8221;) to receive the related interest payment), but only if certain conditions
are satisfied, as described below under the caption &#8220;&#8212;Optional Redemption&#8221;; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">be subject to repurchase by us at the noteholders&#8217; option if a &#8220;fundamental change&#8221; (as defined below
under the caption &#8220;&#8212;Definitions&#8221;) occurs, at a cash repurchase price equal to the principal amount of the notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date (subject
to the right of noteholders on a regular record date to receive the related interest payment), as </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">
described, and subject to the limited exception set forth, below under the caption &#8220;&#8212;Fundamental Change Permits Noteholders to Require Us to Repurchase Notes&#8221;;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">be convertible, at the noteholders&#8217; option, into cash, shares of our common stock, $0.001 par value per share
(subject to the provisions described below under the caption &#8220;&#8212;Conversion Rights&#8212;Effect of Common Stock Change Event,&#8221; our &#8220;common stock&#8221;), or a combination of cash and shares of our common stock (together with
cash in lieu of any fractional share, if applicable), at our election, based on an initial conversion rate of 22.2469 shares of our common stock per $1,000 principal amount of notes (which represents an initial conversion price of approximately
$44.95 per share of our common stock), under the conditions, and subject to the adjustments, described below under the caption &#8220;&#8212;Conversion Rights&#8221;; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">be issued in principal amount denominations of $1,000 or any integral multiple of $1,000 in excess thereof, which we refer
to as an &#8220;authorized denomination&#8221;; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">initially be represented by one or more registered notes in global form, but may, in certain circumstances, be exchanged
for notes in definitive form, as described below under the caption &#8220;&#8212;Book Entry, Settlement and Clearance.&#8221; </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The indenture will
not contain any financial covenants and will not limit us or our subsidiaries from incurring additional indebtedness, paying dividends or issuing or repurchasing any securities. Except to the extent described below under the captions
&#8220;&#8212;Conversion Rights&#8212;Increase in Conversion Rate in Connection with a Make-Whole Fundamental Change,&#8221; &#8220;&#8212;Fundamental Change Permits Noteholders to Require Us to Repurchase Notes&#8221; and
&#8220;&#8212;Consolidation, Merger and Asset Sale,&#8221; the indenture will not contain any provisions designed to protect noteholders upon a highly leveraged transaction involving us or a decline in our credit rating as a result of a
recapitalization, takeover, highly leveraged transaction or other restructuring involving us. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Without the consent of any noteholder, we may issue additional notes
under the indenture with the same terms as the notes we are offering (except for certain differences, such as the date as of which interest begins to accrue and the first interest payment date for such additional notes). However, such additional
notes (and any notes that have been resold after they have been purchased or otherwise acquired by us or our subsidiaries) must be identified by one or more separate CUSIP numbers or by no CUSIP number if they are not fungible, for U.S. federal
income tax purposes, for federal securities laws purposes or for purposes of the &#8220;depositary procedures&#8221; (as defined below under the caption &#8220;&#8212;Definitions&#8221;), with the notes offered hereby or, if applicable, any other
notes we issue under the indenture. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We do not intend to list the notes on any securities exchange or include them in any automated inter-dealer quotation system.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Absent manifest error, a person in whose name a note is registered on the registrar&#8217;s books will be considered to be the holder of that note for all purposes,
and only registered noteholders (which, in the case of notes held through DTC, will initially be DTC&#8217;s nominee, Cede&nbsp;&amp; Co.) will have rights under the indenture as noteholders. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For purposes of the notes, the description below under this section titled &#8220;&#8212;Generally&#8221; supersedes, in its entirety, the information in the
accompanying prospectus under the caption &#8220;Description of Debt Securities&#8212;Repurchases in the Open Market.&#8221; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Subject to applicable law, we or our
subsidiaries may directly or indirectly repurchase notes in the open market or otherwise, whether through private or public tender or exchange offers, cash-settled swaps or other cash-settled derivatives. Any notes that we or our subsidiaries have
purchased or otherwise acquired will be deemed to remain outstanding until such time as we deliver them to the trustee for cancellation. However, subject to the terms of the indenture, notes that we or any of our affiliates own will be deemed not to
be outstanding for purposes of determining whether the noteholders have concurred in any direction, waiver or consent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Payments on the Notes </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For
purposes of the notes, the description below under this section titled &#8220;&#8212;Payments on the Notes&#8221; and in the following section titled &#8220;Registrar, Paying Agent and Conversion Agent&#8221; supersedes, in its entirety, the
information in the accompanying prospectus under the caption &#8220;Description of Debt Securities&#8212;Payment.&#8221; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will pay (or cause the paying agent to
pay) the principal of, and interest on, any global note by wire transfer of immediately available funds. We will pay (or cause the paying agent to pay) the principal of, and interest on, any physical note as follows: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">if the principal amount of such note is at least $2.0&nbsp;million (or such lower amount as we may choose in our sole and
absolute discretion) and the holder of such note entitled to such payment has delivered to the paying agent or the trustee, no later than the time set forth below, a written request to receive payment by wire transfer to an account of such holder
within the United States specified in such request, by wire transfer of immediately available funds to such account; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">in all other cases, by check mailed to the address of such holder set forth in the note register. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To be timely, a written request referred to in the first bullet point above must be delivered no later than the &#8220;close of business&#8221; (as defined below under
the caption &#8220;&#8212;Definitions&#8221;) on the following date: (i)&nbsp;with respect to the payment of any interest due on an interest payment date, the immediately preceding regular record date; (ii)&nbsp;with respect to any cash conversion
consideration, the relevant conversion date; and (iii)&nbsp;with respect to any other payment, the date that is 15 calendar days immediately before the date such payment is due. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If the due date for a payment on a note is not a &#8220;business day&#8221; (as defined below under the caption &#8220;&#8212;Definitions&#8221;), then such payment may
be made on the immediately following business day with the same force and effect as if such payment were made on that due date, and no interest will accrue on such payment as a result of the related delay. Solely for purposes of the immediately
preceding sentence, a day on which the applicable place of payment is authorized or required by law or executive order to close or be closed will be deemed not to be a &#8220;business day.&#8221; </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Registrar, Paying Agent and Conversion Agent </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will maintain one or more
offices or agencies in the continental United States where notes may be presented for registration of transfer or for exchange, payment and conversion, which we refer to as the &#8220;registrar,&#8221; &#8220;paying agent&#8221; and
&#8220;conversion agent,&#8221; respectively. We have appointed the trustee as the initial registrar, paying agent and conversion agent and its office in the United States as a place where notes may be presented for payment. However, without prior
notice to the noteholders, we may change the registrar, paying agent and conversion agent and we or any of our subsidiaries may choose to act in that capacity as well (except that the registrar, paying agent or conversion agent with respect to any
global note must at all times be a person that is eligible to act in that capacity under the depositary procedures). </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Transfers and Exchanges </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For purposes of the notes, the description below under this section titled &#8220;&#8212;Transfers and Exchanges&#8221; supersedes, in its entirety, the information in
the accompanying prospectus under the caption &#8220;Description of Debt Securities&#8212;Transfer and Exchange.&#8221; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A noteholder may transfer or exchange its
notes at the office of the registrar in accordance with the indenture. We, the trustee and the registrar may require the noteholder to, among other things, deliver appropriate endorsements or transfer instruments, and such certificates or other
documentation or evidence as we or they may reasonably require to determine that such transfer or exchange complies with applicable securities laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
In addition, we, the trustee and the registrar may refuse to register the transfer or exchange of any note that is subject to conversion, redemption or required repurchase. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have appointed the trustee&#8217;s office in the United States as a place where notes may be presented for registration of transfer or for exchange. However, we may
change the registrar or act as the registrar ourselves without prior notice to the noteholders. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Interest </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The notes will bear cash interest at an annual rate of 1.625% (which we refer to as the &#8220;stated interest&#8221;), payable semi-annually in arrears on May&nbsp;15
and November&nbsp;15 of each year, beginning on November&nbsp;15, 2026 to the noteholders of record of the notes as of the close of business on the immediately preceding May&nbsp;1 and November&nbsp;1, respectively (whether or not a business day)
(each, a &#8220;regular record date&#8221;). Interest will accrue from, and including, the last date to which interest has been paid or duly provided for (or, if no interest has been paid or duly provided for, from, and including, the date the notes
are initially issued) to, but excluding, the next interest payment date. Interest will be computed on the basis of a <FONT STYLE="white-space:nowrap">360-day</FONT> year comprised of twelve <FONT STYLE="white-space:nowrap">30-day</FONT> months. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to the stated interest on the notes referred to above, special interest will accrue on the notes in the circumstances described below under the caption
&#8220;&#8212;Events of Default&#8212;Special Interest as Sole Remedy for Certain Reporting Defaults.&#8221; All references in this prospectus supplement to interest on the notes include any special interest and default interest (as described below
under the caption &#8220;&#8212;Events of Default&#8212;Default Interest&#8221;) payable on the notes, unless the context requires otherwise. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If the first date on
which any special interest begins to accrue on any global note is on or after the fifth business day before a regular record date and before the next interest payment date, then, notwithstanding anything to the contrary, the amount thereof accruing
in respect of the period from, and including, such first date to, but excluding, such interest payment date will not be payable on such interest payment date but will instead be deemed to accrue (without duplication) entirely on such interest
payment date and be payable on the immediately succeeding interest payment date (and, for the avoidance of doubt, no interest will accrue as a result of the related delay). </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Ranking </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The notes will be our general, unsecured, senior obligations and
will be: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">senior in right of payment to our future indebtedness that is expressly subordinated in right of payment to the notes;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">equal in right of payment with our existing and future indebtedness that is not expressly subordinated to the notes;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">effectively subordinated to our existing and future secured indebtedness, to the extent of the value of the collateral
securing that indebtedness; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to
the extent we are not a holder thereof) preferred equity, if any, of our current or future subsidiaries. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The indenture will not prohibit us from
incurring additional indebtedness, including secured indebtedness, which would be effectively senior to the notes to the extent of the value of the collateral securing that indebtedness, or indebtedness that would rank equal in right of payment with
the notes. The indenture will also </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
not prohibit our subsidiaries from incurring any additional indebtedness or other liabilities that would be structurally senior to our obligations under the notes. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the event of our bankruptcy, liquidation, reorganization or other winding up, our assets that secure any indebtedness will not be available to make payments under the
notes unless all of that indebtedness is first paid in full. In the event of the bankruptcy, liquidation, reorganization or other winding up of any of our subsidiaries, we, as a &#8220;common equity&#8221; (as defined below under the caption
&#8220;&#8212;Definitions&#8221;) holder of that subsidiary, and, therefore, the noteholders, will rank behind that subsidiary&#8217;s creditors, including that subsidiary&#8217;s trade creditors, and (to the extent we are not a holder thereof) that
subsidiary&#8217;s preferred equity holders. Even if we were a creditor of any of our subsidiaries, our rights as a creditor would be effectively subordinated to any security interest of others in the assets of that subsidiary, to the extent of the
value of those assets, and would be subordinated to any indebtedness of that subsidiary that is senior in right of payment to that held by us. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our subsidiaries will
have no obligations under the notes. The ability of our subsidiaries to pay dividends or make other payments to us is restricted by, among other things, corporate and other laws and by agreements to which our subsidiaries may become a party.
Accordingly, we may be unable to gain access to the cash flow or assets of our subsidiaries to enable us to make payments on the notes. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of September&nbsp;30,
2025, the outstanding principal amount of our consolidated indebtedness for borrowed money was $50&nbsp;million, all of which was senior secured indebtedness consisting of the Term Loans. After giving effect to the issuance of the notes (assuming no
exercise of the underwriters&#8217; over-allotment option), and giving effect to the use of proceeds from this offering to repay the Term Loans in full, as of September&nbsp;30, 2025, the aggregate principal amount of our total indebtedness would
have been $200 million. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">See &#8220;Risk Factors&#8212;The notes will be effectively subordinated to our existing and future secured indebtedness and structurally
subordinated to the liabilities of our subsidiaries.&#8221; </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Optional Redemption </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may not redeem the notes at our option at any time before November&nbsp;20, 2029. Subject to the terms of the indenture, we have the right, at our election, to redeem
all, or any portion (subject to the partial redemption limitation described below) in an authorized denomination, of the notes, at any time, and from time to time, on a redemption date on or after November&nbsp;20, 2029 and on or before the 26th
&#8220;scheduled trading day&#8221; (as defined below under the caption &#8220;&#8212;Definitions&#8221;) immediately before the maturity date, for cash, but only if the &#8220;last reported sale price&#8221; (as defined below under the caption
&#8220;&#8212;Definitions&#8221;) per share of our common stock exceeds 130% of the &#8220;conversion price&#8221; (as defined below under the caption &#8220;&#8212;Definitions&#8221;) on (i)&nbsp;each of at least 20 &#8220;trading days&#8221; (as
defined below under the caption &#8220;&#8212;Definitions&#8221;), whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date we send such redemption notice; and
(ii)&nbsp;the trading day immediately before the date we send such notice. However, we will not call less than all of the outstanding notes for redemption unless the excess of the principal amount of notes outstanding as of the time we send the
related redemption notice over the aggregate principal amount of notes set forth in such redemption notice as being subject to redemption is at least $75.0&nbsp;million (such requirement, the &#8220;partial redemption limitation&#8221;). In
addition, calling any note for redemption will constitute a &#8220;make-whole fundamental change&#8221; (as defined below under the caption &#8220;&#8212;Definitions&#8221;) with respect to that note, in which case the conversion rate applicable to
the conversion of that note will be increased in certain circumstances if it is converted after it is called for redemption. If we elect to redeem less than all of the outstanding notes, then the redemption will not constitute a make-whole
fundamental change with respect to the notes not called for redemption, and holders of the notes not called for redemption will not be entitled to an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
increased conversion rate for such notes as described above on account of the redemption, except to the limited extent described further below. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The redemption date will be a day of our choosing that is no more than 50, nor less than 30, scheduled trading days after the date we send the related redemption notice,
as described below that is, as of the redemption notice date, scheduled to be a business day. However, if, in accordance with the provisions described below under the caption &#8220;&#8212;Conversion Rights&#8212;Settlement upon
Conversion&#8212;Settlement Method,&#8221; we elect to settle all conversions for notes called for redemption with a conversion date that occurs during the related make-whole fundamental change conversion period by physical settlement, then we may
instead elect to choose a redemption date that is a business day no more than 60 scheduled trading days, nor less than 15 calendar days, after the date we send such redemption notice. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The redemption price for any note called for redemption will be the principal amount of such note plus accrued and unpaid interest on such note to, but excluding, the
redemption date. However, if the redemption date is after a regular record date and on or before the next interest payment date, then (i)&nbsp;the holder of such note at the close of business on such regular record date will be entitled,
notwithstanding such redemption, to receive, on or, at our election, before such interest payment date, the unpaid interest that would have accrued on such note to, but excluding, such interest payment date; and (ii)&nbsp;the redemption price will
not include accrued and unpaid interest on such note to, but excluding, such redemption date. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will send to each applicable noteholder, the trustee, the
conversion agent (if other than the trustee) and the paying agent (if other than the trustee) notice of the redemption containing certain information set forth in the indenture, including the redemption price and the redemption date. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If only a portion of a note is subject to redemption and that note is converted in part, then the converted portion of that note will be deemed to be from the portion of
that note that was subject to redemption, subject to, in the case of any global note, applicable DTC procedures. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we elect to redeem fewer than all of the
outstanding notes, and the holder of any note, or any owner of a beneficial interest in any global note, is reasonably not able to determine, before the close of business on the 27th scheduled trading day immediately before the relevant redemption
date (or, if, as described above, we irrevocably elect physical settlement for all conversions with a conversion date that occurs during the related make-whole fundamental change conversion period, the 15th calendar day), whether such note or
beneficial interest, as applicable, is to be redeemed pursuant to such redemption, then such holder or owner, as applicable, will be entitled to convert such note or beneficial interest, as applicable, at any time before the close of business on the
second scheduled trading day immediately before such redemption date, and each such conversion will be deemed to be of a note called for redemption for purposes of these redemption provisions and the provisions described below under the captions
&#8220;&#8212;Conversion Rights&#8212;When the Notes May Be Converted&#8212;Conversion Upon Redemption&#8221; and &#8220;&#8212;Conversion Rights&#8212;Increase in Conversion Rate in Connection with a Make-Whole Fundamental Change.&#8221; For the
avoidance of doubt, each reference in this prospectus supplement to (i)&nbsp;any note that is called for redemption (or similar language) includes any note that is deemed to be called for redemption pursuant to the provision described in this
paragraph; and (ii)&nbsp;any note that is not called for redemption (or similar language) excludes any note that is deemed to be called for redemption pursuant to the provision described in this paragraph. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Notwithstanding anything to the contrary above, we may not redeem any notes if the principal amount of the notes has been accelerated and such acceleration has not been
rescinded on or before the redemption date (except as a result of the payment of the related redemption price and any related interest described above on the redemption date). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Conversion Rights </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Generally </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Noteholders will have the right to convert their notes (or
any portion of a note in an authorized denomination), in the circumstances described below, into consideration that consists, at our election, of cash, shares of our common stock or a combination of cash and shares of our common stock (together with
cash in lieu of any fractional share, if applicable), based on an initial conversion rate of 22.2469&nbsp;shares of our common stock per $1,000 principal amount of notes (which represents an initial conversion price of approximately $44.95 per share
of our common stock). </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Noteholders may convert their notes only in the circumstances described below under the caption &#8220;&#8212;When the Notes May Be
Converted.&#8221; </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Treatment of Interest Upon Conversion </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will
not adjust the conversion rate to account for any accrued and unpaid interest on any note being converted, and, except as described below, our delivery of the consideration due in respect of the conversion will be deemed to fully satisfy and
discharge our obligation to pay the principal of, and accrued and unpaid interest, if any, on, such note to, but excluding, the &#8220;conversion date&#8221; (as defined below under the caption &#8220;&#8212;Conversion Procedures&#8221;). As a
result, except as described below, any accrued and unpaid interest on a converted note will be deemed to be paid in full rather than cancelled, extinguished or forfeited. We intend to take the position that upon a conversion of notes, accrued and
unpaid interest is first paid by any cash paid upon such conversion (other than cash paid in lieu of a fractional share) and thereafter by shares of common stock. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Notwithstanding anything to the contrary above, if the conversion date of a note is after a regular record date and before the next interest payment date, then: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the holder of such note at the close of business on such regular record date will be entitled, notwithstanding such
conversion, to receive, on or, at our election, before such interest payment date, the unpaid interest that would have accrued on such note to, but excluding, such interest payment date; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the noteholder surrendering such note for conversion must deliver, at the time it surrenders such note, an amount of cash
equal to the amount of such interest. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">However, such noteholder need not deliver such cash: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">with respect to any note called for redemption, if we have specified a redemption date that is after such regular record
date and on or before the second scheduled trading day immediately after such interest payment date; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">if such conversion date occurs after the regular record date immediately before the maturity date; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">if we have specified a &#8220;fundamental change repurchase date&#8221; (as defined below under the caption
&#8220;&#8212;Fundamental Change Permits Noteholders to Require Us to Repurchase Notes&#8221;) that is after such regular record date and on or before the business day immediately after such interest payment date; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">to the extent of any overdue interest or interest that has accrued on any overdue interest. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Accordingly, for the avoidance of doubt, all noteholders as of the close of business on the regular record date immediately before the maturity date will receive the
full interest payment that would have been due on the maturity date regardless of whether their notes have been converted after such regular record date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>When the Notes May Be Converted </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Noteholders may convert their notes only in the circumstances set forth below. However, in no event may notes be converted after the close of business on the scheduled
trading day immediately before the maturity date. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial"><I>Conversion Upon Satisfaction of Common Stock Sale Price Condition </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Before the close of business on the business day immediately before August&nbsp;15, 2031, a noteholder may convert its notes during any calendar quarter (and only during
such calendar quarter) commencing after the calendar quarter ending on March&nbsp;31, 2026, if the last reported sale price per share of our common stock exceeds 130% of the conversion price for each of at least 20 trading days, whether or not
consecutive, during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial"><I>Conversion Upon Satisfaction of Note Trading Price Condition </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Before the close of business on the business day immediately before August&nbsp;15, 2031, a noteholder may convert its notes during the five consecutive business days
immediately after any 10 consecutive trading day period (such 10 consecutive trading day period, the &#8220;measurement period&#8221;) if the &#8220;trading price&#8221; (as defined below under the caption &#8220;&#8212;Definitions&#8221;) per
$1,000 principal amount of notes, as determined following a request by a noteholder or noteholders in accordance with the procedures described below, for each trading day of the measurement period was less than 98% of the product of the last
reported sale price per share of our common stock on such trading day and the conversion rate on such trading day. We refer to this condition as the &#8220;trading price condition.&#8221; </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The trading price will be determined by the bid solicitation agent as described below and in the definition of &#8220;trading price.&#8221; The bid solicitation agent
(if not us) will have no obligation to determine the trading price of the notes unless we have requested such determination in writing, and we will have no obligation to make such request (or seek bids ourselves) unless a noteholder or noteholders
holding at least $5,000,000 principal amount of notes provide(s) us with reasonable evidence that the trading price per $1,000 principal amount of notes would be less than 98% of the product of the last reported sale price per share of our common
stock and the conversion rate. If a noteholder or noteholders provide(s) such evidence, then we will instruct the bid solicitation agent to (or, if we are acting as the bid solicitation agent, we will) determine the trading price of the notes
beginning on the next trading day and on each successive trading day until the trading price per $1,000 principal amount of notes is greater than or equal to 98% of the product of the last reported sale price per share of our common stock on such
trading day and the conversion rate on such trading day. If the trading price condition has been met as described above, then we will notify the noteholders, the trustee and the conversion agent (if other than the trustee) of the same. If, on any
trading day after the trading price condition has been met as described above, the trading price per $1,000 principal amount of notes is greater than or equal to 98% of the product of the last reported sale price per share of our common stock on
such trading day and the conversion rate on such trading day, then we will notify the noteholders, the trustee and the conversion agent (if other than the trustee) of the same. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will act as the initial bid solicitation agent. However, we may change the bid solicitation agent, and we may appoint any of our subsidiaries to act in that capacity
as well, without prior notice to the noteholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial"><I>Conversion Upon Specified Corporate Events </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:arial"><I>Certain Distributions </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If, before the close of business on the
business day immediately before August&nbsp;15, 2031, we elect to: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">distribute, to all or substantially all holders of our common stock, any rights, options or warrants (other than rights
issued pursuant to a stockholder rights plan, so long as such rights have not separated from our common stock and are not exercisable until the occurrence of a triggering event, except that such rights will be deemed to be distributed under this
bullet point upon their separation from our common stock or upon the occurrence of such triggering event) entitling them, for a period of not more than 60 calendar days after the record date of such distribution, to subscribe for or purchase shares
of our common stock at a price per share that is less than the average of the last reported sale prices per share of our common stock for the 10 consecutive trading days ending on, and including, the trading day immediately before the date such
distribution is announced (determined in accordance with the provisions described in the third paragraph of clause (2)&nbsp;under the heading &#8220;&#8212;Conversion Rate Adjustments&#8212;Generally&#8221; below); or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">distribute, to all or substantially all holders of our common stock, assets or securities of ours or rights to purchase our
securities, which distribution per share of our common stock has a value, as reasonably determined by our board of directors, exceeding 10% of the last reported sale price per share of our common stock on the trading day immediately before the date
such distribution is announced, </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">then, in either case, we will send written notice of such distribution, and of the related right to convert notes,
to noteholders, the trustee and the conversion agent (if other than the trustee) at least 30 scheduled trading days before the <FONT STYLE="white-space:nowrap">&#8220;ex-dividend</FONT> date&#8221; (as defined below under the caption
&#8220;&#8212;Definitions&#8221;) for such distribution (or, if later in the case of any such separation of rights issued pursuant to a stockholder rights plan or the occurrence of any such triggering event under a stockholder rights plan, as soon
as reasonably practicable after we become aware that such separation or triggering event has occurred or will occur). However, if we are then otherwise permitted to settle conversions by physical settlement (and, for the avoidance of doubt, we have
not elected (or been deemed to have elected) another settlement method to apply, including pursuant to the provision described in the third sentence under the caption &#8220;&#8212;Settlement upon Conversion&#8212;Settlement Method&#8221; below),
then we may instead elect to provide such notice at least 10 scheduled trading days before such <FONT STYLE="white-space:nowrap">ex-dividend</FONT> date. In that event, we will be required to settle all conversions with a conversion date occurring
on or after the date we provide such notice and on or before the business day immediately before the <FONT STYLE="white-space:nowrap">ex-dividend</FONT> date for such distribution (or any earlier announcement by us that such distribution will not
take place) by physical settlement, and we will describe the same in the notice. Once we have sent such notice, noteholders may convert their notes at any time until the earlier of the close of business on the business day immediately before such <FONT
STYLE="white-space:nowrap">ex-dividend</FONT> date and our announcement that such distribution will not take place. However, the notes will not become convertible on account of such distribution (but we will still be required to send notice of such
distribution as described above) if each noteholder participates, at the same time and on the same terms as holders of our common stock, and solely by virtue of being a noteholder, in such distribution without having to convert such
noteholder&#8217;s notes and as if such noteholder held a number of shares of our common stock equal to the product of (i)&nbsp;the conversion rate in effect on the record date for such distribution; and (ii)&nbsp;the aggregate principal amount
(expressed in thousands) of notes held by such noteholder on such record date. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:arial"><I>Certain Corporate Events </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If a fundamental change, make-whole fundamental change (other than a make-whole fundamental change pursuant to clause (ii)&nbsp;of the definition thereof) or
&#8220;common stock change event&#8221; (as defined below under the caption &#8220;&#8212;Effect of Common Stock Change Event&#8221;) occurs (other than a merger or other business combination </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
transaction that is effected solely to change our jurisdiction of incorporation and that does not constitute a fundamental change or a make-whole fundamental change), then, in each case,
noteholders may convert their notes at any time from, and including, the effective date of such transaction or event to, and including, the 35th trading day after such effective date (or, if such transaction or event also constitutes a fundamental
change (other than an &#8220;exempted fundamental change,&#8221; as defined below under the caption &#8220;&#8212;Fundamental Change Permits Noteholders to Require Us to Repurchase Notes&#8212;No Repurchase Right in Certain Circumstances&#8221;),
to, but excluding, the related fundamental change repurchase date). No later than the second business day after such effective date, we will send written notice to the noteholders, the trustee and the conversion agent (if other than the trustee) of
such transaction or event, such effective date and the related right to convert notes. If we do not provide such notice by the second business day after the effective date, then the last day on which the notes are convertible will be extended by the
number of business days from, and including, the second business day after the effective date to, but excluding, the date we provide the notice. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:arial"><I>Conversion Upon Redemption </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we call any note for
redemption, then the holder of such note may convert such note at any time before the close of business on the second scheduled trading day immediately before the related redemption date (or, if we fail to pay the redemption price due on such
redemption date in full, at any time until such time as we pay such redemption price in full). </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:arial"><I>Conversions During Free Convertibility Period
</I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A noteholder may convert its notes at any time from, and including, August&nbsp;15, 2031 until the close of business on the scheduled trading day immediately
before the maturity date. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Conversion Procedures </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To convert a
beneficial interest in a global note, the owner of the beneficial interest must: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">comply with the depositary procedures for converting the beneficial interest (at which time such conversion will become
irrevocable unless we, in our sole and absolute discretion, agree to permit the owner of the beneficial interest to withdraw such conversion and such withdrawal is reasonably feasible pursuant to the procedures of the DTC and we deliver a direction
to the conversion agent permitting such withdrawal); </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">if applicable, pay any interest payable on the next interest payment date, as described above under the caption
&#8220;&#8212;Treatment of Interest Upon Conversion&#8221;; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">if applicable, pay any documentary or other taxes as described below. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To convert all or a portion of a physical note, the holder of such note must: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">complete, manually sign and deliver to the conversion agent the conversion notice attached to such note or a facsimile of
such conversion notice; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">deliver such note to the conversion agent (at which time such conversion will become irrevocable unless we, in our sole and
absolute discretion agree to permit the owner of the certificated note to withdraw such conversion and we deliver a direction to the conversion agent permitting such withdrawal); </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">furnish any endorsements and transfer documents that we or the conversion agent may require; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">if applicable, pay any interest payable on the next interest payment date, as described above under the caption
&#8220;&#8212;Treatment of Interest Upon Conversion&#8221;; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">if applicable, pay any documentary or other taxes as described below. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Notes may be surrendered for conversion during a period where the notes are convertible as described herein only after
the &#8220;open of business&#8221; (as defined below under the caption &#8220;&#8212;Definitions&#8221;) and before the close of business on a day that is a business day. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will pay any documentary, stamp or similar issue or transfer tax or duty due on the issue or delivery of any shares of our common stock upon conversion, except any
tax or duty that is due because the converting noteholder requests those shares to be registered in a name other than the noteholder&#8217;s name, in which case the noteholder will pay such tax. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We refer to the first business day on which the requirements described above to convert a note are satisfied as the &#8220;conversion date.&#8221; </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If a noteholder has validly delivered a &#8220;fundamental change repurchase notice&#8221; (as defined below under the caption &#8220;&#8212;Fundamental Change Permits
Noteholders to Require Us to Repurchase Notes&#8221;) with respect to a note, then such note may not be converted, except to the extent (i)&nbsp;such notice is withdrawn in accordance with the procedures described below; or (ii)&nbsp;we fail to pay
the related fundamental change repurchase price for such note when required (or a third party fails to make such payment in lieu of us in accordance with the provisions described below under the caption &#8220;&#8212;Fundamental Change Permits
Noteholders to Require Us to Repurchase Notes&#8212;Repurchase by Third Party&#8221;). </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Settlement Upon Conversion </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial"><I>Generally </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon conversion, we may choose to pay or deliver,
as applicable, cash (&#8220;cash settlement&#8221;), shares of our common stock (&#8220;physical settlement&#8221;) or a combination of cash and shares of our common stock (&#8220;combination settlement&#8221;), as described below. We refer to each
of these settlement methods as a &#8220;settlement method.&#8221; If cash settlement or combination settlement applies to a conversion, then the consideration due will be determined based on the conversion rate, the &#8220;daily VWAPs&#8221; per
share of our common stock over an &#8220;observation period&#8221; consisting of 25<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>consecutive &#8220;VWAP trading days&#8221; and, in the case of combination settlement, the &#8220;specified
dollar amount&#8221; (as those terms are defined below under the caption &#8220;&#8212;Definitions&#8221;) that applies to the conversion. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial"><I>Settlement Method </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will have the right, as described
below, to elect the settlement method applicable to the conversion of any notes. Except as described below, we must use the same settlement method for all conversions with the same conversion date, but we will not be obligated to use the same
settlement method for conversions with different conversion dates. All conversions with a conversion date that occurs on or after August&nbsp;15, 2031 will be settled using the same settlement method, and we will send notice of such settlement
method to noteholders, with a copy to the trustee and the conversion agent (if other than the trustee), no later than the open of business on August&nbsp;15, 2031. If we elect a settlement method for a conversion with a conversion date that occurs
before August&nbsp;15, 2031, then we will send notice of such settlement method to the converting noteholder, with a copy to the trustee and the conversion agent (if other than the trustee), no later than the close of business on the business day
immediately after the conversion date. Notwithstanding anything to the contrary described above, if we call any notes for redemption, then (i)&nbsp;we will specify in the related redemption notice (and, in the case of a redemption of less than all
outstanding notes, in a notice simultaneously sent to all holders of notes not called for redemption) the settlement method that will apply to all conversions with a conversion date that occurs on or after the date we send such redemption notice and
on or before the second scheduled trading day before the related redemption date; and (ii)&nbsp;if the related redemption date is on or after August&nbsp;15, 2031, then such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
settlement method must be the same settlement method that applies to all conversions with a conversion date that occurs on or after August&nbsp;15, 2031. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we do not timely elect a settlement method with respect to any conversion, then we will be deemed to have elected the &#8220;default settlement method&#8221; (as
defined below). If we timely elect combination settlement with respect to a conversion but do not timely notify the converting noteholder of the applicable specified dollar amount, then the specified dollar amount for such conversion will be deemed
to be $1,000 per $1,000 principal amount of notes. For the avoidance of doubt, our failure to timely elect a settlement method or specify the applicable specified dollar amount will not constitute a default under the indenture. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The &#8220;default settlement method&#8221; will initially be combination settlement with a specified dollar amount per $1,000 principal amount of notes of $1,000.
However, we may, from time to time, change the default settlement method to any settlement method that we are then permitted to elect by sending notice of the new default settlement method to the noteholders, the trustee and the conversion agent (if
other than the trustee). In addition, we may, by notice to the noteholders, the trustee and the conversion agent (if other than the trustee), elect to irrevocably fix the settlement method or to irrevocably eliminate any one or more (but not all)
settlement methods (including eliminating combination settlement with a particular specified dollar amount or range of specified dollar amounts), provided we are then otherwise permitted to elect the settlement method so irrevocably elected or the
settlement method(s) remaining after such irrevocable elimination, as applicable. If we make such an irrevocable election, then such election will apply to all note conversions with a conversion date that is on or after the date we send such notice
and we will, if needed, simultaneously change the default settlement method to a settlement method that is consistent with such irrevocable election. However, in all cases, no such irrevocable election or default settlement method change will affect
any settlement method theretofore elected (or deemed to be elected) with respect to any note pursuant to the indenture. For the avoidance of doubt, such an irrevocable election, if made, will be effective without the need to amend the indenture or
the notes, including pursuant to the provisions described in the seventh bullet point of the third paragraph under the caption &#8220;&#8212;Modification and Amendment&#8221; below. However, we may nonetheless choose to execute such an amendment at
our option. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we change the default settlement method or irrevocably fix the settlement method pursuant to the provisions described above, then we will,
substantially concurrently, either post the default settlement method or fixed settlement method, as applicable, on our website or disclose the same in a current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (or any successor form) that
is filed with, or furnished to, the SEC. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial"><I>Consideration Due Upon Conversion </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Subject to the other provisions described in this section, the consideration due upon conversion of each $1,000 principal amount of a note will be as follows: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">if physical settlement applies, a number of shares of our common stock equal to the conversion rate in effect on the
conversion date for such conversion; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">if cash settlement applies, cash in an amount equal to the sum of the &#8220;daily conversion values&#8221; (as defined
below under the caption &#8220;&#8212;Definitions&#8221;) for each VWAP trading day in the observation period for such conversion; or </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">if combination settlement applies, (i)&nbsp;a number of shares of our common stock equal to the sum of the &#8220;daily
share amounts&#8221; (as defined below under the caption &#8220;&#8212;Definitions&#8221;) for each VWAP trading day in the observation period for such conversion; and (ii)&nbsp;an amount of cash equal to the sum of the &#8220;daily cash
amounts&#8221; (as defined below under the caption &#8220;&#8212;Definitions&#8221;) for each VWAP trading day in such observation period. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">However, in lieu of delivering any fractional share of our common stock otherwise due upon conversion, we will pay
cash based on (i)&nbsp;the daily VWAP on the applicable conversion date (or, if such conversion date is not a VWAP trading day, the immediately preceding VWAP trading day), in the case of physical settlement; or (ii)&nbsp;the daily VWAP on the last
VWAP trading day of the applicable observation period, in the case of combination settlement. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If a noteholder converts more than one note on a conversion date, then
the consideration due upon such conversion will (in the case of any global note, to the extent permitted by, and practicable under, the depositary procedures) be computed based on the total principal amount of notes converted on such conversion date
by that noteholder. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial"><I>Delivery of the Conversion Consideration </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Except as described below under the captions &#8220;&#8212;Conversion Rate Adjustments&#8221; and &#8220;&#8212;Effect of Common Stock Change Event,&#8221; we will pay
or deliver, as applicable, the consideration due upon conversion as follows: (i)&nbsp;if cash settlement or combination settlement applies, on or before the second business day immediately after the last VWAP trading day of the observation period
for such conversion; and (ii)&nbsp;if physical settlement applies, on or before the second business day immediately after the conversion date for such conversion. However, if physical settlement applies to the conversion of any note with a
conversion date that is after the regular record date immediately before the maturity date, then, solely for purposes of such conversion, we will pay or deliver, as applicable, the consideration due upon such conversion on or before the maturity
date (or, if the maturity date is not a business day, the next business day) and the conversion date will instead be deemed to be the scheduled trading day immediately before the maturity date. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>When Converting Noteholders Become Stockholders of Record </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The person
in whose name any share of our common stock is issuable upon conversion of any note will be deemed to become the holder of record of that share as of the close of business on (i)&nbsp;the conversion date for such conversion, in the case of physical
settlement; or (ii)&nbsp;the last VWAP trading day of the observation period for such conversion, in the case of combination settlement. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Conversion Rate
Adjustments </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial"><I>Generally </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The conversion rate will
be adjusted for the events described below. However, we are not required to adjust the conversion rate for these events (other than a stock split or combination or a tender or exchange offer) if each noteholder participates, at the same time and on
the same terms as holders of our common stock, and solely by virtue of being a holder of notes, in such transaction or event without having to convert such noteholder&#8217;s notes and as if such noteholder held a number of shares of our common
stock equal to the product of (i)&nbsp;the conversion rate in effect on the related record date; and (ii)&nbsp;the aggregate principal amount (expressed in thousands) of notes held by such noteholder on such date. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(1)&#8195;<I>Stock Dividends, Splits and Combinations</I>. If we issue solely shares of our common stock as a<I> </I>dividend or distribution on all or substantially all
shares of our common stock, or if we effect a stock split or a stock combination of our common stock (in each case excluding an issuance solely pursuant to a common stock change event, as to which the provisions described below under the caption
&#8220;&#8212;Effect of Common Stock Change Event&#8221; will apply), then the conversion rate will be adjusted based on the following formula: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g159388g40n40.jpg" ALT="LOGO" STYLE="width:1.09182in;height:0.396469in;">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">where: </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>CR</I><I><SUB
STYLE="font-size:75%; vertical-align:bottom">0</SUB></I>&#8195;&#061; the conversion rate in effect immediately before the open of business on the <FONT STYLE="white-space:nowrap">ex-dividend</FONT> date for such dividend or distribution, or
immediately before the open of business on the &#8220;effective date&#8221; (as defined below under the caption &#8220;&#8212;Definitions&#8221;) of such stock split or stock combination, as applicable; </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>CR</I><I><SUB STYLE="font-size:75%; vertical-align:bottom">1</SUB></I>&#8195;&#061; the conversion rate in effect immediately after the open of business on such <FONT
STYLE="white-space:nowrap">ex-dividend</FONT> date or effective date, as applicable; </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>OS</I><I><SUB STYLE="font-size:75%; vertical-align:bottom">0</SUB></I>&#8195;&#061; the number of shares of our common stock outstanding immediately before the open
of business on such <FONT STYLE="white-space:nowrap">ex-dividend</FONT> date or effective date, as applicable, without giving effect to such dividend, distribution, stock split or stock combination; and </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>OS</I><I><SUB STYLE="font-size:75%; vertical-align:bottom">1</SUB></I>&#8195;&#061; the number of shares of our common stock outstanding immediately after giving
effect to such dividend, distribution, stock split or stock combination. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If any dividend, distribution, stock split or stock combination of the type described in
this paragraph (1)&nbsp;is declared or announced, but not so paid or made, then the conversion rate will be readjusted, effective as of the date our board of directors determines not to pay such dividend or distribution or to effect such stock split
or stock combination, to the conversion rate that would then be in effect had such dividend, distribution, stock split or stock combination not been declared or announced. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(2)&#8195;<I>Rights, Options and Warrants</I>. If we distribute, to all or substantially all holders of our common stock,<I> </I>rights, options or warrants (other than
rights issued or otherwise distributed pursuant to a stockholder rights plan, as to which the provisions described below in paragraph (3)(a) and under the caption &#8220;&#8212;Stockholder Rights Plans&#8221; will apply) entitling such holders, for
a period of not more than 60 calendar days after the record date of such distribution, to subscribe for or purchase shares of our common stock at a price per share that is less than the average of the last reported sale prices per share of our
common stock for the 10 consecutive trading days ending on, and including, the trading day immediately before the date such distribution is announced, then the conversion rate will be increased based on the following formula: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g159388g41n41.jpg" ALT="LOGO" STYLE="width:1.23282in;height:0.340087in;">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">where: </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>CR</I><I><SUB
STYLE="font-size:75%; vertical-align:bottom">0</SUB></I>&#8195;&#061; the conversion rate in effect immediately before the open of business on the <FONT STYLE="white-space:nowrap">ex-dividend</FONT> date for such distribution; </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>CR</I><I><SUB STYLE="font-size:75%; vertical-align:bottom">1</SUB></I>&#8195;&#061; the conversion rate in effect immediately after the open of business on such <FONT
STYLE="white-space:nowrap">ex-dividend</FONT> date; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>OS</I>&#8195;&#061; the number of shares of our common stock outstanding immediately before the open of
business on such ex-dividend date; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>X</I>&#8195;&#061; the total number of shares of our common stock issuable pursuant to such rights, options or warrants; and
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Y</I>&#8195;&#061; a number of shares of our common stock obtained by dividing (x)&nbsp;the aggregate price payable to exercise such rights, options or warrants
by (y)&nbsp;the average of the last reported sale prices per share of our common stock for the 10 consecutive trading days ending on, and including, the trading day immediately before the date such distribution is announced. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To the extent such rights, options or warrants are not so distributed, the conversion rate will be readjusted to the conversion rate that would then be in effect had the
increase to the conversion rate for such distribution </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
been made on the basis of only the rights, options or warrants, if any, actually distributed. In addition, to the extent that shares of our common stock are not delivered after the expiration of
such rights, options or warrants (including as a result of such rights, options or warrants not being exercised), the conversion rate will be readjusted to the conversion rate that would then be in effect had the increase to the conversion rate for
such distribution been made on the basis of delivery of only the number of shares of our common stock actually delivered upon exercise of such rights, options or warrants. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For purposes of this paragraph (2)&nbsp;and the provisions described above under the caption &#8220;&#8212;When the Notes May Be Converted&#8212;Conversion Upon
Specified Corporate Events&#8212;Certain Distributions,&#8221; in determining whether any rights, options or warrants entitle holders of our common stock to subscribe for or purchase shares of our common stock at a price per share that is less than
the average of the last reported sale prices per share of our common stock for the 10 consecutive trading days ending on, and including, the trading day immediately before the date the distribution of such rights, options or warrants is announced,
and in determining the aggregate price payable to exercise such rights, options or warrants, there will be taken into account any consideration we receive for such rights, options or warrants and any amount payable on exercise thereof, with the
value of such consideration, if not cash, to be determined by us in good faith and in a commercially reasonable manner. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(3)&#8195;<I>Spin-Offs and Other Distributed
Property</I>. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(a)&#8195;<I>Distributions Other Than Spin-Offs</I>. If we distribute shares of our &#8220;capital stock&#8221; (as defined<I> </I>below under the
caption &#8220;&#8212;Definitions&#8221;), evidences of our indebtedness or other assets or property of ours, or rights, options or warrants to acquire our capital stock or other securities, to all or substantially all holders of our common stock,
excluding: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">dividends, distributions, rights, options or warrants for which an adjustment to the conversion rate is required (or would
be required without regard to the &#8220;deferral exception&#8221; (as defined below under the caption &#8220;&#8212;The Deferral Exception&#8221;)) pursuant to paragraph (1)&nbsp;or (2) above; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">dividends or distributions paid exclusively in cash for which an adjustment to the conversion rate is required (or would be
required without regard to the deferral exception) pursuant to paragraph (4)&nbsp;below; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">rights issued or otherwise distributed pursuant to a stockholder rights plan, except to the extent provided below under the
caption &#8220;&#8212;Stockholder Rights Plans&#8221;; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">spin-offs for which an adjustment to the conversion rate is required (or would be required without regard to the deferral
exception) pursuant to paragraph (3)(b) below; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a distribution solely pursuant to a tender offer or exchange offer for shares of our common stock, as to which the
provisions described below in paragraph (5)&nbsp;will apply; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a distribution solely pursuant to a common stock change event, as to which the provisions described below under the caption
&#8220;&#8212;Effect of Common Stock Change Event&#8221; will apply, then the conversion rate will be increased based on the following formula: </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g159388g42n42.jpg" ALT="LOGO" STYLE="width:1.41758in;height:0.339503in;">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">where: </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>CR</I><I><SUB
STYLE="font-size:75%; vertical-align:bottom">0</SUB></I>&#8195;&#061; the conversion rate in effect immediately before the open of business on the <FONT STYLE="white-space:nowrap">ex-dividend</FONT> date for such distribution; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>CR</I><I><SUB STYLE="font-size:75%; vertical-align:bottom">1</SUB></I>&#8195;&#061; the conversion rate in effect
immediately after the open of business on such <FONT STYLE="white-space:nowrap">ex-dividend</FONT> date; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>SP</I>&#8195; &#061; the average of the last reported
sale prices per share of our common stock for the 10 consecutive trading days ending on, and including, the trading day immediately before such <FONT STYLE="white-space:nowrap">ex-dividend</FONT> date; and </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>FMV</I>&#8195;&#061; the fair market value (as determined by us in good faith and in a commercially reasonable manner), as of such
<FONT STYLE="white-space:nowrap">ex-dividend</FONT> date, of the shares of capital stock, evidences of indebtedness, assets, property, rights, options or warrants distributed per share of our common stock pursuant to such distribution. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">However, if <I>FMV</I> is equal to or greater than <I>SP</I>, then, in lieu of the foregoing adjustment to the conversion rate, each noteholder will receive, for each
$1,000 principal amount of notes held by such noteholder on the record date for such distribution, at the same time and on the same terms as holders of our common stock, and without having to convert its notes, the amount and kind of shares of
capital stock, evidences of indebtedness, assets, property, rights, options or warrants that such noteholder would have received in such distribution if such noteholder had owned, on such record date, a number of shares of our common stock equal to
the conversion rate in effect on such record date. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To the extent such distribution is not so paid or made, the conversion rate will be readjusted to the conversion
rate that would then be in effect had the adjustment been made on the basis of only the distribution, if any, actually made or paid. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(b)&#8195;<I>Spin-Offs</I>. If
we distribute or dividend shares of capital stock of any class or series, or similar<I> </I>equity interests, of or relating to an &#8220;affiliate&#8221; or &#8220;subsidiary&#8221; (as those terms are defined below under the caption
&#8220;&#8212;Definitions&#8221;) or other business unit of ours to all or substantially all holders of our common stock (other than solely pursuant to (x)&nbsp;a common stock change event, as to which the provisions described below under the
caption &#8220;&#8212;Effect of Common Stock Change Event&#8221; will apply; or (y)&nbsp;a tender offer or exchange offer for shares of our common stock, as to which the provisions described below in paragraph (5)&nbsp;will apply), and such capital
stock or equity interests are listed or quoted (or will be listed or quoted upon the consummation of the transaction) on a U.S. national securities exchange (a <FONT STYLE="white-space:nowrap">&#8220;spin-off&#8221;),</FONT> then the conversion rate
will be increased based on the following formula: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g159388g43n43.jpg" ALT="LOGO" STYLE="width:1.41789in;height:0.339325in;">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">where: </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>CR</I><I><SUB
STYLE="font-size:75%; vertical-align:bottom">0</SUB></I>&#8195;&#061; the conversion rate in effect immediately before the close of business on the last trading day of the <FONT STYLE="white-space:nowrap">&#8220;spin-off</FONT> valuation
period&#8221; (as defined below) for such <FONT STYLE="white-space:nowrap">spin-off;</FONT> </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>CR</I><I><SUB STYLE="font-size:75%; vertical-align:bottom">1</SUB></I>&#8195;&#061; the conversion rate in effect immediately after the close of business on the last
trading day of the <FONT STYLE="white-space:nowrap">spin-off</FONT> valuation period; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>FMV</I>&#8195;&#061; the product of (x)&nbsp;the average of the last
reported sale prices per share or unit of the capital stock or equity interests distributed in such <FONT STYLE="white-space:nowrap">spin-off</FONT> over the 10 consecutive trading day period (the
<FONT STYLE="white-space:nowrap">&#8220;spin-off</FONT> valuation period&#8221;) beginning on, and including, the <FONT STYLE="white-space:nowrap">ex-dividend</FONT> date for such <FONT STYLE="white-space:nowrap">spin-off</FONT> (such average to be
determined as if references to our common stock in the definitions of &#8220;last reported sale price,&#8221; &#8220;trading day&#8221; and &#8220;market disruption event&#8221; were instead references to such capital stock or equity interests); and
(y)&nbsp;the number of shares or units of such capital stock or equity interests distributed per share of our common stock in such <FONT STYLE="white-space:nowrap">spin-off;</FONT> and </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>SP</I>&#8195; &#061; the average of the last reported sale prices per share of our common stock for each trading day in the
<FONT STYLE="white-space:nowrap">spin-off</FONT> valuation period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Notwithstanding anything to the contrary, (i)&nbsp;if any VWAP trading day of the observation period for a note whose
conversion will be settled pursuant to cash settlement or combination settlement occurs during the <FONT STYLE="white-space:nowrap">spin-off</FONT> valuation period for such <FONT STYLE="white-space:nowrap">spin-off,</FONT> then, solely for purposes
of determining the conversion rate for such VWAP trading day for such conversion, such <FONT STYLE="white-space:nowrap">spin-off</FONT> valuation period will be deemed to consist of the trading days occurring in the period from, and including, the <FONT
STYLE="white-space:nowrap">ex-dividend</FONT> date for such <FONT STYLE="white-space:nowrap">spin-off</FONT> to, and including, such VWAP trading day; and (ii)&nbsp;if the conversion date for a note whose conversion will be settled pursuant to
physical settlement occurs during the <FONT STYLE="white-space:nowrap">spin-off</FONT> valuation period for such <FONT STYLE="white-space:nowrap">spin-off,</FONT> then, solely for purposes of determining the consideration due in respect of such
conversion, such <FONT STYLE="white-space:nowrap">spin-off</FONT> valuation period will be deemed to consist of the trading days occurring in the period from, and including, the <FONT STYLE="white-space:nowrap">ex-dividend</FONT> date for such <FONT
STYLE="white-space:nowrap">spin-off</FONT> to, and including, such conversion date. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To the extent any dividend or distribution of the type described above in this
paragraph (3)(b) is declared but not made or paid, the conversion rate will be readjusted to the conversion rate that would then be in effect had the adjustment been made on the basis of only the dividend or distribution, if any, actually made or
paid. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(4)&#8195;<I>Cash Dividends or Distributions</I>. If any cash dividend or distribution is made to all or substantially all<I> </I>holders of our common stock,
then the conversion rate will be increased based on the following formula: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g159388g01n44.jpg" ALT="LOGO" STYLE="width:1.19451in;height:0.338742in;">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">where: </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>CR</I><I><SUB
STYLE="font-size:75%; vertical-align:bottom">0</SUB></I><I> </I>&#061; the conversion rate in effect immediately before the open of business on the <FONT STYLE="white-space:nowrap">ex-dividend</FONT><I> </I>date for such dividend or distribution;
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>CR</I><I><SUB STYLE="font-size:75%; vertical-align:bottom">1</SUB></I>&#8195;&#061; the conversion rate in effect immediately after the open of business on such <FONT
STYLE="white-space:nowrap">ex-dividend</FONT> date; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>SP</I>&#8195;&#061; the last reported sale price per share of our common stock on the trading day immediately
before such <FONT STYLE="white-space:nowrap">ex-dividend</FONT> date; and </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>D</I>&#8195;&#061; the cash amount distributed per share of our common stock in such
dividend or distribution. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">However, if <I>D</I> is equal to or greater than <I>SP</I>, then, in lieu of the foregoing adjustment to the conversion rate, each
noteholder will receive, for each $1,000 principal amount of notes held by such noteholder on the record date for such dividend or distribution, at the same time and on the same terms as holders of our common stock, and without having to convert its
notes, the amount of cash that such noteholder would have received in such dividend or distribution if such noteholder had owned, on such record date, a number of shares of our common stock equal to the conversion rate in effect on such record date.
To the extent such dividend or distribution is declared but not made or paid, the conversion rate will be readjusted to the conversion rate that would then be in effect had the adjustment been made on the basis of only the dividend or distribution,
if any, actually made or paid. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>(5)</I>&#8195;<I>Tender Offers or Exchange Offers</I>. If we or any of our subsidiaries makes a payment in respect of a<I>
</I>tender offer or exchange offer for shares of our common stock (other than solely pursuant to an <FONT STYLE="white-space:nowrap">odd-lot</FONT> tender offer pursuant to Rule <FONT STYLE="white-space:nowrap">13e-4(h)(5)</FONT> under the Exchange
Act), and the value (determined as of the expiration time by us in good faith and in a commercially reasonable manner) of the cash and other consideration paid or payable per share of our common stock in such tender or exchange offer exceeds the
last reported sale price per share of our common stock on the trading day immediately after the last date (the &#8220;expiration date&#8221;) on which tenders or exchanges may be made pursuant to such tender or exchange offer (as it may be amended),
then the conversion rate will be increased based on the following formula: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g159388g02n44.jpg" ALT="LOGO" STYLE="width:1.50067in;height:0.367633in;">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">where: </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>CR</I><I><SUB
STYLE="font-size:75%; vertical-align:bottom">0</SUB></I>&#8195;&#061; the conversion rate in effect immediately before the close of business on the last trading day of the &#8220;tender/exchange offer valuation period&#8221; (as defined below) for
such tender or exchange offer; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>CR</I><I><SUB STYLE="font-size:75%; vertical-align:bottom">1</SUB></I>&#8195;&#061; the conversion rate in effect immediately
after the close of business on the last trading day of the tender/exchange offer valuation period; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>AC</I>&#8195;&#061; the aggregate value (determined as of the
time (the &#8220;expiration time&#8221;) such tender or exchange offer expires by us in good faith and in a commercially reasonable manner) of all cash and other consideration paid or payable for shares of our common stock purchased or exchanged in
such tender or exchange offer; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>OS</I><I><SUB STYLE="font-size:75%; vertical-align:bottom">0</SUB></I>&#8195;&#061; the number of shares of our common stock
outstanding immediately before the expiration time (including all shares of our common stock accepted for purchase or exchange in such tender or exchange offer); </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>OS</I><I><SUB STYLE="font-size:75%; vertical-align:bottom">1</SUB></I>&#8195;&#061; the number of shares of our common stock outstanding immediately after the
expiration time (excluding all shares of our common stock accepted for purchase or exchange in such tender or exchange offer); and </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>SP</I>&#8195;&#061; the
average of the last reported sale prices per share of our common stock over the 10 consecutive trading day period (the &#8220;tender/exchange offer valuation period&#8221;) beginning on, and including, the trading day immediately after the
expiration date; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>provided</I>,<I> however</I>, that the conversion rate will in no event be adjusted down pursuant to the<I> </I>provisions described in this
paragraph (5), except to the extent provided in the immediately following paragraph. Notwithstanding anything to the contrary, (i)&nbsp;if any VWAP trading day of the observation period for a note whose conversion will be settled pursuant to cash
settlement or combination settlement occurs during the tender/exchange offer valuation period for such tender or exchange offer, then, solely for purposes of determining the conversion rate for such VWAP trading day for such conversion, such
tender/exchange offer valuation period will be deemed to consist of the trading days occurring in the period from, and including, the trading day immediately after the expiration date for such tender or exchange offer to, and including, such VWAP
trading day; and (ii)&nbsp;if the conversion date for a note whose conversion will be settled pursuant to physical settlement occurs during the tender/exchange offer valuation period for such tender or exchange offer, then, solely for purposes of
determining the consideration due in respect of such conversion, such tender/exchange offer valuation period will be deemed to consist of the trading days occurring in the period from, and including, the trading day immediately after the expiration
date to, and including, such conversion date. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To the extent such tender or exchange offer is announced but not consummated (including as a result of being precluded
from consummating such tender or exchange offer under applicable law), or any purchases or exchanges of shares of our common stock in such tender or exchange offer are rescinded, the conversion rate will be readjusted to the conversion rate that
would then be in effect had the adjustment been made on the basis of only the purchases or exchanges of shares of our common stock, if any, actually made, and not rescinded, in such tender or exchange offer. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will not be required to adjust the conversion rate except as described above or below under the caption &#8220;&#8212;Increase in Conversion Rate in Connection with a
Make-Whole Fundamental Change.&#8221; Without limiting the foregoing, we will not be required to adjust the conversion rate on account of: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">except as described above, the sale of shares of our common stock for a purchase price that is less than the market price
per share of our common stock or less than the conversion price; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the issuance of any shares of our common stock pursuant to any present or future plan providing for the reinvestment of
dividends or interest payable on our securities and the investment of additional optional amounts in shares of our common stock under any such plan; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the issuance of any shares of our common stock or options or rights to purchase shares of our common stock pursuant to any
present or future employee, director or consultant benefit plan or program of, or assumed by, us or any of our subsidiaries; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the issuance of any shares of our common stock pursuant to any option, warrant, right or convertible or exchangeable
security of ours outstanding as of the date we first issue the notes; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">solely a change in the par value of our common stock; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">accrued and unpaid interest on the notes. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Notice of Conversion Rate Adjustments </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the effectiveness of any
adjustment to the conversion rate pursuant to the provisions described above under the caption &#8220;&#8212;Conversion Rate Adjustments&#8212;Generally,&#8221; we will promptly send notice to the noteholders, the trustee and the conversion agent
(if other than the trustee) containing (i)&nbsp;a brief description of the transaction or other event on account of which such adjustment was made; (ii)&nbsp;the conversion rate in effect immediately after such adjustment; and (iii)&nbsp;the
effective time of such adjustment. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Voluntary Conversion Rate Increases </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To the extent permitted by law and applicable stock exchange rules, we, from time to time, may (but are not required to) increase the conversion rate by any amount if
(i)&nbsp;our board of directors determines that such increase is in our best interest or that such increase is advisable to avoid or diminish any income tax imposed on holders of our common stock or rights to purchase our common stock as a result of
any dividend or distribution of shares (or rights to acquire shares) of our common stock or any similar event; (ii)&nbsp;such increase is in effect for a period of at least 20 business days; and (iii)&nbsp;such increase is irrevocable during such
period. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Tax Considerations </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A holder or beneficial owner of the notes
may, in some circumstances, including a distribution of money or other property to our common stockholders, be deemed to have received a distribution that is subject to U.S. federal income tax as a result of an adjustment or the <FONT
STYLE="white-space:nowrap">non-occurrence</FONT> of an adjustment to the conversion rate. Any applicable withholding taxes (including backup withholding) may be withheld from interest and payments upon conversion, repurchase, redemption or maturity
of the notes. In addition, if any withholding taxes (including backup withholding) are paid on behalf of a holder or beneficial owner, then those withholding taxes may be withheld from or set off against payments of cash or the delivery of shares of
our common stock, if any, in respect of the notes (or, in some circumstances, any payments on our common stock) or sales proceeds received by, or other funds or assets of, that holder or beneficial owner. For a discussion of the U.S. federal income
tax treatment of an adjustment to the conversion rate (or the <FONT STYLE="white-space:nowrap">non-occurrence</FONT> of an adjustment to the conversion rate), see &#8220;Material U.S. Federal Income Tax Considerations.&#8221; </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>The Deferral Exception </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If an adjustment to the conversion rate otherwise
required by the indenture would result in a change of less than 1% to the conversion rate, then we may, at our election, defer and carry forward such adjustment, except </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
that all such deferred adjustments must be given effect immediately upon the earliest of the following: (i)&nbsp;when all such deferred adjustments would, had they not been so deferred and
carried forward, result in a change of at least 1% to the conversion rate; (ii)&nbsp;the conversion date of any note (in the case of physical settlement), or each VWAP trading day of an observation period for any note (in the case of cash settlement
or combination settlement); (iii) the date a fundamental change or make-whole fundamental change occurs; (iv)&nbsp;the date we call any notes for redemption; and (v)&nbsp;August&nbsp;15, 2031. We refer to our ability to defer adjustments as
described above as the &#8220;deferral exception.&#8221; </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Special Provisions for Adjustments that Are Not Yet Effective and Where Converting Noteholders
Participate in the Relevant Transaction or Event </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Notwithstanding anything to the contrary, if: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a note is to be converted and physical settlement or combination settlement applies to such conversion;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the record date, effective date or expiration time for any event that requires an adjustment to the conversion rate
pursuant to the provisions described above under the caption &#8220;&#8212;Conversion Rate Adjustments&#8212;Generally&#8221; has occurred on or before the conversion date for such conversion (in the case of physical settlement) or on or before any
VWAP trading day in the observation period for such conversion (in the case of combination settlement), but an adjustment to the conversion rate for such event has not yet become effective as of such conversion date or VWAP trading day, as
applicable; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the consideration due upon such conversion includes any whole shares of our common stock (in the case of physical
settlement) or due in respect of such VWAP trading day includes any whole or fractional shares of our common stock (in the case of combination settlement); and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">such shares are not entitled to participate in such event (because they were not held on the related record date or
otherwise), </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">then, solely for purposes of such conversion, we will, without duplication, give effect to such adjustment on such conversion date (in
the case of physical settlement) or such VWAP trading day (in the case of combination settlement). In such case, if the date we are otherwise required to deliver the consideration due upon such conversion is before the first date on which the amount
of such adjustment can be determined, then we will delay the settlement of such conversion until the second business day after such first date. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Notwithstanding
anything to the contrary, if: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a conversion rate adjustment for any dividend or distribution becomes effective on any
<FONT STYLE="white-space:nowrap">ex-dividend</FONT> date pursuant to the provisions described above under the caption &#8220;&#8212;Conversion Rate Adjustments&#8212;Generally&#8221;; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a note is to be converted pursuant to physical settlement or combination settlement; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the conversion date for such conversion (in the case of physical settlement) or any VWAP trading day in the observation
period for such conversion (in the case of combination settlement) occurs on or after such <FONT STYLE="white-space:nowrap">ex-dividend</FONT> date and on or before the related record date; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the consideration due upon such conversion includes any whole shares of our common stock (in the case of physical
settlement) or due in respect of such VWAP trading day includes any whole or fractional shares of our common stock (in the case of combination settlement), in each case based on a conversion rate that is adjusted for such dividend or distribution;
and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">such shares would be entitled to participate in such dividend or distribution, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">then: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">in the case of physical settlement, such conversion rate adjustment will not be given effect for such conversion and the
shares of common stock issuable upon such conversion based on such unadjusted conversion rate will not be entitled to participate in such dividend or distribution, but there will be added, to the consideration otherwise due upon such conversion, the
same kind and amount of consideration that would have been delivered in such dividend or distribution with respect to such shares of common stock had such shares been entitled to participate in such dividend or distribution; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">in the case of combination settlement, the conversion rate adjustment relating to such
<FONT STYLE="white-space:nowrap">ex-dividend</FONT> date will be made for such conversion in respect of such VWAP trading day, but the shares of our common stock issuable with respect to such VWAP trading day based on such adjusted conversion rate
will not be entitled to participate in such dividend or distribution. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Stockholder Rights Plans </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If any shares of our common stock are to be issued upon conversion of any note and, at the time of such conversion, we have in effect any stockholder rights plan, then
the holder of that note will be entitled to receive, in addition to, and concurrently with the delivery of, the consideration otherwise due upon such conversion, the rights set forth in such stockholder rights plan, unless such rights have separated
from our common stock at such time, in which case, and only in such case, the conversion rate will be adjusted pursuant to the provisions described above in paragraph (3)(a) under the caption &#8220;&#8212;Conversion Rate
Adjustments&#8212;Generally&#8221; on account of such separation as if, at the time of such separation, we had made a distribution of the type referred to in such paragraph to all holders of our common stock, subject to potential readjustment
pursuant to the provisions described in such paragraph. We currently do not have a stockholder rights plan in effect. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Increase in Conversion Rate in
Connection with a Make-Whole Fundamental Change </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Generally </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If a
make-whole fundamental change occurs and the conversion date for the conversion of a note occurs during the related &#8220;make-whole fundamental change conversion period&#8221; (as defined below under the caption &#8220;&#8212;Definitions&#8221;),
then, subject to the provisions described below, the conversion rate applicable to such conversion will be increased by a number of shares (the &#8220;additional shares&#8221;) set forth in the table below corresponding (after interpolation as
described below) to the &#8220;make-whole fundamental change effective date&#8221; (as defined below under the caption &#8220;&#8212;Definitions&#8221;) and the &#8220;stock price&#8221; (as defined below under the caption
&#8220;&#8212;Definitions&#8221;) of such make-whole fundamental change: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000;">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="40" STYLE="BORDER-TOP:2.00pt solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial"><B><FONT STYLE="white-space:nowrap">Make-Whole&nbsp;Fundamental</FONT></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="38" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000;"><FONT STYLE="font-size:8pt"><B>Stock Price </B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000;"><B>Change&nbsp;Effective&nbsp;Date</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000;"><B>$31.00</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000;"><B>$37.50</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000;"><B>$44.95</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000;"><B>$51.00</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000;"><B>$58.44</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000;"><B>$80.00</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000;"><B>$125.00</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000;"><B>$175.00</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000;"><B>$275.00</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000;"><B>$400.00</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">November&nbsp;18, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.0111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.3349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.3853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.3073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.3583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.8239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.6771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.2689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">November 15, 2026</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.0111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.3349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.3226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.2061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.2339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.6946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.5927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.2211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">November 15, 2027</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.0111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.2603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.1326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.9867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.0039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.4946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.4798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">November 15, 2028</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.0111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.0461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.8198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.6471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.6644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.2240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.3457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">November 15, 2029</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.0111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.6493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.3012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.1096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.1514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">November 15, 2030</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.0111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.8885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.3528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.1733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.3190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.3866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">November 15, 2031</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.0111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.4197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If such make-whole fundamental change effective date or stock price is not set forth in the table above, then: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">if such stock price is between two stock prices in the table above or the make-whole fundamental change effective date is
between two dates in the table above, then the number of additional shares will be determined by straight-line interpolation between the numbers of additional shares set forth for the higher and lower stock prices in the table above or the earlier
and later dates in the table above, based on a <FONT STYLE="white-space:nowrap">365-</FONT> or <FONT STYLE="white-space:nowrap">366-day</FONT> year, as applicable; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">if the stock price is greater than $400.00 (subject to adjustment in the same manner as the stock prices set forth in the
column headings of the table above are adjusted, as described below under the caption &#8220;&#8212;Adjustment of Stock Prices and Number of Additional Shares&#8221;), or less than $31.00 (subject to adjustment in the same manner), per share of our
common stock, then no additional shares of our common stock will be added to the conversion rate. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Notwithstanding anything to the contrary, in no
event will the conversion rate be increased to an amount that exceeds 32.2580&nbsp;shares of our common stock per $1,000 principal amount of notes, which amount is subject to adjustment in the same manner as, and at the same time and for the same
events for which, the conversion rate is required to be adjusted pursuant to the provisions described above under the caption &#8220;&#8212;Conversion Rate Adjustments&#8212;Generally.&#8221; </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the avoidance of doubt, calling any notes for redemption will constitute a make-whole fundamental change only with respect to the notes called (or deemed called) for
redemption, and not with respect to the notes not called (or deemed called) for redemption. Accordingly, if we elect to redeem fewer than all of the outstanding notes, then holders of the notes not called for redemption will not be entitled to an
increased conversion rate for such notes as described above on account of the redemption, except to the limited extent described above under the caption &#8220;&#8212;Optional Redemption.&#8221; </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As set forth in the definition of &#8220;make-whole fundamental change conversion period&#8221; below under the caption &#8220;&#8212;Definitions,&#8221; if the
conversion date for the conversion of a note occurs during a make-whole fundamental change conversion period relating to both a make-whole fundamental change resulting from our calling such note for redemption and another make-whole fundamental
change, then, solely for purposes of that conversion, such conversion date will be deemed to occur only during the period relating to the make-whole fundamental change with the earlier make-whole fundamental change effective date. In that
circumstance, the make-whole fundamental change with the later make-whole fundamental change effective date will be deemed not to occur for purposes of such conversion. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Adjustment of Stock Prices and Number of Additional Shares </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The stock prices
in the first row (<I>i.e.</I>, the column headers) of the table above will be adjusted in the same manner as, and at the same time and for the same events for which, the conversion price is adjusted as a result of the operation of the provisions
described above under the caption &#8220;&#8212;Conversion Rate Adjustments&#8212;Generally.&#8221; The numbers of additional shares in the table above will be adjusted in the same manner as, and at the same time and for the same events for which,
the conversion rate is adjusted pursuant to the provisions described above under the caption &#8220;&#8212;Conversion Rate Adjustments&#8212;Generally.&#8221; </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Notice of Make-Whole Fundamental Change </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will notify noteholders, the
trustee, the paying agent (if other than the trustee) and the conversion agent (if other than the trustee) of each make-whole fundamental change in accordance with the provisions described above under the captions &#8220;&#8212;When the Notes May Be
Converted&#8212;Conversion Upon Specified Corporate Events&#8212;Certain Corporate Events&#8221; and &#8220;&#8212;Optional Redemption.&#8221; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Enforceability </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our
obligation to increase the conversion rate as described above in connection with a make-whole fundamental change could be considered a penalty, in which case its enforceability would be subject to general principles of reasonableness and equitable
remedies. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Effect of Common Stock Change Event </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Generally
</I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If there occurs any: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">recapitalization, reclassification or change of our common stock, other than (x)&nbsp;changes solely resulting from a
subdivision or combination of our common stock, (y)&nbsp;a change only in par value or from par value to no par value or no par value to par value or (z)&nbsp;stock splits and stock combinations that do not involve the issuance of any other series
or class of securities; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">consolidation, merger, combination or binding or statutory share exchange involving us; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">sale, lease or other transfer of all or substantially all of the assets of us and our subsidiaries, taken as a whole, to
any person; or </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">other similar event, </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">and, as a result of which, our common stock is converted into, or is exchanged for, or represents solely the right to receive, other securities, cash or other property,
or any combination of the foregoing (such an event, a &#8220;common stock change event,&#8221; and such other securities, cash or property, the &#8220;reference property,&#8221; and the amount and kind of reference property that a holder of one
share of our common stock would be entitled to receive on account of such common stock change event (without giving effect to any arrangement not to issue or deliver a fractional portion of any security or other property), a &#8220;reference
property unit&#8221;), then, notwithstanding anything to the contrary, </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">from and after the effective time of such common stock change event, (i)&nbsp;the consideration due upon conversion of any
note, and the conditions to any such conversion, will be determined in the same manner as if each reference to any number of shares of our common stock in the provisions described under this &#8220;&#8212;Conversion Rights&#8221; section (or in any
related definitions) were instead a reference to the same number of reference property units; (ii)&nbsp;for purposes of the redemption provisions described above under the caption &#8220;&#8212;Optional Redemption,&#8221; each reference to any
number of shares of our common stock in such provisions (or in any related definitions) will instead be deemed to be a reference to the same number of reference property units; and (iii)&nbsp;for purposes of the definitions of &#8220;fundamental
change&#8221; and &#8220;make-whole fundamental change,&#8221; references to our &#8220;common stock&#8221; and &#8220;common equity&#8221; will be deemed to refer to the common equity (including depositary receipts representing common equity), if
any, forming part of such reference property; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">if such reference property unit consists entirely of cash, then (i)&nbsp;each conversion of any note with a conversion date
that occurs on or after the effective date of such common stock change event will be settled entirely in cash in an amount, per $1,000 principal amount of such note being converted, equal to the product of (x)&nbsp;the conversion rate in effect on
such conversion date (including, for the avoidance of doubt, any increase to such conversion rate pursuant to the provisions described above under the caption &#8220;&#8212;Increase in Conversion Rate in Connection with a Make-Whole Fundamental
Change,&#8221; if applicable); and (y)&nbsp;the amount of cash constituting such reference property unit; and (ii)&nbsp;we will settle each such conversion no later than the second business day after the relevant conversion date; and
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">for these purposes, (i)&nbsp;the daily VWAP of any reference property unit or portion thereof that consists of a class of
common equity securities will be determined by reference to the definition of &#8220;daily VWAP,&#8221; substituting, if applicable, the Bloomberg page for such class of securities in such definition; and (ii)&nbsp;the daily VWAP of any reference
property unit or portion thereof that does not consist of a class of common equity securities, and the last reported sale price of any reference property unit or portion thereof that does not consist of a class of securities, will be the fair value
of such reference property unit or portion thereof, as applicable, determined in good faith and in a commercially reasonable manner by us (or, in the case of cash denominated in U.S. dollars, the face amount thereof). </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If the reference property consists of more than a single type of consideration to be determined based in part upon any form of stockholder election, then the composition
of the reference property unit will be deemed to be the weighted average of the types and amounts of consideration actually received, per share of our common stock, by the holders of our common stock. We will notify the noteholders, the trustee and
the conversion agent (if other than the trustee) of such weighted average as soon as practicable after such determination is made. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will not become a party to any
common stock change event unless its terms are consistent with the provisions described under this &#8220;&#8212;Effect of Common Stock Change Event&#8221; caption. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Execution of Supplemental Indenture </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">At or before the effective time of the
common stock change event, we and the resulting, surviving or transferee person (if not us) of such common stock change event (the &#8220;successor person&#8221;) will execute and deliver to the trustee a supplemental indenture that
(i)&nbsp;provides for subsequent adjustments to the conversion rate in a manner consistent with the provisions described above; and (ii)&nbsp;contains such other provisions, if any, that we reasonably determine are appropriate to preserve the
economic interests of the noteholders and to give effect to the provisions described above. If the reference property includes shares of stock or other securities or assets (other than cash) of a person other than the successor person, then such
other person will also execute such supplemental indenture and such supplemental indenture will contain such additional provisions, if any, that we reasonably determine are appropriate to preserve the economic interests of noteholders. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Notice of Common Stock Change Event </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will provide notice of each common
stock change event to noteholders, the trustee and the conversion agent (if other than the trustee) no later than the second business day after the effective date of the common stock change event, including a brief description of the event, its
effective date and a brief description of the anticipated change in the conversion right of the notes. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Exchange in Lieu of Conversion </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Notwithstanding anything to the contrary, and subject to the terms of the indenture, if a note is submitted for conversion, we may elect to arrange to have such note
exchanged in lieu of conversion by a financial institution we designate. To make such election, we must send notice of such election to the holder of such note, the trustee and the conversion agent (if other than the trustee) before the close of
business on the business day immediately following the conversion date for such note, and we must arrange for the financial institution to deliver the consideration due upon such conversion in the same manner and at the same time as we would have
been required to do so. We will remain responsible to deliver such consideration if the financial institution fails to timely deliver the same. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Equitable Adjustments to Prices </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Whenever any provision of the indenture requires us to calculate the average of the last reported sale prices, or any function thereof, the daily VWAPs, the daily
conversion values, the daily cash amounts or the daily share amounts over a period of multiple days (including over an observation period, to calculate an adjustment to the conversion rate and the period, if any, for determining the &#8220;stock
price&#8221; for purposes of a make-whole fundamental change), we will, acting in good faith and in a commercially reasonable manner, make appropriate adjustments, if any, to those calculations to account for any adjustment to the conversion rate
that becomes effective, or any event requiring an adjustment to the conversion rate where the <FONT STYLE="white-space:nowrap">ex-dividend</FONT> date, effective date or expiration date, as applicable, of the event occurs, at any time during such
period or observation period, as applicable. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Fundamental Change Permits Noteholders to Require Us to Repurchase Notes </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Generally </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If a fundamental change occurs, then each noteholder will
have the right (the &#8220;fundamental change repurchase right&#8221;) to require us to repurchase its notes (or any portion thereof in an authorized denomination) for cash on a date (the &#8220;fundamental change repurchase date&#8221;) of our
choosing, which must be a business day that is no more than 35, nor less than 20, business days after the date we send the related fundamental change notice, as described below. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The repurchase price (the &#8220;fundamental change repurchase price&#8221;) for a note tendered for repurchase will be the principal amount of such note plus accrued
and unpaid interest on such note to, but excluding, the fundamental change repurchase date. However, if the fundamental change repurchase date is after a regular record date and on or before the next interest payment date, then (i)&nbsp;the holder
of such note at the close of business on such regular record date will be entitled, notwithstanding such repurchase, to receive, on or, at our election, before such interest payment date, the unpaid interest that would have accrued on such note to,
but excluding, such interest payment date; and (ii)&nbsp;the fundamental change repurchase price will not include accrued and unpaid interest on such note to, but excluding, the fundamental change repurchase date. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Notwithstanding anything to the contrary above, we may not repurchase any notes if the principal amount of the notes has been accelerated and such acceleration has not
been rescinded on or before the fundamental change repurchase date (including as a result of the payment of the related fundamental change repurchase price and any related interest described above on the fundamental change repurchase date). </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Notice of Fundamental Change </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On or before the 20th calendar day after
the effective date of a fundamental change, we will send to each noteholder, the trustee, the paying agent (if other than the trustee) and the conversion agent (if other than the trustee) notice of such fundamental change containing certain
information set forth in the indenture, including the fundamental change repurchase date, the fundamental change repurchase price and the procedures noteholders must follow to tender their notes for repurchase. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Procedures to Exercise the Fundamental Change Repurchase Right </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To
exercise its fundamental change repurchase right with respect to a note, the holder thereof must deliver a notice (a &#8220;fundamental change repurchase notice&#8221;) to the paying agent before the close of business on the business day immediately
before the related fundamental change repurchase date (or such later time as may be required by law). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The fundamental change repurchase notice must contain certain information set forth in the indenture, including the
certificate number of any physical notes to be repurchased, or must otherwise comply with the depositary procedures in the case of a global note. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A noteholder that
has delivered a fundamental change repurchase notice with respect to a note may withdraw that notice by delivering a withdrawal notice to the paying agent at any time before the close of business on the business day immediately before the
fundamental change repurchase date. The withdrawal notice must contain certain information set forth in the indenture, including the certificate number of any physical notes with respect to which the withdrawal notice is being delivered, or must
otherwise comply with the depositary procedures in the case of a global note. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Notes to be repurchased must be delivered to the paying agent (in the case of physical
notes) or the depositary procedures must be complied with (in the case of global notes) for the holder of those notes to be entitled to receive the fundamental change repurchase price. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Compliance with Securities Laws </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will comply, in all material
respects, with all federal and state securities laws in connection with a repurchase following a fundamental change (including complying with Rules <FONT STYLE="white-space:nowrap">13e-4</FONT> and <FONT STYLE="white-space:nowrap">14e-1</FONT> under
the Exchange Act and filing any required Schedule TO, to the extent applicable) so as to permit effecting such repurchase in the manner described above. However, to the extent that our obligations to offer to repurchase and to repurchase notes
pursuant to the provisions described above conflict with any law or regulation that is applicable to us and enacted after the date we initially issue the notes, our compliance with such law or regulation will not be considered to be a default of
those obligations; rather, we will be deemed to be in compliance with those obligations if we comply with our obligation to repurchase notes upon a fundamental change in accordance with the indenture, modified as necessary by us in good faith to
permit compliance with such law or regulation. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Repurchase by Third Party </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Notwithstanding anything to the contrary, we will be deemed to satisfy our obligations to repurchase notes pursuant to the provisions described above if (i)&nbsp;one or
more third parties conduct the repurchase offer and repurchase tendered notes in a manner that would have satisfied our obligations to do the same if conducted directly by us; and (ii)&nbsp;an owner of a beneficial interest in any note repurchased
by such third party or parties will not receive a lesser amount (including as a result of withholding or other similar taxes) than such owner would have received had we repurchased such note. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>No Repurchase Right in Certain Circumstances </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Notwithstanding anything
to the contrary, we will not be required to send a fundamental change notice, or offer to repurchase or repurchase any notes, as described above, in connection with a common stock change event that constitutes a fundamental change pursuant to clause
(ii)(2) of the definition thereof (regardless of whether such common stock change event also constitutes a fundamental change pursuant to any other clause of such definition), if: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the reference property of such common stock change event consists entirely of cash in U.S. dollars; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">immediately after such fundamental change, the notes become convertible (pursuant to the provisions described above under
the captions &#8220;&#8212;Conversion Rights&#8212;Effect of Common Stock Change Event&#8221; and, if </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">
applicable, &#8220;&#8212;Conversion Rights&#8212;Increase in Conversion Rate in Connection with a Make-Whole Fundamental Change&#8221;) into consideration that consists solely of U.S. dollars in
an amount per $1,000 principal amount of notes that equals or exceeds the fundamental change repurchase price per $1,000 principal amount of notes (calculated (i)&nbsp;assuming that the same includes accrued and unpaid interest to, but excluding,
the latest possible fundamental change repurchase date for such fundamental change and (ii)&nbsp;without regard to the provision described in the second sentence of the second paragraph under the caption &#8220;&#8212;Fundamental Change Permits
Noteholders to Require Us to Repurchase Notes&#8212;Generally&#8221;); and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we timely send the notice relating to such fundamental change required pursuant to the provisions described above under the
caption &#8220;&#8212;Conversion Rights&#8212;When the Notes May Be Converted&#8212;Conversion Upon Specified Corporate Events&#8212;Certain Corporate Events&#8221; and include, in such notice, a statement that we are relying on the provisions
described in this &#8220;&#8212;No Repurchase Right in Certain Circumstances&#8221; section. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We refer to any fundamental change with respect to
which, in accordance with the provisions described above, we do not offer to repurchase any notes as an &#8220;exempted fundamental change.&#8221; </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Consolidation, Merger and Asset Sale </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For purposes of the notes, the
description below under this section titled &#8220;&#8212;Consolidation, Merger and Asset Sale&#8221; supersedes, in its entirety, the information in the accompanying prospectus under the caption &#8220;Description of Debt Securities&#8212;Merger,
Consolidation or Sale of Assets.&#8221; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will not consolidate with or merge with or into, or (directly, or indirectly through one or more of our subsidiaries)
sell, lease or otherwise transfer, in one transaction or a series of transactions, all or substantially all of the assets of us and our subsidiaries, taken as a whole, to another person (a &#8220;business combination event&#8221;), unless: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the resulting, surviving or transferee person is us or, if not us, is a &#8220;qualified successor entity&#8221; (as
defined below under the caption &#8220;&#8212;Definitions&#8221;) (such qualified successor entity, the &#8220;successor entity&#8221;) duly organized and existing under the laws of the United States of America, any State thereof or the District of
Columbia that expressly assumes (by executing and delivering to the trustee, at or before the effective time of such business combination event, a supplemental indenture) all of our obligations under the indenture and the notes; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">immediately after giving effect to such business combination event, no default or event of default will have occurred and
be continuing. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">At the effective time of a business combination event that complies with the provisions described above, the successor entity (if
not us) will succeed to, and may exercise every right and power of, us under the indenture and the notes, and, except in the case of a lease, the predecessor company will be discharged from its obligations under the indenture and the notes. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Notwithstanding anything to the contrary above, the provisions described above will not apply to any transfer of assets (other than by merger or consolidation) between
or among us and any one or more of our &#8220;wholly owned subsidiaries&#8221; (as defined below under the caption &#8220;&#8212;Definitions&#8221;). </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The definition
of &#8220;business combination event&#8221; includes a reference to &#8220;all or substantially all&#8221; of our and our subsidiaries&#8217; assets. There is no precise, established definition of the phrase &#8220;all or substantially all&#8221;
under applicable law. Accordingly, there may be uncertainty as to whether the provisions described above would apply to a sale, lease or transfer of less than all of our and our subsidiaries&#8217; assets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Events of Default </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For
purposes of the notes, the description below under this section titled &#8220;&#8212;Events of Default&#8221; supersedes, in its entirety, the information in the accompanying prospectus under the caption &#8220;Description of Debt
Securities&#8212;Events of Default and Remedies.&#8221; </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Generally </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">An &#8220;event of default&#8221; means the occurrence of any of the following: </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(1)
a default in the payment when due (whether at maturity, upon redemption or repurchase upon fundamental change or otherwise) of the principal of, or the redemption price or fundamental change repurchase price for, any note; </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(2) a default for 30 consecutive days in the payment when due of interest on any note; </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(3) our failure to deliver, when required by the indenture, a fundamental change notice or a notice pursuant to the provisions described above under the caption
&#8220;&#8212;Conversion Rights&#8212;When the Notes May Be Converted&#8212;Conversion Upon Specified Corporate Events,&#8221; if (in the case of any notice other than a notice pursuant to the provisions described above under the caption
&#8220;&#8212;Conversion Rights&#8212;When the Notes May Be Converted&#8212;Conversion Upon Specified Corporate Events&#8212;Certain Distributions&#8221;) such failure is not cured within three business days after its occurrence (or, in the case of
a notice pursuant to the provisions described above under the caption &#8220;&#8212;Conversion Rights&#8212;When the Notes May Be Converted&#8212;Conversion Upon Specified Corporate Events&#8212;Certain Distributions&#8221;, when due); </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(4) a default in our obligation to convert a note in accordance with the indenture upon the exercise of the conversion right with respect thereto, if such default is not
cured within three business days after its occurrence; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(5) a default in our obligations described above under the caption &#8220;&#8212;Consolidation, Merger and
Asset Sale&#8221;; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(6) a default in any of our obligations or agreements under the indenture or the notes (other than a default set forth in paragraphs (1), (2),
(3), (4) or (5)&nbsp;above) where such default is not cured or waived within 60 days after notice to us by the trustee, or to us and the trustee by holders of at least 25% of the aggregate principal amount of notes then outstanding, which notice
must specify such default, demand that it be remedied and state that such notice is a &#8220;notice of default&#8221;; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(7) a default by us or any of our
&#8220;significant subsidiaries&#8221; (as defined below under the caption &#8220;&#8212;Definitions&#8221;) with respect to any one or more mortgages, agreements or other instruments under which there is outstanding, or by which there is secured or
evidenced, any indebtedness for money borrowed of at least $20,000,000 (or its foreign currency equivalent) in the aggregate of us or any of our significant subsidiaries, whether such indebtedness exists as of the date we first issue the notes or is
thereafter created, where such default: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">constitutes a failure to pay the principal of such indebtedness when due and payable at its stated maturity, upon required
repurchase, upon declaration of acceleration or otherwise, in each case after the expiration of any applicable grace period; or </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">results in such indebtedness becoming or being declared due and payable before its stated maturity, </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">in each case where such default is not cured or waived within 30 days after notice to us by the trustee or to us and the trustee by holders of at least 25% of the
aggregate principal amount of notes then outstanding; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(8) a final judgment being rendered against us or any of our significant subsidiaries for the payment of at least
$20,000,000 (or its foreign currency equivalent) (excluding any amounts covered by insurance), where such judgment is not discharged or stayed within 60 days after (i)&nbsp;the date on which the right to appeal the same has expired, if no such
appeal has commenced; or (ii)&nbsp;the date on which all rights to appeal have been extinguished; and </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(9) certain events of bankruptcy, insolvency and
reorganization with respect to us or any of our significant subsidiaries. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the avoidance of doubt, any failure by us to provide any notice under the indenture
other than as set forth in clause (3)&nbsp;above shall be subject to clause (6)&nbsp;above (including the <FONT STYLE="white-space:nowrap">60-day</FONT> cure period contained therein). </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Acceleration </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If an event of default described in paragraph
(9)&nbsp;above occurs with respect to us (and not solely with respect to a significant subsidiary of ours), then the principal amount of, and all accrued and unpaid interest on, all of the notes then outstanding will immediately become due and
payable without any further action or notice by any person. If an event of default (other than an event of default described in paragraph (9)&nbsp;above with respect to us and not solely with respect to a significant subsidiary of ours) occurs and
is continuing, then, except as described below under the caption &#8220;&#8212;Special Interest as Sole Remedy for Certain Reporting Defaults,&#8221; the trustee, by notice to us, or noteholders of at least 25% of the aggregate principal amount of
notes then outstanding, by notice to us and the trustee, may declare the principal amount of, and all accrued and unpaid interest on, all of the notes then outstanding to become due and payable immediately. For the avoidance of doubt, if such event
of default is not continuing at the time such notice is provided (that is, such event of default has been cured or waived as of such time), then such notice will not be effective to cause such amounts to become due and payable immediately. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Noteholders of a majority in aggregate principal amount of the notes then outstanding, by notice to us and the trustee, may, on behalf of all noteholders, rescind any
acceleration of the notes and its consequences if (i)&nbsp;such rescission would not conflict with any judgment or decree of a court of competent jurisdiction; and (ii)&nbsp;all existing events of default (except the
<FONT STYLE="white-space:nowrap">non-payment</FONT> of principal of, or interest on, the notes that has become due solely because of such acceleration) have been cured or waived. No such rescission will affect any subsequent default or impair any
right consequent thereto. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If any portion of the amount payable on the notes upon acceleration is considered by a court to be unearned interest (through the
allocation of the value of the instrument to the embedded warrant or otherwise), then the court could disallow recovery of any such portion. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Waiver of Past
Defaults </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">An event of default pursuant to paragraph (1), (2), (4) or (6)&nbsp;above (that, in the case of paragraph (6)&nbsp;only, results from a default
under any covenant that cannot be amended without the consent of each affected noteholder), and a default that could lead to such an event of default, can be waived only with the consent of each affected noteholder. Each other default or event of
default may be waived, on behalf of all noteholders, by noteholders of a majority in aggregate principal amount of the notes then outstanding. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Cure of
Defaults; Ability to Cure or Waive Before Event of Default Occurs </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the avoidance of doubt, and without limiting the manner in which any default or event
of default can be cured, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a default or event of default consisting of a failure to send a notice in accordance with the terms of the indenture will
be cured upon the sending of such notice; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a default or event of default in making any payment on (or delivering any other consideration in respect of) any note will
be cured upon the delivery, in accordance with the indenture, of such payment (or other consideration) together, if applicable, with &#8220;default interest&#8221; (as defined below under the caption &#8220;&#8212;Default Interest&#8221;) thereon;
and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a default or event of default that is (or, after notice, passage of time or both, would be) a &#8220;reporting event of
default&#8221; (as defined below under the caption &#8220;&#8212;Special Interest as Sole Remedy for Certain Reporting Defaults&#8221;) will be cured upon the filing of the relevant report(s) giving rise to such reporting event of default;
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>provided </I>that (x)&nbsp;the cure of any event of default shall not invalidate any acceleration of the notes on<I> </I>account of such event
of default that was properly effected prior to such time as such event of default was cured and (y)&nbsp;the cure of any reporting event of default shall not affect our obligation to pay any special interest that accrues prior to the time of such
cure. In addition, for the avoidance of doubt, if a default that is not an event of default is cured or waived before such default would have constituted an event of default, then no event of default will result from such default. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Notice of Defaults </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If a default or event of default occurs, then we
will, within 30 days after we first obtain knowledge of its occurrence, notify the trustee, setting forth what action we are taking or propose to take with respect thereto. However, we will not be required to provide such notification at any time
after such default is cured or waived. We must also provide the trustee, within 120 days after the end of each fiscal year (beginning with the fiscal year ending on December&nbsp;31, 2025), with a certificate as to whether any defaults or events of
default have occurred or are continuing. If a default or event of default occurs and is continuing and is actually known to a responsible officer of the trustee, then the trustee must notify the noteholders of the same within 90 days after it occurs
or, if it is not actually known to a responsible officer of the trustee at such time, promptly (and in any event within 10 business days) after it becomes actually known to a responsible officer of the trustee. However, except in the case of a
default or event of default in the payment of the principal of, or interest on, any note, or a default in the payment or delivery of the consideration due upon conversion, the trustee may withhold such notice if and for so long as it in good faith
determines that withholding such notice is in the interests of the noteholders. For the avoidance of doubt, the trustee will not be required to deliver such notice at any time after such default or event of default is cured or waived. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Limitation on Suits; Absolute Rights of Noteholders </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Except with
respect to the rights referred to below, no noteholder may pursue any remedy with respect to the indenture or the notes, unless: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">such noteholder has previously delivered to the trustee notice that an event of default is continuing;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">noteholders of at least 25% in aggregate principal amount of the notes then outstanding deliver a written request to the
trustee to pursue such remedy; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">such noteholder(s) offer and, if requested, provide to the trustee security and indemnity satisfactory to the trustee
against any loss, liability or expense to the trustee that may result from the trustee&#8217;s following such request; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the trustee does not comply with such request within 60 calendar days after its receipt of such request and such offer of
security or indemnity; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">during such 60 calendar day period, noteholders of a majority in aggregate principal amount of the notes then outstanding
do not deliver to the trustee a direction that is inconsistent with such request. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">However, notwithstanding anything to the contrary, but without
limiting the provisions described under the caption &#8220;&#8212;Modification and Amendment&#8221; relating to amendments and supplements without the consent of any noteholder, the right of each holder of a note to receive payment or delivery, as
applicable, of the principal of, or the redemption price or fundamental change repurchase price for, or any interest on, or the consideration due upon conversion of, such note on or after the respective due dates therefor, or to bring suit for the
enforcement of any such payment or delivery on or after such respective due dates, will not be impaired or affected without the consent of such holder. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Noteholders
of a majority in aggregate principal amount of the notes then outstanding may direct the time, method and place of conducting any proceeding for exercising any remedy available to the trustee or exercising any trust or power conferred on it.
However, the trustee may refuse to follow any direction that conflicts with law, the indenture or the notes, or that, subject to the terms of the indenture, the trustee determines may be unduly prejudicial to the rights of other noteholders or may
involve the trustee in liability, unless the trustee is offered (and, if requested, provided with) security and indemnity satisfactory to the trustee against any loss, liability or expense to the trustee that may result from the trustee&#8217;s
following such direction. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Default Interest </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Payments of any
amounts due on the notes that are not made when due will accrue interest at a rate per annum equal to the rate per annum at which stated interest accrues on the notes. We refer to such interest, if any, as &#8220;default interest.&#8221; </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Special Interest as Sole Remedy for Certain Reporting Defaults </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Notwithstanding anything to the contrary described above, we may elect that the sole remedy for any event of default (a &#8220;reporting event of default&#8221;)
pursuant to paragraph (6)&nbsp;above arising from our failure to comply with our obligations described below under the caption &#8220;&#8212;Exchange Act Reports&#8221; (including our obligations under Section&nbsp;314(a)(1) of the Trust Indenture
Act) will, for each of the first 365 calendar days on which such reporting event of default has occurred and is continuing, consist exclusively of the accrual of special interest on the notes. If we have made such an election, then (i)&nbsp;the
notes will be subject to acceleration as described above on account of the relevant reporting event of default from, and including, the 366th calendar day on which such reporting event of default has occurred and is continuing or if we fail to pay
any accrued and unpaid special interest when due; and (ii)&nbsp;special interest will cease to accrue on any notes from, and including, such 366th&nbsp;calendar day. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any special interest that accrues on a note will be payable on the same dates and in the same manner as the stated interest on such note and will accrue at a rate per
annum equal to 0.25% of the principal amount thereof for the first 180 days on which such reporting event of default is continuing and special interest accrues and, thereafter, at a rate per annum equal to 0.50% of the principal amount thereof, to,
and including, the 365th day on which such reporting event of default is continuing and special interest accrues. For the avoidance of doubt, any special interest that accrues on a note will be in addition to the stated interest that accrues on such
note. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To make the election to pay special interest as described above, we must provide notice of such election to noteholders, the trustee and the paying agent (if
other than the trustee) before the date on which each </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
reporting event of default first occurs. The notice will also, among other things, briefly describe the periods during which and rate at which special interest will accrue and the circumstances
under which the notes will be subject to acceleration on account of such reporting event of default. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Modification and Amendment </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For purposes of the notes, the description below under this section titled &#8220;&#8212;Modification and Amendment&#8221; supersedes, in its entirety, the information
in the accompanying prospectus under the caption &#8220;Description of Debt Securities&#8212;Amendment, Supplement and Waiver.&#8221; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We and the trustee may, with
the consent of holders of a majority in aggregate principal amount of the notes then outstanding, amend or supplement the indenture or the notes or waive compliance with any provision of the indenture or the notes. However, without the consent of
each affected noteholder, no amendment or supplement to the indenture or the notes, or waiver of any provision of the indenture or the notes, may: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reduce the principal, or change the stated maturity, of any note; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reduce the redemption price or fundamental change repurchase price for any note or change the times at which, or the
circumstances under which, the notes may or will be redeemed or repurchased by us; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reduce the rate, or extend the time for the payment, of interest on any note; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">make any change that adversely affects the conversion rights of any note; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">impair the absolute rights of any holder of a note to receive payment or delivery, as applicable, of the principal of, or
the redemption price or fundamental change repurchase price for, or any interest on, or the consideration due upon conversion of, such note on or after the respective due dates therefor, or to bring suit for the enforcement of any such payment or
delivery on or after such respective due dates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">change the ranking of the notes; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">make any note payable in money, or at a place of payment, other than that stated in the indenture or the note;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reduce the amount of notes whose holders must consent to any amendment, supplement, waiver or other modification; or
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">make any direct or indirect change to any amendment, supplement, waiver or modification provision of the indenture or the
notes that requires the consent of each affected noteholder. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Notwithstanding anything to the contrary above, we and the trustee may amend or
supplement the indenture or the notes without the consent of any noteholder to: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">cure any ambiguity or correct any omission, defect or inconsistency in the indenture or the notes; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">add guarantees with respect to our obligations under the indenture or the notes; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">secure the notes; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">add to our covenants or events of default for the benefit of noteholders or surrender any right or power conferred on us;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">provide for the assumption of our obligations under the indenture and the notes pursuant to, and in compliance with, the
provisions described above under the caption &#8220;&#8212;Consolidation, Merger and Asset Sale&#8221;; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">enter into supplemental indentures pursuant to, and in accordance with, the provisions described above under the caption
&#8220;&#8212;Conversion Rights&#8212;Effect of Common Stock Change Event&#8221; in connection with a common stock change event; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">irrevocably elect or eliminate any settlement method or specified dollar amount; provided, however, that no such election
or elimination will affect any settlement method theretofore elected (or deemed to be elected) with respect to any note pursuant to the provisions described above under the caption &#8220;&#8212;Conversion Rights&#8212;Settlement Upon
Conversion&#8212;Settlement Method&#8221;; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">evidence or provide for the acceptance of the appointment of a successor trustee; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">conform the provisions of the indenture and the notes to the &#8220;Description of Notes&#8221; section of the preliminary
prospectus supplement for this offering, as supplemented by the related pricing term sheet; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">provide for or confirm the issuance of additional notes pursuant to the indenture; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">provide for any transfer restrictions that apply to any notes issued under the indenture (other than the notes issued in
this offering, and any notes issued in exchange therefor or in substitution thereof) that, at the time of their original issuance, constitute &#8220;restricted securities&#8221; within the meaning of Rule 144 under the Securities Act or that are
originally issued in reliance upon Regulation S under the Securities Act; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">comply with any requirement of the SEC in connection with effecting or maintaining the qualification of the indenture or
any supplemental indenture under the Trust Indenture Act, as then in effect; or </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">make any other change to the indenture or the notes that does not, individually or in the aggregate with all other such
changes, adversely affect the rights of noteholders, as such, in any material respect, as determined by us in good faith. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Exchange Act Reports
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will send to the trustee copies of all reports that we are required to file with the SEC pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act (other
than current reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or any successor form) within 15 calendar days after the date that we are required to so file the same (after giving effect to all applicable grace periods under the Exchange
Act). However, we need not send to the trustee any material for which we have received, or are seeking in good faith and have not been denied, confidential treatment by the SEC. Any such report that we file with the SEC through the EDGAR system (or
any successor thereto) will be deemed to be sent to the trustee at the time such report is so filed via the EDGAR system (or such successor). Delivery of reports, information and documents to the trustee is for informational purposes only and
receipt of such reports and documents will not constitute actual or constructive notice of any information contained therein or determinable from information contained therein, including our compliance with any of our covenants under the indenture
or the notes (as to which the trustee is entitled to rely exclusively on officer&#8217;s certificates). The trustee will not be obligated to monitor or confirm, on a continuing basis or otherwise, our compliance with the covenants under the
indenture or the notes or with respect to any reports or other documents filed with the SEC through the EDGAR system or any website under the indenture. Upon the request of any noteholder, the trustee will provide to the noteholder a copy of any
report that we have sent the trustee pursuant to the provisions described above, other than a report that is deemed to be sent to the trustee as a result of us filing such report with the SEC through the EDGAR system (or any successor thereto). We
will also comply with our other obligations under Section&nbsp;314(a)(1) of the Trust Indenture Act. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The &#8220;grace periods&#8221; referred to in the preceding
paragraph with respect to any report will include the maximum period afforded by Rule <FONT STYLE="white-space:nowrap">12b-25</FONT> (or any successor rule thereto) under the Exchange Act regardless of whether we file, or indicate in the related
Form <FONT STYLE="white-space:nowrap">12b-25</FONT> (or any successor form thereto) that we expect to or will file, such report before the expiration of such maximum period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Discharge </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For purposes of
the notes, the description below under this section titled &#8220;&#8212;Discharge&#8221; supersedes, in its entirety, the information in the accompanying prospectus under the caption &#8220;Description of Debt Securities&#8212;Defeasance,
Satisfaction and Discharge.&#8221; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Subject to the terms of the indenture, our obligations with respect to the notes under the indenture will be discharged if we
deliver all outstanding notes to the trustee for cancellation, or if all outstanding notes have become due and payable (including upon conversion, if the consideration due upon such conversion has been determined) and we have irrevocably deposited
with the trustee, or caused to be delivered to noteholders, sufficient cash or other consideration to satisfy all amounts that have become due and payable. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Calculations </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Except as otherwise provided in the indenture, we will be
responsible for making all calculations called for under the indenture or the notes, including determinations of the last reported sale price, the daily conversion value, the daily cash amount, the daily share amount, the daily VWAP, the trading
price, accrued interest on the notes, including any special interest, the redemption price, the fundamental change repurchase price and the conversion rate (including adjustments to the conversion rate). We will make all calculations in good faith,
and, absent manifest error, our calculations will be final and binding on all noteholders. We will provide a schedule of our calculations to the trustee, and the trustee will promptly forward a copy of each such schedule to any noteholder upon
written request. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Trustee </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The trustee under the indenture is U.S. Bank
Trust Company, National Association. The trustee assumes no responsibility for the accuracy or completeness of the information contained in this prospectus supplement or the related documents. The trustee and/or its affiliates have in the past
provided and may from time to time in the future provide banking and other services to us in the ordinary course of business. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notices </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will send all notices or communications to noteholders pursuant to the indenture in writing by first class mail, certified or registered, return receipt requested, or
by overnight air courier guaranteeing next day delivery, to the noteholders&#8217; respective addresses shown on the register for the notes. However, in the case of global notes, we are permitted to, and will, send notices or communications to
noteholders pursuant to the depositary procedures, and notices and communications that we send in this manner will be deemed to have been properly sent to such noteholders in writing. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>No Personal Liability of Directors, Officers, Employees and Stockholders </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">No
past, present or future director, officer, employee, incorporator or stockholder of ours, as such, will have any liability for any obligations of ours under the indenture or the notes or for any claim based on, in respect of, or by reason of, such
obligations or their creation. By accepting any note, each noteholder will be deemed to waive and release all such liability, and such waiver and release are part of the consideration for the issuance of the notes. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Governing Law; Waiver of Jury Trial </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For purposes of the notes, the
description below under this section titled &#8220;&#8212;Governing Law&#8221; supersedes, in its entirety, the information in the accompanying prospectus under the caption &#8220;Description of Debt Securities&#8212;Governing Law.&#8221; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The indenture and the notes, and any claim, controversy or dispute arising under or related to the indenture or the
notes, will be governed by and construed in accordance with the laws of the State of New York. The indenture will provide that we and the trustee will irrevocably waive, to the fullest extent permitted by applicable law, any and all right to trial
by jury in any legal proceeding arising out of or relating to the indenture, the notes or the transactions contemplated by the indenture or the notes. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Submission to Jurisdiction </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any legal suit, action or proceeding arising out
of or based upon the indenture or the transactions contemplated by the indenture may be instituted in the federal courts of the United States of America located in the City of New York or the courts of the State of New York, in each case located in
the City of New York (collectively, the &#8220;specified courts&#8221;), and each party will be deemed to irrevocably submit to the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> jurisdiction of those courts in any such suit, action or
proceeding. Service of any process, summons, notice or document by mail (to the extent allowed under any applicable statute or rule of court) to any party&#8217;s address as provided in the indenture will be effective service of process for any such
suit, action or proceeding brought in any such court. Each of us, the trustee and each noteholder (by its acceptance of any note) will be deemed to irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or
other proceeding in the specified courts and to irrevocably and unconditionally waive and agree not to plead or claim any such suit, action or other proceeding has been brought in an inconvenient forum. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Definitions </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Affiliate&#8221; has the meaning set forth in Rule 144
under the Securities Act as in effect on the date we first issue the notes. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Bid solicitation agent&#8221; means the person who is required to obtain bids for
the trading price in accordance with the provisions described under the caption &#8220;&#8212;Conversion Rights&#8212;When the Notes May Be Converted&#8212;Conversion Upon Satisfaction of Note Trading Price Condition&#8221; and in the definition of
&#8220;trading price.&#8221; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Board of directors&#8221; means our board of directors or a committee of such board duly authorized to act on behalf of such
board. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Business day&#8221; means any day other than a Saturday, a Sunday or any day on which the Federal Reserve Bank of New York is authorized or required
by law or executive order to close or be closed. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Capital stock&#8221; of any person means any and all shares of, interests in, rights to purchase, warrants
or options for, participations in, or other equivalents of, in each case however designated, the equity of such person, but excluding any debt securities convertible into, or exchangeable for, such equity. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Close of business&#8221; means 5:00 p.m., New York City time. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Common
equity&#8221; of any person means capital stock of such person that is generally entitled (i)&nbsp;to vote in the election of directors of such person; or (ii)&nbsp;if such person is not a corporation, to vote or otherwise participate in the
selection of the governing body, partners, managers or others that will control the management or policies of such person. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Conversion price&#8221; means, as
of any time, an amount equal to (i) $1,000 divided by (ii)&nbsp;the conversion rate in effect at such time. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Conversion rate&#8221; initially means 22.2469
shares of our common stock per $1,000 principal amount of notes, which amount is subject to adjustment as described above under the caption &#8220;&#8212;Conversion Rights.&#8221; Whenever </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
in this prospectus supplement we refer to the conversion rate as of a particular date without setting forth a particular time on such date, such reference will be deemed to be to the conversion
rate immediately after the close of business on such date. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Daily cash amount&#8221; means, with respect to any VWAP trading day, the lesser of (i)&nbsp;the
applicable daily maximum cash amount; and (ii)&nbsp;the daily conversion value for such VWAP trading day. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Daily conversion value&#8221; means, with respect
to any VWAP trading day, <FONT STYLE="white-space:nowrap">one-25th</FONT> of the product of (i)&nbsp;the conversion rate on such VWAP trading day; and (ii)&nbsp;the daily VWAP per share of our common stock on such VWAP trading day. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Daily maximum cash amount&#8221; means, with respect to the conversion of any note, the quotient obtained by dividing (i)&nbsp;the specified dollar amount
applicable to such conversion by (ii) 25. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Daily share amount&#8221; means, with respect to any VWAP trading day, the quotient obtained by dividing
(i)&nbsp;the excess, if any, of the daily conversion value for such VWAP trading day over the applicable daily maximum cash amount by (ii)&nbsp;the daily VWAP for such VWAP trading day. For the avoidance of doubt, the daily share amount will be zero
for such VWAP trading day if such daily conversion value does not exceed such daily maximum cash amount. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Daily VWAP&#8221; means, for any VWAP trading day,
the per share volume-weighted average price of our common stock as displayed under the heading &#8220;Bloomberg VWAP&#8221; on Bloomberg page &#8220;COGT &lt;EQUITY&gt; AQR&#8221; (or, if such page is not available, its equivalent successor page) in
respect of the period from the scheduled open of trading until the scheduled close of trading of the primary trading session on such VWAP trading day (or, if such volume-weighted average price is unavailable, the market value of one share of our
common stock on such VWAP trading day, determined, using a volume-weighted average price method, by a nationally recognized independent investment banking firm we select, which may be any of the underwriters). The daily VWAP will be determined
without regard to after-hours trading or any other trading outside of the regular trading session. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Default&#8221; means any event that is (or, after notice,
passage of time or both, would be) an event of default. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Default interest&#8221; has the meaning set forth above under the caption &#8220;&#8212;Events of
Default&#8212;Default Interest.&#8221; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Depositary procedures&#8221; means, with respect to any conversion, transfer, exchange or other transaction involving
a global note or any beneficial interest therein, the rules and procedures of the depositary applicable to such conversion, transfer, exchange or transaction. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;DTC&#8221; means The Depository Trust Company. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Effective date,&#8221;
in relation to a stock split or stock combination of our common stock, means the first date on which the shares of our common stock trade on the relevant stock exchange, regular way, reflecting the relevant stock split or stock combination, as
applicable. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap">&#8220;Ex-dividend</FONT> date&#8221; means, with respect to an issuance, dividend or distribution on our common stock,
the first date on which shares of our common stock trade on the applicable exchange or in the applicable market, regular way, without the right to receive such issuance, dividend or distribution (including pursuant to due bills or similar
arrangements required by the relevant stock exchange). For the avoidance of doubt, any alternative trading convention on the applicable exchange or market in respect of our common stock under a separate ticker symbol or CUSIP number will not be
considered &#8220;regular way&#8221; for this purpose. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Exchange Act&#8221; means the U.S. Securities Exchange Act of 1934, as amended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Fundamental change&#8221; means any of the following events: </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial">(i) a &#8220;person&#8221; or &#8220;group&#8221; (within the meaning of Section&nbsp;13(d)(3) of the Exchange Act), other than us or our &#8220;wholly
owned subsidiaries&#8221; (as defined below), or any employee benefit plans of ours or our wholly owned subsidiaries, files any report with the SEC indicating that such person or group has become the direct or indirect &#8220;beneficial owner&#8221;
(as defined below) of shares of our common stock representing more than 50% of the voting power of all of our common stock; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial">(ii) the consummation
of: (1)&nbsp;any sale, lease or other transfer, in one transaction or a series of transactions, of all or substantially all of the assets of us and our subsidiaries, taken as a whole, to any person, other than solely to one or more of our wholly
owned subsidiaries; or (2)&nbsp;any transaction or series of related transactions in connection with which (whether by means of merger, consolidation, share exchange, combination, reclassification, recapitalization, acquisition, liquidation or
otherwise) all of our common stock is exchanged for, converted into, acquired for, or constitutes solely the right to receive, other securities, cash or other property; <I>provided</I>, <I>however</I>, that any merger, consolidation, share exchange
or combination of us pursuant to which the persons that directly or indirectly &#8220;beneficially owned&#8221; (as defined below) all classes of our common equity immediately before such transaction directly or indirectly &#8220;beneficially
own,&#8221; immediately after such transaction, more than 50% of all classes of common equity of the surviving, continuing or acquiring company or other transferee, as applicable, or the parent thereof, in substantially the same proportions <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT> each other as immediately before such transaction will be deemed not to be a fundamental change pursuant to this clause (ii); </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial">(iii) our stockholders approve any plan or proposal for our liquidation or dissolution; or </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial">(iv) our common stock ceases to be listed on any of the New York Stock Exchange, the Nasdaq Capital Market, the Nasdaq Global Market or the Nasdaq Global
Select Market (or any of their respective successors); </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>provided</I>,<I> however</I>, that a transaction or event described in clause (i)&nbsp;or (ii) above will
not constitute a<I> </I>fundamental change if at least 90% of the consideration received or to be received by the holders of our common stock (excluding cash payments for fractional shares or pursuant to dissenters rights), in connection with such
transaction or event, consists of shares of common stock or other corporate common equity interests listed (or depositary receipts representing shares of common stock or other corporate common equity interests, which depositary receipts are listed)
on any of the New York Stock Exchange, the Nasdaq Capital Market, the Nasdaq Global Market or the Nasdaq Global Select Market (or any of their respective successors), or that will be so listed when issued or exchanged in connection with such
transaction or event, and such transaction or event constitutes a common stock change event whose reference property consists of such consideration. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the
purposes of this definition, (x)&nbsp;any transaction or event described in both clause (i)&nbsp;and in clause (ii)(1) or (2)&nbsp;above (without regard to the proviso in clause (ii)) will be deemed to occur solely pursuant to clause (ii)&nbsp;above
(subject to such proviso); and (y)&nbsp;whether a person is a &#8220;beneficial owner,&#8221; whether shares are &#8220;beneficially owned,&#8221; and percentage beneficial ownership, will be determined in accordance with Rule <FONT
STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the avoidance of doubt, references to our &#8220;common stock&#8221; and &#8220;common
equity&#8221; in this definition will be subject to the provision described in the fifth bullet point under the caption &#8220;&#8212;Conversion Rights&#8212;Effect of Common Stock Change Event&#8212;Generally&#8221; above. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Holder&#8221; and &#8220;noteholder&#8221; mean a person in whose name a note is registered in the register for the notes. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Last reported sale price&#8221; of our common stock for any trading day means the closing sale price per share (or, if no closing sale price is reported, the
average of the last bid price and the last ask price per share or, if more </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
than one in either case, the average of the average last bid prices and the average last ask prices per share) of our common stock on such trading day as reported in composite transactions for
the principal U.S. national or regional securities exchange on which our common stock is then listed. If our common stock is not listed on a U.S. national or regional securities exchange on such trading day, then the last reported sale price will be
the last quoted bid price per share of our common stock on such trading day in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market as reported by OTC Markets Group Inc. or a similar
organization. If our common stock is not so quoted on such trading day, then the last reported sale price will be the average of the <FONT STYLE="white-space:nowrap">mid-point</FONT> of the last bid price and the last ask price per share of our
common stock on such trading day from a nationally recognized independent investment banking firm we select, which may be any of the underwriters. The &#8220;last reported sale price&#8221; will be determined without regard to after-hours trading or
any other trading outside of the regular trading session hours. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Make-whole fundamental change&#8221; means (i)&nbsp;a fundamental change (determined after
giving effect to the proviso immediately after clause (iv)&nbsp;of the definition thereof, but without regard to the proviso to clause (ii)(2) of such definition); or (ii)&nbsp;the sending of any notice of redemption pursuant to the provisions
described above under the caption &#8220;&#8212;Optional Redemption&#8221;; <I>provided</I>, <I>however</I>, that the sending of any such notice of redemption will constitute a make-whole fundamental change only with respect to the notes called (or
deemed to be called pursuant to the provisions described above under the caption &#8220;&#8212;Optional Redemption&#8221;) for redemption pursuant to such notice and not with respect to any other notes. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Make-whole fundamental change conversion period&#8221; has the following meaning: </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial">(i) in the case of a make-whole fundamental change pursuant to clause (i)&nbsp;of the definition thereof, the period from, and including, the make-whole
fundamental change effective date of such make-whole fundamental change to, and including, the 35th trading day after such make-whole fundamental change effective date (or, if such make-whole fundamental change also constitutes a fundamental change
(other than an exempted fundamental change), to, but excluding, the related fundamental change repurchase date); and </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial">(ii) in the case of a
make-whole fundamental change pursuant to clause (ii)&nbsp;of the definition thereof, the period from, and including, the date we send the redemption notice for the related redemption to, and including, the second scheduled trading day immediately
before the related redemption date; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>provided</I>,<I> however</I>, that if the conversion date for the conversion of a note that has been called (or deemed
called) for<I> </I>redemption occurs during the make-whole fundamental change conversion period for both a make-whole fundamental change occurring pursuant to clause (i)&nbsp;of the definition of &#8220;make-whole fundamental change&#8221; and a
make-whole fundamental change resulting from such redemption pursuant to clause (ii)&nbsp;of such definition, then, solely for purposes of such conversion, (x)&nbsp;such conversion date will be deemed to occur solely during the make-whole
fundamental change conversion period for the make-whole fundamental change with the earlier make-whole fundamental change effective date; and (y)&nbsp;the make-whole fundamental change with the later make-whole fundamental change effective date will
be deemed not to have occurred. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Make-whole fundamental change effective date&#8221; means (i)&nbsp;with respect to a make-whole fundamental change pursuant
to clause (i)&nbsp;of the definition thereof, the date on which such make-whole fundamental change occurs or becomes effective; and (ii)&nbsp;with respect to a make-whole fundamental change pursuant to clause (ii)&nbsp;of the definition thereof, the
applicable &#8220;redemption notice date&#8221; (as defined below). </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Market disruption event&#8221; means, with respect to any date, the occurrence or
existence, during the <FONT STYLE="white-space:nowrap">one-half</FONT> hour period ending at the scheduled close of trading on such date on the principal U.S. national or regional securities exchange or other market on which our common stock is
listed for trading or trades, of any material </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
suspension or limitation imposed on trading (by reason of movements in price exceeding limits permitted by the relevant exchange or otherwise) in our common stock or in any options contracts or
futures contracts relating to our common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Maturity date&#8221; means November&nbsp;15, 2031. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Observation period&#8221; means, with respect to any note to be converted, (i)&nbsp;subject to clause (ii)&nbsp;below, if the conversion date for such note occurs
before August&nbsp;15, 2031, the 25 consecutive VWAP trading days beginning on, and including, the second VWAP trading day immediately after such conversion date; (ii)&nbsp;if such conversion date occurs on or after the date we have sent a
redemption notice calling all or any notes for redemption and on or before the second scheduled trading day before the related redemption date, the 25 consecutive VWAP trading days beginning on, and including, the 26th scheduled trading day
immediately before such redemption date; and (iii)&nbsp;subject to clause (ii)&nbsp;above, if such conversion date occurs on or after August&nbsp;15, 2031, the 25&nbsp;consecutive VWAP trading days beginning on, and including, the 26th scheduled
trading day immediately before the maturity date. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Open of business&#8221; means 9:00 a.m., New York City time. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Person&#8221; means any individual, corporation, partnership, limited liability company, joint venture, association, joint-stock company, trust, unincorporated
organization or government or other agency or political subdivision thereof. Any division or series of a limited liability company, limited partnership or trust will constitute a separate &#8220;person.&#8221; </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Qualified successor entity&#8221; means, with respect to a business combination event, a corporation; <I>provided</I>,<I> however</I>, that (i)&nbsp;if such
business combination event is an exempted fundamental change, a limited liability company, limited partnership or other similar entity will also constitute a qualified successor entity with respect to such business combination event; and (ii)&nbsp;a
limited liability company or limited partnership that is the resulting, surviving or transferee person of such business combination event will also constitute a qualified successor entity with respect to such business combination event,
<I>provided</I> that, in the case of this clause (ii)&nbsp;all of the following conditions are satisfied: (1)&nbsp;either (x) such limited liability company or limited partnership is treated as a corporation or is a direct or indirect, wholly owned
subsidiary of, and disregarded as an entity separate from, a corporation, in each case for U.S. federal income tax purposes; or (y)&nbsp;we have received an opinion of a nationally recognized tax counsel to the effect that such business combination
event will not be treated as an exchange under Section&nbsp;1001 of the Internal Revenue Code of 1986, as amended, for holders or beneficial owners of the notes; (2)&nbsp;such business combination event constitutes a common stock change event whose
reference property consists solely of any combination of cash in U.S. dollars and shares of common stock or other corporate common equity interests of an entity that is (x)&nbsp;treated as a corporation for U.S. federal income tax purposes;
(y)&nbsp;duly organized and existing under the laws of the United States of America, any State thereof or the District of Columbia; and (z)&nbsp;a direct or indirect parent of such limited liability company or limited partnership; and (3)&nbsp;if
such limited liability company or limited partnership is disregarded as separate from its owner for U.S. federal income tax purposes, its regarded owner for those purposes is an entity described in clause (ii)(2). </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Redemption notice date&#8221; means, with respect to a redemption, the date on which we send the related redemption notice pursuant to the provisions described
above under the caption &#8220;&#8212;Optional Redemption.&#8221; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Scheduled trading day&#8221; means any day that is scheduled to be a trading day on the
principal U.S. national or regional securities exchange on which our common stock is then listed or, if our common stock is not then listed on a U.S. national or regional securities exchange, on the principal other market on which our common stock
is then traded. If our common stock is not so listed or traded, then &#8220;scheduled trading day&#8221; means a business day. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Securities Act&#8221; means the U.S. Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Significant subsidiary&#8221; of any person means any subsidiary of that person that constitutes a &#8220;significant subsidiary&#8221; (as defined in Rule <FONT
STYLE="white-space:nowrap">1-02(w)</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the Exchange Act) of that person. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Specified dollar
amount&#8221; means, with respect to the conversion of a note to which combination settlement applies, the maximum cash amount per $1,000 principal amount of such note deliverable upon such conversion (excluding cash in lieu of any fractional share
of our common stock). </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Stated interest&#8221; has the meaning set forth above under the caption &#8220;&#8212;Interest.&#8221; </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Stock price&#8221; has the following meaning for any make-whole fundamental change: (i)&nbsp;if the holders of our common stock receive only cash in consideration
for their shares of our common stock in such make-whole fundamental change and such make-whole fundamental change is pursuant to clause (ii)&nbsp;of the definition of &#8220;fundamental change,&#8221; then the stock price is the amount of cash paid
per share of our common stock in such make-whole fundamental change; and (ii)&nbsp;in all other cases, the stock price is the average of the last reported sale prices per share of our common stock for the five consecutive trading days ending on, and
including, the trading day immediately before the make-whole fundamental change effective date of such make-whole fundamental change. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Subsidiary&#8221;
means, with respect to any person, (i)&nbsp;any corporation, association or other business entity (other than a partnership or limited liability company) of which more than 50% of the total voting power of the capital stock entitled (without regard
to the occurrence of any contingency, but after giving effect to any voting agreement or stockholders&#8217; agreement that effectively transfers voting power) to vote in the election of directors, managers or trustees, as applicable, of such
corporation, association or other business entity is owned or controlled, directly or indirectly, by such person or one or more of the other subsidiaries of such person; and (ii)&nbsp;any partnership or limited liability company where (x)&nbsp;more
than 50% of the capital accounts, distribution rights, equity and voting interests, or of the general and limited partnership interests, as applicable, of such partnership or limited liability company are owned or controlled, directly or indirectly,
by such person or one or more of the other subsidiaries of such person, whether in the form of membership, general, special or limited partnership or limited liability company interests or otherwise; and (y)&nbsp;such person or any one or more of
the other subsidiaries of such person is a controlling general partner of, or otherwise controls, such partnership or limited liability company. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Trading
day&#8221; means any day on which (i)&nbsp;trading in our common stock generally occurs on the principal U.S. national or regional securities exchange on which our common stock is then listed or, if our common stock is not then listed on a U.S.
national or regional securities exchange, on the principal other market on which our common stock is then traded; and (ii)&nbsp;there is no &#8220;market disruption event&#8221; (as defined above in this &#8220;&#8212;Definitions&#8221; section). If
our common stock is not so listed or traded, then &#8220;trading day&#8221; means a business day. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Trading price&#8221; of the notes on any trading day means
the average of the secondary market bid quotations, expressed as a cash amount per $1,000 principal amount of notes, obtained by the bid solicitation agent for $1,000,000 (or such lesser amount as may then be outstanding) in principal amount of
notes at approximately 3:30 p.m., New York City time, on such trading day from three nationally recognized independent securities dealers we select, which may include any of the underwriters; <I>provided</I>, <I>however</I>, that, if three such bids
cannot reasonably be obtained by the bid solicitation agent but two such bids are obtained, then the average of the two bids will be used, and if only one such bid can reasonably be obtained by the bid solicitation agent, then that one bid will be
used. If, on any trading day, (i)&nbsp;the bid solicitation agent cannot reasonably obtain at least one bid for $1,000,000 (or such lesser amount as may then be outstanding) in principal amount of notes from a nationally recognized independent
securities dealer; (ii)&nbsp;we are not acting as the bid solicitation agent and we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
fail to instruct the bid solicitation agent to obtain bids when required; or (iii)&nbsp;the bid solicitation agent fails to solicit bids when required, then, in each case, the trading price per
$1,000 principal amount of notes on such trading day will be deemed to be less than 98% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;VWAP market disruption event&#8221; means, with respect to any date, (i)&nbsp;the failure by the principal U.S. national or regional securities exchange on which
our common stock is then listed, or, if our common stock is not then listed on a U.S. national or regional securities exchange, the principal other market on which our common stock is then traded, to open for trading during its regular trading
session on such date; or (ii)&nbsp;the occurrence or existence, for more than one half hour period in the aggregate, of any suspension or limitation imposed on trading (by reason of movements in price exceeding limits permitted by the relevant
exchange or otherwise) in our common stock or in any options contracts or futures contracts relating to our common stock, and such suspension or limitation occurs or exists at any time before 1:00 p.m., New York City time, on such date. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;VWAP trading day&#8221; means a day on which (i)&nbsp;there is no VWAP market disruption event; and (ii)&nbsp;trading in our common stock generally occurs on the
principal U.S. national or regional securities exchange on which our common stock is then listed or, if our common stock is not then listed on a U.S. national or regional securities exchange, on the principal other market on which our common stock
is then traded. If our common stock is not so listed or traded, then &#8220;VWAP trading day&#8221; means a business day. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8220;Wholly owned subsidiary&#8221; of a
person means any subsidiary of such person all of the outstanding capital stock or other ownership interests of which (other than directors&#8217; qualifying shares) are owned by such person or one or more wholly owned subsidiaries of such person.
</P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Book Entry, Settlement and Clearance </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Global Notes </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The notes will be initially issued in the form of one or more notes registered in the name of Cede&nbsp;&amp; Co., as nominee of DTC, without interest coupons (the
&#8220;global notes&#8221;), and will be deposited with the trustee as custodian for DTC. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Only persons who have accounts with DTC (&#8220;DTC participants&#8221;)
or persons who hold interests through DTC participants may own beneficial interests in a global note. We expect that, under procedures established by DTC: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">upon deposit of a global note with DTC&#8217;s custodian, DTC will credit portions of the principal amount of the global
note to the accounts of the DTC participants designated by the underwriters; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">ownership of beneficial interests in a global note will be shown on, and transfers of such interests will be effected only
through, records maintained by DTC (with respect to interests of DTC participants) and the records of DTC participants (with respect to other owners of beneficial interests in the global note). </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Book-Entry Procedures for Global Notes </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">All interests in a global note
will be subject to the operations and procedures of DTC. Accordingly, you must allow for sufficient time in order to comply with those operations and procedures if you wish to exercise any of your rights with respect to global notes. The operations
and procedures of DTC are controlled by DTC and may be changed at any time. None of us, the trustee, the paying agent or any of the underwriters will be responsible for those operations or procedures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">DTC has advised us that it is: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a limited purpose trust company organized under the laws of the State of New York; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a &#8220;banking organization&#8221; within the meaning of the New York State Banking Law; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a member of the Federal Reserve System; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a &#8220;clearing corporation&#8221; within the meaning of the Uniform Commercial Code; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a &#8220;clearing agency&#8221; registered under Section&nbsp;17A of the Exchange Act. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">DTC was created to hold securities for its participants and to facilitate the clearance and settlement of securities transactions between its participants through
electronic book-entry changes to the accounts of its participants. DTC&#8217;s participants include securities brokers and dealers (including the underwriters), banks and trust companies, clearing corporations and other organizations. Indirect
access to DTC&#8217;s book-entry system is also available to other &#8220;indirect participants,&#8221; such as banks, brokers, dealers and trust companies, who directly or indirectly clear through or maintain a custodial relationship with a DTC
participant. Purchasers of notes who are not DTC participants may beneficially own securities held by or on behalf of DTC only through DTC participants or indirect participants in DTC. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">So long as DTC or its nominee is the registered owner of a global note, DTC or that nominee will be considered the sole owner or holder of the notes represented by that
global note for all purposes under the indenture. Except as provided below, owners of beneficial interests in a global note: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">will not be entitled to have notes represented by the global note registered in their names; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">will not receive or be entitled to receive physical, certificated notes; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">will not be considered the owners or holders of the notes under the indenture for any purpose. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As a result, each investor who owns a beneficial interest in a global note must rely on the procedures of DTC (and, if the investor is not a participant or an indirect
participant in DTC, on the procedures of the DTC participant through whom the investor owns its interest) to exercise any rights of a noteholder under the indenture. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Payments on any global notes will be made to DTC or its nominee as the registered holder of the global note. None of us, the trustee (including in its capacity as paying
agent) or any of the underwriters will have any responsibility or liability for the payment of amounts to owners of beneficial interests in a global note, for any aspect of the records relating to, or payments made on account of, those interests by
DTC or for maintaining, supervising or reviewing any records of DTC relating to those interests. Payments by participants and indirect participants in DTC to the owners of beneficial interests in a global note will be governed by standing
instructions and customary industry practice and will be the responsibility of those participants or indirect participants and DTC. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Transfers between participants
in DTC will be effected under DTC&#8217;s procedures and will be settled in <FONT STYLE="white-space:nowrap">same-day</FONT> funds. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Physical Notes
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A global note will be exchanged, pursuant to customary procedures, for one or more physical notes only if: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">DTC notifies us or the trustee that it is unwilling or unable to continue as depositary for such global note or DTC ceases
to be a &#8220;clearing agency&#8221; registered under Section&nbsp;17A of the Exchange Act and, in each case, we fail to appoint a successor depositary within 90 days of such notice or cessation; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">an event of default has occurred and is continuing and we, the trustee or the registrar has received a written request from
DTC, or from a holder of a beneficial interest in such global note, to exchange such global note or beneficial interest, as applicable, for one or more physical notes; or </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">we, in our sole discretion, permit the exchange of any beneficial interest in such global note for one or more physical notes at the request of the owner of such
beneficial interest. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="supptoc159388_9"></A>DESCRIPTION OF THE CONCURRENT EQUITY OFFERING </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Concurrently with this offering, we are offering 9,677,420 shares of our common stock (or 11,129,033&nbsp;shares of our common stock if the underwriters in the
Concurrent Equity Offering exercise their option to purchase additional shares of common stock in full) pursuant to a separate prospectus supplement in an underwritten public offering. On November&nbsp;11, 2025, the last reported sale price of our
common stock was $33.42 per share. Based on 164,155,222 shares of common stock outstanding as of September&nbsp;30, 2025, after giving effect to the conversion of 67,414 shares of our outstanding Series A
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred Stock into 16,853,500 shares of common stock, the conversion of 6,868 shares of our outstanding Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Convertible
Preferred Stock into 6,868,000 shares of common stock, and the exercise of our outstanding <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants into 606,060 shares of common stock, and assuming the sale of 9,677,420 shares of our common stock
in the Concurrent Equity Offering, we will have 173,832,642 shares of common stock outstanding immediately following the Concurrent Equity Offering (assuming the underwriters of the Concurrent Equity Offering do not exercise their option to purchase
additional shares of common stock). </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The closing of this offering is not conditioned upon the closing of the Concurrent Equity Offering, and the closing of the
Concurrent Equity Offering is not conditioned upon the closing of this offering. We cannot assure you that the Concurrent Equity Offering will be completed or, if completed, on what terms it will be completed. The Concurrent Equity Offering is being
made pursuant to a separate prospectus supplement, and nothing contained herein shall constitute an offer to sell or the solicitation of an offer to buy securities in the Concurrent Equity Offering. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">See &#8220;Use of Proceeds&#8221; for additional information regarding the use of proceeds from the Concurrent Equity Offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="supptoc159388_10"></A>DESCRIPTION OF OTHER INDEBTEDNESS </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following discussion provides summary information about certain of our existing indebtedness and does not purport to be a complete description of all the information
that might be important to you. It does not reflect the effects of any additional liquidity we may seek in the private markets. See the &#8220;Risk Factors&#8221; section of this prospectus supplement for a discussion of the risks related to our
current liquidity position. For additional information regarding the terms of our existing indebtedness, see our periodic reports, including our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> in particular the consolidated
financial statements contained therein and the notes thereto, and subsequent Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> as filed with the SEC and incorporated by reference into this prospectus supplement and the
accompanying prospectus. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Loan and Security Agreement </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On June&nbsp;11,
2025 (the &#8220;Closing Date&#8221;), we entered into a loan and security agreement (the &#8220;Loan and Security Agreement&#8221;) as a borrower with our subsidiaries (each a &#8220;Guarantor,&#8221; collectively, the &#8220;Guarantors&#8221;)
with the lenders party thereto (the &#8220;Lenders&#8221;), and SLR Investment Corp., as the administrative agent and collateral agent for itself and the Lenders (&#8220;SLR&#8221;). The Loan and Security Agreement provides for the Credit Facility
of up to an aggregate principal amount of $400.0&nbsp;million, of which a first tranche of $50.0&nbsp;million was fully funded on the Closing Date, with future tranches at our election subject to achievement of milestones consisting of (a)&nbsp;a
second tranche of $25.0&nbsp;million subject to us announcing positive data from our phase 2 SUMMIT clinical trial, (b)&nbsp;a third tranche of $75.0&nbsp;million subject to us announcing positive data from our phase 3 PEAK clinical trial,
(c)&nbsp;a fourth tranche of $50.0&nbsp;million subject to us achieving at least $85.0&nbsp;million in net product revenue on a trailing six month basis on or prior to June&nbsp;30, 2027, and (d)&nbsp;a fifth tranche of $200.0&nbsp;million subject
to mutual agreement between us and SLR. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Credit Facility matures on June&nbsp;1, 2030 (the &#8220;Maturity Date&#8221;) and bears interest at an annual rate
equal to 4.75% plus the greater of <FONT STYLE="white-space:nowrap">(i)&nbsp;one-month</FONT> term Secured Overnight Financing Rate, and (ii) 4.15% per annum. We are permitted to use the proceeds of the Credit Facility for working capital and
general business purposes. We are obligated to make monthly interest-only payments with respect to the Credit Facility until June&nbsp;1, 2028; however, if certain conditions are satisfied, then we may elect to defer principal payments until
June&nbsp;1, 2029. Thereafter, we shall make (i)&nbsp;monthly payments of interest plus (ii)&nbsp;consecutive equal monthly payments of principal through to the Maturity Date. All unpaid principal and accrued and unpaid interest with respect to the
Credit Facility is due and payable in full on the Maturity Date. We may, at our option at any time, prepay all loans under the Credit Facility by paying the principal balance, plus accrued and unpaid interest, subject to a prepayment premium ranging
from 3.0% to 1.0%. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">All obligations under the Loan and Security Agreement will be secured on a first-priority basis, subject to certain exceptions, by security
interests in substantially all of the assets of the Company and the Guarantors. The Loan and Security Agreement also contains customary covenants, as well as certain events of default after which loans under the Credit Facility may be due and
payable immediately. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="supptoc159388_11"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following is a summary of the material U.S. federal income tax considerations of the ownership, conversion and disposition of the notes issued pursuant to this
offering and the ownership and disposition of the shares of our common stock into which the notes may be converted, but does not purport to be a complete analysis of all potential U.S. federal income or other tax effects. The effects of other U.S.
federal tax laws, such as estate and gift tax laws, and any applicable state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws are not discussed. This summary is based upon provisions of the U.S. Internal Revenue Code of 1986, as
amended (the &#8220;Code&#8221;), Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the U.S. Internal Revenue Service (the &#8220;IRS&#8221;), in each case as of the date
hereof. These authorities may change or be subject to differing interpretations so as to result in U.S. federal income tax consequences different from those discussed below, including in a manner that may adversely affect an investor in the notes or
the shares of our common stock into which the notes may be converted. Any such change or differing interpretation may be applied retroactively. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below.
There can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax consequences of the ownership, conversion or disposition of the notes, or of the ownership or disposition of the shares of our
common stock into which the notes may be converted. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This summary addresses only notes held as a &#8220;capital asset&#8221; within the meaning of Section&nbsp;1221
of the Code (generally, property held for investment) by a beneficial owner who purchased the notes on original issuance for cash at their &#8220;issue price&#8221; (generally, the first price at which a substantial amount of the notes is sold for
cash to persons other than bond houses, brokers, or similar persons or organizations acting in the capacity of underwriters, placement agents or wholesalers), and shares of common stock received upon conversion of such a note and held as a capital
asset. This summary does not address all aspects of U.S. federal income taxes that may be relevant to investors in the notes or the shares of our common stock into which the notes may be converted (including any alternative minimum tax, the
potential application of the Medicare contribution tax on net investment income and the special tax accounting rules under Section&nbsp;451(b) of the Code), nor does it address all tax consequences that may be relevant to investors in light of their
personal circumstances or particular situations, or the tax consequences applicable to taxpayers subject to special rules, such as: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">brokers, dealers or traders in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">banks, insurance companies or other financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">regulated investment companies or real estate investment trusts; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> entities or governmental organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#8220;controlled foreign corporations,&#8221; &#8220;passive foreign investment companies,&#8221; or corporations that
accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#8220;qualified foreign pension funds&#8221; as defined in Section&nbsp;897(l)(2) of the Code and entities all of the
interests of which are held by qualified foreign pension funds; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">persons holding notes or shares of common stock received upon conversion of the notes as a part of an integrated or
conversion transaction or as part of a hedge, straddle, or other risk reduction strategy; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">persons deemed to sell notes or common stock received upon conversion of the notes under the constructive sale provisions
of the Code; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">U.S. holders (as defined below) whose &#8220;functional currency&#8221; is not the U.S. dollar; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">partnerships, S corporations or other pass-through entities or arrangements or investors in such entities or arrangements;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">persons holding (actually or constructively) more than 5% of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">persons that participate in the Concurrent Common Stock Offering; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">persons holding indebtedness issued pursuant to the Term Loans that is repaid with the proceeds from this offering; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">U.S. expatriates and former citizens or long-term residents of the United States. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If an entity or arrangement, domestic or foreign, that is classified as a partnership for U.S. federal income tax purposes holds notes or shares of our common stock, the
tax treatment of a partner in the partnership generally will depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Accordingly, partnerships holding the notes or shares of our
common stock received upon conversion of the notes and the partners in such partnerships should consult their tax advisors. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>THIS DISCUSSION IS FOR INFORMATIONAL
PURPOSES ONLY AND IS NOT TAX ADVICE. YOU ARE URGED TO CONSULT YOUR TAX ADVISOR WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO YOUR PARTICULAR SITUATION AS WELL AS ANY TAX CONSEQUENCES OF THE OWNERSHIP, CONVERSION AND
DISPOSITION OF NOTES AND THE OWNERSHIP AND DISPOSITION OF THE SHARES OF COMMON STOCK INTO WHICH THE NOTES ARE CONVERTIBLE ARISING UNDER OTHER U.S. FEDERAL TAX LAWS (INCLUDING ESTATE AND GIFT TAX LAWS), UNDER THE LAWS OF ANY STATE, LOCAL OR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> TAXING JURISDICTION OR UNDER ANY APPLICABLE TAX TREATY. </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As used herein, a &#8220;U.S. holder&#8221; is a beneficial
owner of a note or share of our common stock received upon conversion of a note that is, for U.S. federal income tax purposes: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a corporation created or organized in or under the laws of the United States, any state thereof or the District of
Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">an estate the income of which is subject to U.S. federal income taxation regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a trust, if it (i)&nbsp;is subject to the primary supervision of a court within the United States and one or more
&#8220;United States persons&#8221; (within the meaning of Section&nbsp;7701(a)(30) of the Code) have the authority to control all substantial decisions of the trust, or (ii)&nbsp;has a valid election in effect to be treated as a United States
person. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As used herein, a <FONT STYLE="white-space:nowrap">&#8220;non-U.S.</FONT> holder&#8221; is a beneficial owner (other than a partnership)
of a note or share of our common stock received upon conversion of a note that is not a U.S. holder. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>U.S. Holder Considerations </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Interest on the Notes </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">It is anticipated, and this discussion assumes,
that the notes will be issued with less than a de minimis amount of original issue discount for U.S. federal income tax purposes. In such case, stated interest on the notes generally will be taxable to a U.S. holder as ordinary income at the time it
is paid or accrued in accordance with the U.S. holder&#8217;s regular method of accounting for U.S. federal income tax purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Sale, Exchange, Redemption, Repurchase or Other Taxable Disposition of Notes </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Except as provided below under &#8220;&#8212;<I>Conversion of Notes</I>,&#8221; a U.S. holder generally will recognize gain or loss upon the sale, exchange, redemption,
repurchase or other taxable disposition of a note (including an exchange with a designated financial institution in lieu of conversion, as described in &#8220;<I>Description of Notes</I>&#8212;Exchange in Lieu of Conversion&#8221; and a conversion
entirely paid in cash) equal to the difference between the amount realized (less accrued but unpaid interest, which will be treated as described above under &#8220;&#8212;<I>Interest on the Notes</I>&#8221;) upon such sale, exchange, redemption,
repurchase, or other taxable disposition and such U.S. holder&#8217;s adjusted tax basis in the note. The amount realized by a U.S. holder will include the amount of any cash and the fair market value of any other property received for the note upon
such taxable disposition. A U.S. holder&#8217;s adjusted tax basis in a note generally will be equal to the amount that the U.S. holder paid for the note, increased by the amount, if any, included in income on any adjustment (or failure to make an
adjustment) to the conversion rate of the note, as described in &#8220;&#8212;<I>Constructive Distributions</I>&#8221; below. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any gain or loss recognized on a sale,
exchange, redemption, repurchase or other taxable disposition of a note generally will be capital gain or loss. If, at the time of the sale, exchange, redemption, repurchase or other taxable disposition of the note, a U.S. holder is treated as
holding the note for more than one year, such gain or loss generally will be long-term capital gain or loss. Otherwise, such gain or loss will be short-term capital gain or loss. In the case of certain
<FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. holders (including individuals), long-term capital gains are generally eligible for a reduced rate of U.S. federal income tax. The deductibility of capital losses is subject to limitations.
</P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Conversion of Notes </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If a U.S. holder presents a note for
conversion, the U.S. holder may receive solely cash, solely shares of our common stock, or a combination of cash and shares of our common stock in exchange for the note, depending upon our chosen settlement method. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Conversion of notes into cash </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If a U.S. holder receives solely cash
in exchange for a note upon conversion, the U.S. holder generally will recognize gain or loss upon such conversion, and the U.S. holder&#8217;s gain or loss generally will be determined in the same manner as if the U.S. holder disposed of the note
in a sale, exchange, redemption, repurchase or other taxable disposition (as described above under &#8220;&#8212;<I>Sale, Exchange, Redemption, Repurchase or Other Taxable Disposition of Notes</I>&#8221;). </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Conversion of notes into common stock or a combination of our common stock and cash </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As described below, the tax treatment of a conversion of a note into common stock, or into a combination of cash and common stock, is, in each case, uncertain and
subject to different possible characterizations. U.S. holders are urged to consult their tax advisors regarding the consequences of such a conversion. In general, the U.S. federal income tax treatment will depend on whether the conversion is treated
as a recapitalization (which requires that a note be treated as a &#8220;security&#8221; for U.S. federal income tax purposes) or, alternatively, as a conversion of a portion of the note into common stock and a taxable sale of a portion of the note
for cash. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We intend to take the position that the notes are securities for relevant U.S. federal income tax purposes, and that if common stock, or a combination of
cash and shares of our common stock, is received by a U.S. holder upon conversion of a note (other than an exchange with a designated financial institution in lieu of conversion, as described in &#8220;<I>Description of Notes</I>&#8212;<I>Exchange
in Lieu of Conversion</I>,&#8221; which would be taxable as described above under &#8220;&#8212;<I>Sale, Exchange, Redemption, Repurchase or Other Taxable Disposition of Notes</I>&#8221;), we intend to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
treat the conversion as a recapitalization for U.S. federal income tax purposes. However, as noted above, this position is not free from doubt and there can be no assurance in this regard. For
example, the term &#8220;security&#8221; is not defined in the Code or the Treasury Regulations and has not been clearly defined by judicial decisions. Therefore, a note may not constitute a &#8220;security&#8221; for U.S. federal income tax
purposes notwithstanding our position. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Possible treatment as a recapitalization </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If the notes are securities and the conversion is treated as a recapitalization for U.S. federal income tax purposes, a U.S. holder would be required to recognize gain
(but not loss) in an amount equal to the excess of (i)&nbsp;(A) the fair market value of our common stock received (treating fractional shares as received for this purpose) and (B)&nbsp;the amount of cash received in the conversion (other than any
cash or common stock attributable to accrued but unpaid interest, which will be treated as described above under &#8220;&#8212;<I>Interest on the Notes</I>,&#8221; and other than any cash received in lieu of a fractional share, which will be treated
as described below under &#8220;&#8212;<I>Treatment of cash in lieu of a fractional share</I>&#8221;) over (ii)&nbsp;the U.S. holder&#8217;s adjusted tax basis in the note; but in no event would the gain recognized exceed the amount of cash received
upon conversion (other than any cash received in lieu of a fractional share or attributable to accrued but unpaid interest). </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The U.S. holder would have an aggregate
tax basis in the shares of our common stock received upon such a conversion (including any fractional share deemed to be received by the U.S. holder, but other than any common stock received with respect to accrued but unpaid interest, the tax basis
of which would equal its fair market value) would equal the aggregate adjusted tax basis of the notes converted, decreased by the amount of any cash received on conversion (other than cash received in lieu of a fractional share or cash attributable
to accrued but unpaid interest), and increased by the amount of gain, if any, recognized on conversion (other than gain recognized on any cash received in lieu of fractional shares). A U.S. holder&#8217;s tax basis in a fractional share of our
common stock will be determined by allocating such U.S. holder&#8217;s tax basis in the shares of our common stock, as determined in accordance with the previous sentence, between the shares of our common stock actually received and the fractional
share of our common stock deemed received upon conversion, in accordance with their respective fair market values. A U.S. holder&#8217;s holding period for the shares of our common stock would include the period during which the U.S. holder held the
note. Any gain or loss recognized by a U.S. holder on conversion of a note generally would be capital gain or loss and generally would be long-term capital gain or loss if, at the time of the conversion, the U.S. holder has held the note for more
than one year. The deductibility of capital losses is subject to limitations. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Possible treatment as part conversion and part redemption </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If the conversion of a note into common stock, or into a combination of cash and shares of our common stock (other than an exchange with a designated financial
institution in lieu of conversion, as described in &#8220;<I>Description of Notes</I>&#8212;<I>Exchange in Lieu of Conversion</I>,&#8221; which would be taxable as described above under &#8220;&#8212;<I>Sale, Exchange, Redemption</I>, <I>Repurchase
or Other Taxable Disposition of Notes</I>&#8221;) were not treated as a recapitalization as discussed above, the cash received on conversion (excluding cash attributable to accrued but unpaid interest) may be treated as proceeds from the redemption
of a portion of the note and taxed in the manner described above under &#8220;&#8212;<I>Sale, Exchange, Redemption, Repurchase or Other Taxable Disposition of Notes</I>.&#8221; A U.S. holder would not recognize any income, gain or loss with respect
to the portion of the note considered to be converted into stock, except with respect to any cash received in lieu of a fractional share of stock or any common stock attributable to accrued interest (as described above). The U.S. holder&#8217;s tax
basis in the stock received upon conversion (other than common stock received with respect to accrued interest) generally would be equal to the portion of its adjusted tax basis in the note allocable to the portion of the note deemed converted. The
holding period for our common stock received in such a conversion would include the holding period for the note. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Although the law on this point is not entirely clear, a U.S. holder may allocate its adjusted tax basis in a note
among the portion of the note that is deemed to have been converted and the portion of the note that is deemed to have been redeemed based on the relative fair market value of our common stock and the amount of cash received upon conversion. In
light of the uncertainty in the law, holders are urged to consult their tax advisors regarding such basis allocation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">U.S. holders are urged to consult their tax
advisors with respect to the U.S. federal income tax consequences resulting from the exchange of notes into a combination of cash and our common stock. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Treatment of cash in lieu of a fractional share </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Cash received in lieu
of a fractional share of our common stock upon a conversion of a note generally will be treated as if the fractional share were redeemed for cash. Accordingly, a U.S. holder generally will recognize capital gain or loss with respect to the receipt
of cash in lieu of a fractional share, which will equal the difference between the amount of cash received in lieu of such fractional share and the portion of the U.S. holder&#8217;s adjusted tax basis in shares of our common stock received that is
allocated to such fractional share. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Treatment of amounts attributable to accrued but unpaid interest </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any cash and the value of any common stock received that is attributable to accrued interest on the notes not yet included in income will be taxed as ordinary interest
income. The basis in any shares of our common stock attributable to accrued interest will equal the fair market value of such shares when received. The holding period for any shares of our common stock attributable to accrued interest will begin the
day after the date of receipt. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As described above in the section titled &#8220;<I>Description of Notes</I>&#8212;<I>Conversion Rights</I>&#8212;<I>Treatment of
Interest Upon Conversion</I>,&#8221; our delivery of cash, shares of our common stock, or a combination of cash and shares of our common stock will generally be deemed to satisfy our obligation with respect to accrued and unpaid interest on the
notes. We intend to take the position that upon a conversion of notes, accrued and unpaid interest is first paid by any cash paid upon such conversion (other than cash paid in lieu of a fractional share), and this discussion assumes that such
position will be respected. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Exchange in lieu of conversion </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In
the case of an exchange with a designated financial institution in lieu of conversion, as described in &#8220;<I>Description of Notes</I><I></I><I>&#8212;Exchange in Lieu of Conversion</I>,&#8221; the U.S. holder will be taxed on the transfer as a
taxable disposition of the notes, as described above under &#8220;&#8212;<I>Sale, Exchange, Redemption, Repurchase or Other Taxable Disposition of Notes</I>.&#8221; In such case, the U.S. holder&#8217;s tax basis in any shares of our common stock
received will equal the fair market value of such shares on the date of the exchange, and the U.S. holder&#8217;s holding period in such shares will begin the day after the date of the exchange. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Possible effect of a change in conversion consideration </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In certain
situations, the notes may become convertible into shares of an acquirer or other consideration. Depending on the circumstances, such an event could result in a deemed taxable exchange of the notes to a U.S. holder, potentially resulting in the
recognition of taxable gain or loss, and the modified notes could be treated as newly issued at that time. Furthermore, depending on the circumstances, subsequent to any such event, the U.S. federal income tax consequences of the ownership and
conversion of the modified notes as well as the ownership of the shares of the applicable acquirer or other consideration may be different from the U.S. federal income tax considerations addressed in this discussion. In particular, whether or not
such an event results in a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
deemed taxable exchange of the outstanding notes, a subsequent conversion of the notes might be treated as a fully taxable disposition of the notes if the property into which the notes are
convertible is no longer stock of the notes&#8217; obligor. Holders of the notes are urged to consult their tax advisors regarding U.S. federal income tax considerations relating to a change in conversion consideration. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This &#8220;&#8212;<I>Conversion of Notes</I>&#8221; section should be read in conjunction with the discussion under &#8220;&#8212;<I>Constructive
Distributions</I>&#8221; below regarding the possibility that an adjustment to the conversion rate of a note converted in connection with a make-whole fundamental change may be treated as a taxable stock dividend. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Constructive Distributions </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The conversion rate of the notes will be
adjusted in certain circumstances. Adjustments (or failures to make adjustments) that have the effect of increasing a holder&#8217;s proportionate interest in our assets or earnings and profits may, in some circumstances, result in a deemed
distribution to a holder for U.S. federal income tax purposes even though no cash or property is received. Adjustments to the conversion rate made pursuant to a <I>bona fide</I> reasonable adjustment formula that have the effect of preventing the
dilution of the interest of the holders of the notes, however, generally will not result in a deemed distribution to a holder. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Certain of the possible conversion
rate adjustments (or failures to make adjustments) provided in the notes (including, without limitation, adjustments in respect of taxable dividends to holders of our common stock) will not qualify as being pursuant to a <I>bona fide</I> reasonable
adjustment formula. If such adjustments are made (or not made), a holder generally will be deemed to have received a distribution even though the holder has not received any cash or property as a result of such conversion rate adjustment. In
addition, an adjustment to the conversion rate in connection with a make-whole fundamental change may, in some circumstances, be treated as a deemed distribution. Any deemed distribution will be taxable as a dividend, return of capital, or capital
gain as described below under &#8220;&#8212;<I>Distribution</I>s <I>on our Common Stock</I>.&#8221; If an event occurs that increases the interests of holders of the notes and the conversion rate is not adjusted, the resulting increase in the
proportionate interests of holders of the notes could be treated as a taxable stock dividend to such holders. Conversely, if an event occurs that dilutes the interests of holders of the notes and the conversion rate is not adjusted, the resulting
increase in the proportionate interests of our stockholders could be treated as a taxable stock dividend to those stockholders. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Although there is no authority
directly on point, the IRS may take the position that a constructive dividend deemed paid to a <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. holder would not be eligible for the preferential rates of U.S. federal income tax applicable
in respect of certain dividends received as described below under &#8220;&#8212;<I>Distributions on our Common Stock</I>.&#8221; It is also unclear whether corporate U.S. holders would be entitled to claim the dividends received deduction with
respect to any such constructive dividends. Because a constructive dividend deemed received by a U.S. holder would not give rise to any cash from which any applicable withholding tax could be satisfied, if we or other payors pay backup withholding
on behalf of a U.S. holder (because such U.S. holder failed to establish an exemption from backup withholding) or any other withholding taxes on behalf of a U.S. holder, it is possible that we or such payor may set off any such payment against
payments of cash and common stock payable on the notes (or, in certain circumstances, against payments on our common stock). Generally, a U.S. holder&#8217;s adjusted tax basis in a note will be increased to the extent any such constructive
distribution is treated as a dividend. U.S. holders are urged to consult their tax advisors regarding the tax treatment of a constructive distribution. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are
currently required to report the amount of any deemed distributions on our website or to the IRS and to holders of notes not exempt from information reporting. Proposed Treasury Regulations address the amount and timing of deemed distributions, as
well as obligations of withholding agents and filing and notice obligations of issuers in respect of such deemed distributions. If adopted as proposed, the regulations would </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
generally provide that (i)&nbsp;the amount of a deemed distribution is the excess of the fair market value of the right to acquire stock immediately after the conversion rate adjustment over the
fair market value of the right to acquire stock without the adjustment, (ii)&nbsp;the deemed distribution occurs at the earlier of the date the adjustment occurs under the terms of the note and the date of the actual distribution of cash or property
that results in the deemed distribution, (iii)&nbsp;subject to certain limited exceptions, a withholding agent is required to impose any applicable withholding on deemed distributions and, if there is no associated cash payment, may withhold the
required amounts from, or set off the required amounts against, payments on the notes, payments on our common stock or sales proceeds received by, or other funds or assets of, an investor, and (iv)&nbsp;we are required to report the amount of any
deemed distributions on our website or to the IRS and all holders of notes (including holders of notes that would otherwise be exempt from information reporting). The regulations, if finalized, will be effective for deemed distributions occurring on
or after the date of their adoption as final regulations, but holders of notes and withholding agents may rely on the proposed regulations prior to that date under certain circumstances. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Holders are urged to carefully review the conversion rate adjustment provisions and consult their tax advisors with respect to the tax consequences of any such
adjustment, including the impact a deemed distribution may have on their holding period in the notes. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Distributions on our Common Stock </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Distributions, if any, made on our common stock received upon conversion of the notes, other than certain <I>pro rata</I> distributions of common stock or rights to
acquire common stock, generally will be included in the income of a U.S. holder of our common stock as ordinary dividend income to the extent of our current or accumulated earnings and profits, as determined under U.S. federal income tax principles.
Distributions in excess of our current and accumulated earnings and profits generally will be treated as a <FONT STYLE="white-space:nowrap">tax-free</FONT> return of capital and, to the extent in excess of such U.S. holder&#8217;s adjusted tax basis
in our common stock, will be treated as capital gain from the sale, exchange, redemption or other taxable disposition of such common stock and taxed as described below in &#8220;&#8212;<I>Sale, Exchange, Certain Redemptions or Other Taxable
Dispositions of Common Stock</I>.&#8221; Dividends received by a corporate U.S. holder may be eligible for a dividends received deduction, subject to applicable limitations. Dividends received by certain
<FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. holders (including individuals) generally are taxed at the lower applicable long-term capital gains rates, provided certain holding period and other requirements are satisfied. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">U.S. holders are urged to consult their tax advisors regarding the holding period and other requirements that must be satisfied in order to qualify for the
dividends-received deduction and the reduced maximum tax rate on dividends. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Sales, Certain Redemptions or Other Taxable Dispositions of Common Stock
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon sales, certain redemptions or other taxable dispositions of our common stock, a U.S. holder generally will recognize capital gain or loss equal to the
difference between (i)&nbsp;the amount of cash and the fair market value of any property received upon such sale, redemption or other taxable disposition, and (ii)&nbsp;the U.S. holder&#8217;s adjusted tax basis in our common stock. Such capital
gain or loss will be long-term capital gain or loss if a U.S. holder&#8217;s holding period at the time of the sale, redemption or other taxable disposition of our common stock is more than one year. In the case of certain <FONT
STYLE="white-space:nowrap">non-corporate</FONT> U.S. holders (including individuals), long-term capital gains generally are eligible for a reduced rate of U.S. federal income tax. The deductibility of capital losses is subject to limitations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder Considerations </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Interest on the Notes </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Subject to the discussions below under
&#8220;<I>Information Reporting and Backup Withholding</I>&#8212;<I><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders</I>&#8221; and &#8220;<I>Foreign Account Tax Compliance Act</I>,&#8221; interest paid on a note to a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will not be subject to U.S. federal income or withholding tax in respect of interest income on a note, provided that: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">interest paid on the note is not effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder&#8217;s conduct of a trade or business in the United States; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder does not actually or constructively (pursuant to the conversion
feature of the notes or otherwise) own 10% or more of the total combined voting power of all classes of our stock that are entitled to vote within the meaning of Section&nbsp;871(h)(3) of the Code; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is not a &#8220;controlled foreign corporation&#8221; that is
related to us (actually or constructively) through stock ownership as described in Section&nbsp;881(c)(3)(C) of the Code; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is not a bank whose receipt of interest on the note is
described in Section&nbsp;881(c)(3)(A) of the Code; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder (a)&nbsp;provides its name and address, and certifies, under
penalties of perjury, that it is not a U.S. person (which certification may be made on an IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT>
(or other applicable form)) or (b)&nbsp;holds the notes through certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> intermediaries or certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> partnerships, and the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> intermediary or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> partnership satisfies the certification requirements of applicable
Treasury Regulations. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder cannot satisfy the requirements described above, payments of
interest will be subject to U.S. federal withholding tax at a rate of 30%, unless the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder provides the applicable withholding agent with a properly executed (i)&nbsp;IRS Form <FONT
STYLE="white-space:nowrap">W-8BEN</FONT> or IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or other applicable form) claiming an exemption from or reduction in withholding under an applicable
income tax treaty or (ii)&nbsp;IRS Form <FONT STYLE="white-space:nowrap">W-8ECI</FONT> (or other applicable form) stating that interest paid on the notes is not subject to withholding tax because it is effectively connected with the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s conduct of a trade or business in the United States and includible in the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s gross income. If a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is engaged in a trade or business in the United States and interest on a note is effectively connected with the conduct of that trade or business and, if required by an applicable income tax
treaty, is attributable to a U.S. permanent establishment or fixed place of business, then (although the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be exempt from the 30% withholding tax provided the certification requirements
discussed above are satisfied) the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be subject to U.S. federal income tax on that interest on a net income basis generally in the same manner as if the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder were a U.S. holder. In addition, if a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a corporation for U.S. federal income tax purposes, it may be subject to a branch profits tax
equal to 30% (or lesser rate under an applicable income tax treaty) of its earnings and profits for the taxable year, subject to adjustments, that are effectively connected with its conduct of a trade or business in the United States. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Dividends and Constructive Distributions </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Subject to the discussions
below under &#8220;<I>Information Reporting and Backup Withholding</I>&#8212;<I><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders</I>&#8221; and &#8220;<I>Foreign Account Tax Compliance Act</I>,&#8221; any amount treated as a dividend (as
discussed above under &#8220;<I>U.S. Holder</I> <I>Considerations</I>&#8212;<I>Distributions</I>&#8221;) paid to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder with respect to shares of common stock received upon conversion (and any
deemed dividends resulting from certain adjustments, or failures to make adjustments, to the conversion rate of the notes, as described above under &#8220;<I>U.S. Holder Considerations</I>&#8212;<I></I><I>Constructive Distributions</I>&#8221;)
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
generally will be subject to U.S. federal withholding tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty. However, dividends (including constructive
dividends) that are effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s conduct of a trade or business in the United States and, if required by an applicable income tax treaty, are attributable to a U.S.
permanent establishment or fixed place of business, are not subject to the withholding tax, but instead are subject to U.S. federal income tax on a net income basis at applicable individual or corporate rates. Certain certification requirements and
disclosure requirements must be complied with in order for effectively connected income to be exempt from withholding. Any such effectively connected income received (or deemed received) by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
corporation may, under certain circumstances, be subject to a branch profits tax at a 30% rate, or such lower rate as may be specified by an applicable income tax treaty. Any applicable withholding taxes (including backup withholding) with respect
to deemed dividends may be withheld from or set off against payments of interest and payments of cash or common stock upon conversion, repurchase, redemption or maturity of the notes, payments on our common stock received upon conversion of the
notes or sales proceeds received by, or other funds or assets of, such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of the notes or shares of our common stock received upon conversion of the notes that wishes to claim the benefit of an applicable income tax treaty rate is required to satisfy applicable
certification and other requirements. If a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is eligible for an exemption from or a reduced rate of U.S. federal withholding tax pursuant to an income tax treaty, it may obtain a refund of any
excess amounts withheld by timely filing an appropriate claim for refund with the IRS. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Sale, Exchange, Certain Redemptions and Repurchases, Certain
Conversions or Other Taxable Dispositions of Notes or Common Stock </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Subject to the discussion below under &#8220;<I>Information Reporting and Backup
Withholding</I>&#8212;<I><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders</I>,&#8221; any gain recognized by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder on the sale, exchange (including an exchange with a designated financial
institution in lieu of conversion, as described in &#8220;<I>Description of Notes</I>&#8212;<I>Exchange in Lieu of Conversion</I>&#8221;), certain redemptions and repurchases, certain conversions or other taxable dispositions of a note or common
stock received upon conversion of a note into cash, common stock, or into a combination of cash and shares of our common stock will not be subject to U.S. federal income tax unless: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">that gain is effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s conduct of a
trade or business in the United States (and, if required by an applicable income tax treaty, is attributable to a U.S. permanent establishment or fixed place of business); </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is an individual who is present in the United States for 183
days or more in the taxable year of that disposition and certain other conditions are met; or </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we are or have been a &#8220;United States real property holding corporation&#8221; (&#8220;USRPHC&#8221;), for U.S.
federal income tax purposes at any time during the shorter of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s holding period or the five-year period ending on the date of disposition of the note or common stock, as the case may
be, and certain other conditions are met. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s gain is described in the first
bullet point above, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be subject to tax at regular graduated U.S. federal income tax rates on the net gain derived from the sale, exchange, redemption, repurchase, conversion or other
taxable disposition of a note or common stock received upon conversion of the notes, generally in the same manner as if the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder were a U.S. holder. In addition, if a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder described in the first bullet point above is a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder additionally may be
subject to a branch profits tax equal to 30% of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s effectively connected earnings and profits for that taxable year, or at such lower rate as may be specified by an applicable income
tax treaty. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s gain is described in the second bullet point
above, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be subject to a flat 30% tax (or lower applicable income tax treaty rate) on the gain recognized on the sale, exchange, redemption, conversion or other taxable disposition of a
note or common stock received upon conversion of the notes (which gain may be offset by certain U.S.-source capital losses) even though the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is not considered a resident of the United States.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">With respect to the third bullet point above, we believe we currently are not, and do not anticipate becoming, a USRPHC. Because the determination of whether we are
a USRPHC depends, on the fair market value of our U.S. real property interests relative to the fair market value of our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> real property interests and other business assets, however, there can be no
assurance we currently are not a USRPHC or will not become one in the future. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any amounts (including common stock) that a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder receives on a sale, exchange, redemption, conversion or other taxable disposition of a note that are attributable to accrued but unpaid interest will be treated as interest and subject to the
rules described above under &#8220;<I><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder Considerations</I>&#8212;<I>Interest on the Notes</I>.&#8221; </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Conversion of Notes </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s conversion of a note into shares of our common stock or a combination of cash and shares of our common stock may be treated for U.S. federal income tax purposes as a <FONT
STYLE="white-space:nowrap">non-taxable</FONT> exchange or, alternatively, may give rise to gain recognized on the disposition of a note or a fractional share and/or income recognized on the receipt of accrued but unpaid interest, as described above
under &#8220;<I>U.S. Holder Considerations&#8212;Conversion of Notes</I>.&#8221; To the extent a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder recognizes gain with respect to the disposition of a note or a fractional share, such gain will
be treated as described above under &#8220;<I>&#8212;Sale, Exchange, Certain Redemptions and Repurchases, Certain Conversions or Other Taxable Dispositions of Notes or Common Stock</I>.&#8221; To the extent a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder receives amounts attributable to accrued but unpaid interest in connection with a conversion, such amounts will be taxed in the manner described above under &#8220;<I>&#8212;Interest on the
Notes</I>.&#8221; </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Information Reporting and Backup Withholding </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>U.S. Holders </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Information reporting requirements generally will apply
to payments of interest on and deemed dividends with respect to the notes (if any), dividends on our common stock received upon conversion of the notes and the proceeds of a sale, exchange, redemption, repurchase or other taxable disposition of a
note or common stock received upon conversion of the notes paid to a U.S. holder, unless the U.S. holder is an exempt recipient, and if required, certifies as to that status. Backup withholding generally will apply to those payments if the U.S.
holder fails to provide an appropriate certification with its correct taxpayer identification number or otherwise establish an exemption. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules will be
allowed as a refund or a credit against a U.S. holder&#8217;s U.S. federal income tax liability provided the required information is timely furnished to the IRS. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Generally,
we and other withholding agents must report annually to the IRS and to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders the amount of interest and deemed distributions on the notes (if any) and distributions on our common stock received upon
conversion of the notes to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders and the amount of tax, if any, withheld with respect to those payments, must be reported annually to the IRS and to the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders. Copies of the information returns reporting such interest, deemed distributions, distributions and withholding may also be made available to the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
tax authorities in the country in which a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder resides under the provisions of an applicable income tax treaty. In general, a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder will not be subject to backup withholding with respect to payments of interest or deemed dividends on a note or dividends on our common stock that we make, provided that (a)&nbsp;the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder certifies IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or other applicable form or
(b)&nbsp;the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds the notes through certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> intermediaries or certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> partnerships, and the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder and the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> intermediary or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> partnership satisfies the certification requirements of applicable Treasury
Regulations and, in each case, we do not or another payor does not have actual knowledge or reason to know that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a U.S. person, as defined under the Code, that is not an exempt recipient.
In addition, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be subject to information reporting and, depending on the circumstances, backup withholding with respect to payments of the proceeds of the sale or other taxable disposition
of a note or share of our common stock conducted within the United States or conducted through certain U.S.-related financial intermediaries, unless the certification described above has been received, and the payor does not have actual knowledge or
reason to know that a holder is a U.S. person, as defined under the Code, that is not an exempt recipient, or the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder otherwise establishes an exemption. Backup withholding is not an additional
tax. Any amounts withheld under the backup withholding rules will be allowed as a refund or a credit against a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s U.S. federal income tax liability, if any, provided the required
information is timely furnished to the IRS. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Foreign Account Tax Compliance Act </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under Sections 1471 through 1474 of the Code and the Treasury Regulations promulgated thereunder (commonly referred to as &#8220;FATCA&#8221;), a 30% U.S. federal
withholding tax may apply to certain &#8220;withholdable payments,&#8221; including interest paid on the notes and dividends paid on our common stock (including constructive dividends deemed paid), in each case paid to (i)&nbsp;a &#8220;foreign
financial institution&#8221; (as specifically defined in the Code), whether such foreign financial institution is a beneficial owner or an intermediary, unless (x)&nbsp;such foreign financial institution enters into an agreement with the Department
of Treasury to, among other things, collect and provide to it substantial information regarding such foreign financial institution&#8217;s U.S. financial account holders, including certain account holders that are
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities with U.S. owners or (y)&nbsp;in the case of a foreign financial institution in a jurisdiction that has entered into an intergovernmental agreement with the United States, such foreign
financial institution complies with the requirements of such agreement, or (ii)&nbsp;a <FONT STYLE="white-space:nowrap">&#8220;non-financial</FONT> foreign entity&#8221; (as specifically defined in the Code) (whether such <FONT
STYLE="white-space:nowrap">non-financial</FONT> foreign entity is a beneficial owner or an intermediary), unless such entity provides the paying agent with a certification that it does not have any substantial U.S. owners or a certification
identifying the direct and indirect substantial U.S. owners of the entity, unless in each case, an exemption applies. While a payment with respect to the notes or our common stock could be subject to both FATCA withholding and the withholding tax
discussed above under &#8220;<I><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder Considerations&#8212;Interest on the Notes</I>&#8221; and &#8220;<I><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder Considerations&#8212;Dividends and
Constructive Distributions</I>,&#8221; the maximum rate of U.S. withholding on such payment would not exceed 30%. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prospective investors are urged to consult their
tax advisors regarding the application of FATCA to the notes. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The preceding discussion of material U.S. federal income tax considerations is for general
information only and is not tax advice. Accordingly, each investor should consult its tax advisor as to particular tax consequences to it of holding and disposing of the notes and the common stock, including the applicability and effect of any
state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws, and of any pending or subsequent changes in applicable laws. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="supptoc159388_12"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are offering the notes described in this prospectus supplement through a number of underwriters. Jefferies LLC and J.P. Morgan Securities LLC are acting as joint
book-running managers of the offering and as representatives of the underwriters. We have entered into an underwriting agreement with the representatives. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to
the underwriters, and each underwriter has severally agreed to purchase the principal amount of notes shown next to its name in the following table: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000;">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:2.00pt solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000;"><B>Underwriter</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000;"><B>Principal&nbsp;Amount<BR>of&nbsp;Notes</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$108,000,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$&#8199;92,000,000</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$200,000,000</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="3" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters are committed to purchase all the notes offered by us if they purchase any notes. The underwriting agreement also
provides that if an underwriter defaults, the purchase commitments of <FONT STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may also be increased or the offering may be terminated. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The notes will constitute a new class of securities with no established trading market. The underwriters propose to offer the notes directly to the public at the public
offering price set forth on the cover page of this prospectus supplement and to certain dealers at that price less a concession not in excess of $18.00 per note. After the offering of the notes to the public, if all of the notes are not sold at the
public offering price, the underwriters may change the offering price and the other selling terms. Sales of any notes made outside of the United States may be made by affiliates of the underwriters. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Over-allotment Option </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters have an option to buy up to an
additional $30,000,000 principal amount of notes, solely to cover over-allotments, from us at the public offering price set forth on the cover page of this prospectus supplement, less underwriting discounts and commissions. The underwriters have 30
days from the date of this prospectus supplement to exercise this over-allotment option. If any notes are purchased with this over-allotment option, the underwriters will purchase shares in approximately the same proportion as shown in the table
above. If any additional notes are purchased, the underwriters will offer the additional notes on the same terms as those on which the shares are being offered. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Commissions and Expenses </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table shows the public offering
price, the underwriting discounts and commissions that we are to pay the underwriters and the proceeds, before expenses, to us in connection with this offering (expressed as a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
percentage of the principal amount of the notes). Such amounts are shown assuming both no exercise and full exercise of the underwriters&#8217; over-allotment option. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000;">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000;">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000;">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000;">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Per&nbsp;Note&nbsp;Without<BR>Option&nbsp;to&nbsp;Purchase<BR>Additional Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>With&nbsp;Option<BR>to Purchase<BR>Additional&nbsp;Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total&nbsp;Without<BR>Option&nbsp;to&nbsp;Purchase<BR>Additional Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>With&nbsp;Option<BR>to&nbsp;Purchase<BR>Additional&nbsp;Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Public offering price<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.00</TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">200,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">230,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Underwriting discounts and commissions paid by us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.00</TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,900,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Proceeds to us, before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97.00</TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">194,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">223,100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="16" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Plus accrued interest from November 18, 2025. </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We estimate that the total expenses of this offering, including
registration, filing and listing fees, printing fees and legal and accounting expenses, but excluding the underwriting discounts and commissions, will be approximately $400,000. We have also agreed to reimburse the underwriters for certain of their
expenses up to $30,000. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Settlement </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect to deliver the notes in
book-entry form through the facilities of DTC on or about November 18, 2025, which will be the fourth business day after the initial trade date for the notes (this settlement cycle being referred to as &#8220;T&#043;4&#8221;). Under Rule 15c6-1
under the Exchange Act, trades in the secondary market generally are required to settle in one business day, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade notes prior to the business day
preceding the settlement date will be required, by virtue of the fact that the notes initially will settle T&#043;4, to specify an alternate settlement cycle at the time of any such trade to prevent a failed settlement. Purchasers of the notes who
wish to trade the notes prior to the business day preceding the settlement date should consult their own advisors. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Electronic Distribution </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A prospectus supplement and accompanying prospectus in electronic format may be made available on the web sites maintained by one or more underwriters, or selling group
members, if any, participating in the offering. The underwriters may agree to allocate an amount of notes to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by the
representatives to underwriters and selling group members that may make Internet distributions on the same basis as other allocations. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>No Sales of Similar
Securities </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have agreed that we will not (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or
contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the SEC a registration statement under the Securities Act relating to, any shares of our
common stock or securities convertible into or exercisable or exchangeable for any shares of our common stock, or publicly disclose the intention to make any offer, sale, pledge, loan, disposition or filing, or (ii)&nbsp;enter into any swap or other
arrangement that transfers all or a portion of the economic consequences associated with the ownership of any shares of common stock or any such other securities (regardless of whether any of these transactions are to be settled by the delivery of
shares of common stock or such other securities, in cash or otherwise), in each case without the prior written consent of the representatives for a period of 45 days after the date of this prospectus, other than the shares of our common stock to be
sold in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The restrictions on our actions, as described above, do not apply to certain transactions, including (i)&nbsp;the
securities to be sold hereunder, (ii)&nbsp;the issuance of common stock upon the exercise of an option or warrant or the conversion of a security outstanding on the date of this prospectus supplement pursuant to stock plans existing as of the date
of this prospectus supplement, (iii)&nbsp;the filing of a registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> or a successor form thereto in respect of any shares of common stock or any securities convertible into or
exercisable or exchangeable for common stock issued under or the grant of any award pursuant to stock plans existing as of the date of this prospectus supplement, (iv)&nbsp;sales of shares of Common Stock pursuant to the Sales Agreement, dated
May&nbsp;6, 2022, as amended by that certain Amendment No.&nbsp;1 to the Sales Agreement, dated November&nbsp;7, 2025 by and between the Company and Guggenheim Securities, LLC or any replacement &#8220;at the market offering&#8221; program; provided
that in the case of clause (iv), no such sales may be made prior to 30&nbsp;days from the date of this prospectus supplement unless the underwriters have exercised their option to purchase additional shares in full and all such additional shares
have been issued, (v)&nbsp;sales of shares of Common Stock to be issued and sold pursuant to the Concurrent Equity Offering, (vi)&nbsp;the entry into an agreement providing for the issuance of shares of common stock or any security convertible into
or exercisable for common stock in connection with the acquisition of the securities, business, property or other assets of another person or entity or pursuant to an employee benefit plan assumed in connection with such acquisition, and the
issuance of any such securities pursuant to any such agreement, or (vii)&nbsp;the entry into an agreement providing for the issuance of shares of common stock or any security convertible into or exercisable for shares of common stock in connection
with joint ventures, commercial relationships or other strategic transactions, and the issuance of any such securities pursuant to any such agreement; provided that in the case of (vi)&nbsp;or (vii), the aggregate number of shares of common stock or
any security convertible into or exercisable for common stock (on an <FONT STYLE="white-space:nowrap">as-converted,</FONT> <FONT STYLE="white-space:nowrap">as-exercised</FONT> or <FONT STYLE="white-space:nowrap">as-exchanged</FONT> basis) that we
may sell or issue or agree to sell or issue do not exceed 5% of the total number of shares of our common stock issued and outstanding immediately following the completion of this offering and all recipients of shares of common stock or any security
convertible into or exercisable for common stock enter into a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement with respect to the remaining portion of the <FONT STYLE="white-space:nowrap">45-day</FONT>
<FONT STYLE="white-space:nowrap">lock-up</FONT> period. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our directors and executive officers, and certain stockholder (such persons, the <FONT
STYLE="white-space:nowrap">&#8220;lock-up</FONT> parties&#8221;) have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters prior to the commencement of this offering pursuant to which each <FONT
STYLE="white-space:nowrap">lock-up</FONT> party, with limited exceptions, for a period of 45 days after the date of this prospectus supplement, may not (and may not cause any of their direct or indirect affiliates to), without the prior written
consent of the representatives, (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose
of, directly or indirectly, any shares of our common stock or any securities convertible into or exercisable or exchangeable for our common stock (including, without limitation, common stock or such other securities which may be deemed to be
beneficially owned by such <FONT STYLE="white-space:nowrap">lock-up</FONT> parties in accordance with the rules and regulations of the SEC and securities which may be issued upon exercise of a stock option or warrant (collectively with the common
stock, the <FONT STYLE="white-space:nowrap">&#8220;lock-up</FONT> securities&#8221;)), (ii) enter into any hedging, swap or other agreement or transaction that transfers, in whole or in part, any of the economic consequences of ownership of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> securities, whether any such transaction described in clause (i)&nbsp;or (ii) above is to be settled by delivery of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, in cash or otherwise,
(iii)&nbsp;make any demand for, or exercise any right with respect to, the registration of any <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, or (iv)&nbsp;publicly disclose the intention to do any of the foregoing. Such persons or
entities have further acknowledged that these undertakings preclude them from engaging in any hedging or other transactions or arrangements (including, without limitation, any short sale or the purchase or sale of, or entry into, any put or call
option, or combination thereof, forward, swap or any other derivative transaction or instrument, however described or defined) designed or intended, or which could reasonably be expected to lead to or result in, a sale or disposition or transfer (by
any person or entity, whether or not a signatory to such agreement) of any economic consequences of ownership, in whole or in part, directly </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
or indirectly, of any <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, whether any such transaction or arrangement (or instrument provided for thereunder) would be settled by delivery
of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, in cash or otherwise. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The restrictions described in the immediately preceding paragraph and contained
in the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements between the underwriters and the <FONT STYLE="white-space:nowrap">lock-up</FONT> parties do not apply, subject in certain cases to various conditions, to certain transactions,
including (a)&nbsp;transactions relating to shares of common stock or other securities acquired in this offering or acquired in open market transactions after the completion of this offering; (b)&nbsp;transfers of shares of common stock or any
security convertible into or exercisable or exchangeable for common stock as a bona fide gift, including without limitation to a charitable organization; (c)&nbsp;distributions of shares of common stock or any security convertible into or
exercisable or exchangeable for common stock to limited partners, general partners, managers, directors, officers, employees, members, stockholders or trust beneficiaries of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or its affiliates
(as defined in Rule 405 promulgated under the Securities Act) or to any investment fund or other entity controlled or managed by the <FONT STYLE="white-space:nowrap">lock-up</FONT> party; (d)&nbsp;transfers or dispositions of shares of common stock
or any security convertible into or exercisable or exchangeable for common stock by will or other testamentary document or by intestacy; (e)&nbsp;transfers or dispositions of shares of common stock or any security convertible into or exercisable or
exchangeable for common stock to any trust for the direct or indirect benefit of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or the immediate family of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party in a transaction not
involving a disposition for value; (f)&nbsp;the exercise of options to purchase shares of common stock granted under a stock incentive plan or stock purchase plan and outstanding as of the date of this prospectus supplement or the exercise of
warrants to purchase shares of common stock (or any security convertible into or exercisable or exchangeable for common stock) and outstanding as of the date of this prospectus supplement; (g)&nbsp;transfers of shares of common stock or any security
convertible into or exercisable or exchangeable for common stock that occur by operation of law pursuant to a qualified domestic order or in connection with a divorce settlement; (h)&nbsp;transfers or dispositions of shares of common stock or any
security convertible into or exercisable or exchangeable for common stock to the Company pursuant to any contractual arrangement disclosed to the representatives and in effect on the date of this prospectus supplement that provides for the
repurchase of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party&#8217;s shares of common stock or such other securities by the Company solely in connection with the termination of the <FONT STYLE="white-space:nowrap">lock-up</FONT>
party&#8217;s employment with the Company; (i)&nbsp;the establishment of a trading plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of shares of common stock; (j)&nbsp;transfers to the
Company of shares of common stock upon a vesting of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party&#8217;s common stock or upon the exercise of options or warrants to purchase common stock, in each case on a &#8220;cashless&#8221; or
&#8220;net exercise&#8221; basis solely to cover tax withholding obligations of the undersigned in connection with such vesting or exercise; and (k)&nbsp;transfers in connection with a bona fide third party tender offer, merger, consolidation or
other similar transaction involving a change of control of the Company that is approved by the Board of Directors of the Company, made to all holders of the common stock and occurring after the closing of this offering, provided that in the event
that the tender offer, merger, consolidation or other such transaction is not completed, the shares of common stock owned by the <FONT STYLE="white-space:nowrap">lock-up</FONT> party remain subject to <FONT STYLE="white-space:nowrap">lock-up.</FONT>
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The representatives, in their sole discretion, may release the securities subject to any of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the
underwriters described above, in whole or in part at any time. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>No Listing </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The notes will not be listed on any securities exchange or included in any quotation system. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Stabilization </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters have advised us that they, pursuant to
Regulation M under the Exchange Act, and certain persons participating in the offering may engage in short sale transactions, stabilizing transactions, syndicate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
covering transactions or the imposition of penalty bids in connection with this offering. These activities may have the effect of raising or maintaining the market price of the notes at a level
above that which might otherwise prevail in the open market, or preventing or retarding a decline in the market price of the notes. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Establishing short sales
positions may involve either &#8220;covered&#8221; short sales or &#8220;naked&#8221; short sales. &#8220;Covered&#8221; short sales are sales made in an amount not greater than the underwriters&#8217; over-allotment option. The underwriters may
close out any covered short position by exercising their over-allotment option, in whole or in part, or by purchasing notes on the open market. In determining the source of notes to close out the covered short position, the underwriters will
consider, among other things, the price of notes available for purchase in the open market as compared to the price at which they may purchase notes through the underwriters&#8217; <FONT STYLE="white-space:nowrap">over-allotment</FONT> option.
&#8220;Naked&#8221; short sales are sales in excess of the underwriters&#8217; over-allotment option. The underwriters must close out any naked short position by purchasing notes in the open market. A naked short position is more likely to be
created if the underwriters are concerned that there may be downward pressure on the price of notes in the open market after pricing that could adversely affect investors who purchase in this offering. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A stabilizing bid is a bid for the purchase of notes on behalf of the underwriters for the purpose of fixing or maintaining the price of the notes. A syndicate covering
transaction is the bid for or the purchase of notes on behalf of the underwriters to reduce a short position incurred by the underwriters in connection with the offering. Similar to other purchase transactions, the underwriters&#8217; purchases to
cover the syndicate short sales may have the effect of raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher
than the price that might otherwise exist in the open market. A penalty bid is an arrangement permitting the underwriters to reclaim the selling concession otherwise accruing to a syndicate member in connection with the offering if the notes
originally sold by such syndicate member are purchased in a syndicate covering transaction and therefore have not been effectively placed by such syndicate member. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Neither we, nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may
have on the price of the notes. The underwriters are not obligated to engage in these activities and, if commenced, any of the activities may be discontinued at any time. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Other Activities and Relationships </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Certain of the underwriters and their
affiliates have provided in the past to us and our affiliates and may provide from time to time in the future certain commercial banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of
their business, for which they have received and may continue to receive customary fees and commissions. In addition, from time to time, certain of the underwriters and their affiliates may effect transactions for their own account or the account of
customers, and hold on behalf of themselves or their customers, long or short positions in our debt or equity securities or loans, and may do so in the future. Certain of the underwriters are also acting as joint book-running managers in the
Concurrent Equity Offering. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Selling Restrictions </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Other than in the
United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus supplement in any jurisdiction where action for that purpose is required. The securities offered by
this prospectus supplement may not be offered or sold, directly or indirectly, nor may this prospectus supplement or any other offering material or advertisements in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and
regulations of that jurisdiction. Persons into whose possession this prospectus supplement comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus supplement. This
prospectus supplement does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to Prospective Investors in the European Economic Area </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In relation to
each Member State of the European Economic Area (each, a &#8220;Member State&#8221;), no notes have been offered or will be offered pursuant to the offering to the public in that Member State prior to the publication of a prospectus in relation to
the notes which has been approved by the competent authority in that Member State, all in accordance with the Prospectus Regulation, except that offers of notes may be made to the public in that Member State at any time under the following
exemptions under the Prospectus Regulation: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">to any legal entity which is a qualified investor as defined in the Prospectus Regulation; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation),
subject to obtaining the prior consent of the underwriters for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">provided that no such offer of notes shall require the Company or any of the underwriters to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or
supplement a prospectus pursuant to Article&nbsp;23 of the Prospectus Regulation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the purposes of this provision, the expression an &#8220;offer to the
public&#8221; in relation to any notes in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any notes to be offered so as to enable an investor to decide to purchase or
subscribe for any notes, and the expression &#8220;Prospectus Regulation&#8221; means Regulation (EU) 2017/1129. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to Prospective Investors in the United
Kingdom </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In relation to the United Kingdom, no notes have been offered or will be offered pursuant to the offering to the public in the United Kingdom prior to
the publication of a prospectus in relation to the notes which has been approved by the Financial Conduct Authority, or (ii)&nbsp;is to be treated as if it had been approved by the Financial Conduct Authority in accordance with the transitional
provision in Regulation 74 of the Prospectus (Amendment etc.) (EU Exit) Regulations 2019, except that offers of securities may be made to the public in the United Kingdom of any notes at any time under the following exemptions under the UK
Prospectus Regulation: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the UK Prospectus
Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">in any other circumstances falling within Section&nbsp;86 of the FSMA, </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">provided that no such offer of the notes shall require the Company or any of the underwriters to publish a prospectus pursuant to Section&nbsp;85 of the FSMA or
supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the purposes of this provision, the expression an &#8220;offer to the
public&#8221; in relation to the notes in the United Kingdom means the communication in any form and by any means of sufficient information on the terms of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
offer and any notes to be offered so as to enable an investor to decide to purchase or subscribe for any notes and the expression &#8220;UK Prospectus Regulation&#8221; means Regulation (EU)
2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, this prospectus supplement and the accompanying
prospectus are only being distributed to, and is only directed at, and any investment or investment activity to which this prospectus supplement and the accompanying prospectus relate is available only to, and will be engaged in only with, persons
who are outside the United Kingdom or persons in the United Kingdom (i)&nbsp;having professional experience in matters relating to investments who fall within the definition of &#8220;investment professionals&#8221; in Article 19(5) of the Financial
Services and Markets Act 2000 (Financial Promotion) Order 2005, or the Order; or (ii)&nbsp;who are high net worth entities falling within Article 49(2)(a) to (d)&nbsp;of the Order (all such persons together being referred to as &#8220;relevant
persons&#8221;). Persons who are not relevant persons should not take any action on the basis of this prospectus supplement and the accompanying prospectus and should not act or rely on them. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to Prospective Investors in Hong Kong </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">No securities have been offered
or sold, and no securities may be offered or sold, in Hong Kong, by means of any document, other than: (i)&nbsp;to persons whose ordinary business is to buy or sell shares or debentures, whether as principal or agent; or (ii)&nbsp;to
&#8220;professional investors&#8221; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong (the &#8220;SFO&#8221;) and any rules made under that Ordinance; or in other circumstances which do not result in the document being a
&#8220;prospectus&#8221; as defined in the Companies Ordinance (Cap. 32) of Hong Kong (the &#8220;CO&#8221;) or which do not constitute an offer or invitation to the public for the purpose of the CO or the SFO. No document, invitation or
advertisement relating to the securities has been issued or may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), that is directed at, or the contents of which are likely
to be accessed or read by, the public of Hong Kong (except if permitted under the securities laws of Hong Kong) other than with respect to securities that are or are intended to be disposed of only to persons outside Hong Kong or only to
&#8220;professional investors&#8221; as defined in the SFO and any rules made under that Ordinance. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus supplement and the accompanying prospectus have
not been registered with the Registrar of Companies in Hong Kong. Accordingly, this prospectus supplement and the accompanying prospectus may not be issued, circulated or distributed in Hong Kong, and the securities may not be offered for
subscription to members of the public in Hong Kong. Each person acquiring the securities will be required, and is deemed by the acquisition of the securities, to confirm that he is aware of the restriction on offers of the securities described in
this prospectus supplement and accompanying prospectus and that he is not acquiring, and has not been offered, any securities in circumstances that contravene any such restrictions. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to Prospective Investors in Japan </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The offering has not been and will
not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948 of Japan, as amended, the &#8220;FIEL&#8221;) and the underwriters will not offer or sell any securities, directly or indirectly, in Japan or to, or
for the benefit of, any resident of Japan (the term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT>
or resale, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with the FIEL and any other applicable laws,
regulations and ministerial guidelines of Japan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to Prospective Investors in Singapore </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus supplement and the accompanying prospectus have not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore.
Accordingly, this prospectus supplement and the accompanying prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the notes offered hereby may not be circulated or
distributed, nor may the notes be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than: (i)&nbsp;to an institutional investor under Section&nbsp;274
of the Securities and Futures Act, Chapter 289 of Singapore (the &#8220;SFA&#8221;); (ii) to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions specified in
Section&nbsp;275, of the SFA; or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Where the
notes are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person that is: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)), the sole business of which
is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of
the trust is an individual who is an accredited investor, securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries&#8217; rights and interest (howsoever described) in that trust shall not be transferred
within six months after that corporation or that trust has acquired the notes pursuant to an offer made under Section&nbsp;275 of the SFA except: </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising
from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">where the transfer is by operation of law; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">as specified in Section&nbsp;276(7) of the SFA; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations
2005 of Singapore. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to Prospective Investors in Canada </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Resale Restrictions </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The offering of the notes in Canada is being made
only in the provinces of Ontario, Quebec, Alberta and British Columbia on a private placement basis exempt from the requirement that the we prepare and file a prospectus with the securities regulatory authorities in each province where trades of
these securities are made. Any resale of the notes in Canada must be made under applicable securities laws which may vary depending on the relevant jurisdiction and which may require resales to be made under available statutory exemptions or under a
discretionary exemption granted by the applicable Canadian securities regulatory authority. Purchasers are advised to seek legal advice prior to any resale of the securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Representations of Canadian Purchasers </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">By purchasing notes in Canada and accepting delivery of a purchase confirmation, a purchaser is representing to us and the dealer from whom the purchase confirmation is
received that: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the purchaser is entitled under applicable provincial securities laws to purchase the notes without the benefit of a
prospectus qualified under those securities laws, as it is an &#8220;accredited investor&#8221; as defined under National Instrument <FONT STYLE="white-space:nowrap">45-106&#8212;</FONT><I>Prospectus Exemptions</I>; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the purchaser is a &#8220;permitted client&#8221; as defined under National Instrument
<FONT STYLE="white-space:nowrap">31-103&#8212;</FONT><I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">where required by law, the purchaser is purchasing as principal and not as agent; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the purchaser has reviewed the text above under &#8220;Resale Restrictions.&#8221; </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Conflicts of Interest </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Canadian purchasers are hereby notified that
the underwriters relying on the exemption set out in section 3A.3 or 3A.4, if applicable, of National Instrument <FONT STYLE="white-space:nowrap">33-105&#8212;</FONT><I>Underwriting Conflicts, </I>to not provide certain conflict of interest
disclosures in this document. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Statutory Rights of Action </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if the offering memorandum
(including any amendment thereto) such as this document contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the
purchaser&#8217;s province or territory. The purchaser of these securities in Canada should refer to any applicable provisions of the securities legislation of the purchaser&#8217;s province or territory for particulars of these rights or consult
with a legal advisor. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Enforcement of Legal Rights </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">All of our
directors and officers as well as the experts named herein may be located outside of Canada, and, as a result, it may not be possible for Canadian purchasers to effect service of process within Canada upon us or those persons. All or a substantial
portion of our assets, and the assets of those persons may be located outside of Canada, and, as a result, it may not be possible to satisfy a judgment against us or those persons in Canada or to enforce a judgment obtained in Canadian courts
against us or those persons outside of Canada. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Taxation and Eligibility for Investment </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Canadian purchasers of the notes should consult their own legal and tax advisors with respect to the tax consequences of an investment in the notes in their particular
circumstances and about the eligibility of the notes for investment by the purchaser under relevant Canadian legislation. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to Prospective Investors in
Australia </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus supplement and the accompanying prospectus is not a disclosure document for the purposes of Australia&#8217;s Corporations Act 2001
(Cth) of Australia (the &#8220;Corporations Act&#8221;), has not been lodged with the Australian Securities and Investments Commission and is only directed to the categories of exempt persons set </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
out below. Accordingly, if you receive this prospectus supplement and the accompanying prospectus in Australia, you confirm and warrant that you are either: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a &#8220;sophisticated investor&#8221; under Section&nbsp;708(8)(a) or (b)&nbsp;of the Corporations Act;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a &#8220;sophisticated investor&#8221; under Section&nbsp;708(8)(c) or (d)&nbsp;of the Corporations Act and that you have
provided an accountant&#8217;s certificate to the Company that complies with the requirements of Section&nbsp;708(8)(c)(i) or (ii)&nbsp;of the Corporations Act and related regulations before the offer has been made; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a person associated with the Company under Section&nbsp;708(12) of the Corporations Act; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a &#8220;professional investor&#8221; under Section&nbsp;708(11)(a) or (b)&nbsp;of the Corporations Act.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To the extent that you are unable to confirm or warrant that you are an exempt sophisticated investor, associated person or professional investor
under the Corporations Act, any offer made to you under this prospectus supplement and the accompanying prospectus is void and incapable of acceptance. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Further, you
warrant and agree that you will not offer any of the securities issued to you pursuant to this prospectus supplement and the accompanying prospectus for resale in Australia within 12 months of those securities being issued unless any such resale
offer is exempt from the requirement to issue a disclosure document under Section&nbsp;708 of the Corporations Act. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to Prospective Investors in Israel
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This document does not constitute a prospectus under the Israeli Securities Law, 5728-1968 (the &#8220;Israeli Securities Law&#8221;), and has not been filed
with or approved by the Israel Securities Authority. In Israel, this prospectus supplement and the accompanying prospectus is being distributed only to, and is directed only at, and any offer of the notes offered hereby is directed only at:
(i)&nbsp;a limited number of persons in accordance with the Israeli Securities Law; and (ii)&nbsp;investors listed in the first addendum to the Israeli Securities Law, as it may be amended from time to time (the &#8220;Addendum&#8221;), consisting
primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS
50&nbsp;million and &#8220;qualified individuals,&#8221; each as defined in the Addendum, collectively referred to as qualified investors (in each case, purchasing for their own account or, where permitted under the Addendum, for the accounts of
their clients who are investors listed in the Addendum). Qualified investors are required to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of the Addendum and agree to it. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to Prospective Investors in Switzerland </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The notes may not be publicly
offered in Switzerland and will not be listed on the SIX Swiss Exchange (&#8220;SIX&#8221;) or on any other stock exchange or regulated trading facility in Switzerland. This prospectus supplement and the accompanying prospectus has been prepared
without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules
of any other stock exchange or regulated trading facility in Switzerland. Neither this prospectus supplement and the accompanying prospectus, nor any other offering or marketing material relating to the notes or the offering, may be publicly
distributed or otherwise made publicly available in Switzerland. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Neither this prospectus supplement and the accompanying prospectus, nor any other offering or
marketing material relating to the offering, the Company or the notes offered hereby, have been or will be filed with or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
approved by any Swiss regulatory authority. In particular, this prospectus supplement and the accompanying prospectus will not be filed with, and the offer of securities will not be supervised
by, the Swiss Financial Market Supervisory Authority FINMA, and the offer of securities has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (the &#8220;CISA&#8221;). The investor protection afforded
to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of notes offered hereby. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to Prospective Investors
in the United Arab Emirates </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The securities have not been, and are not being, publicly offered, sold, promoted or advertised in the United Arab Emirates
(including the Dubai International Financial Centre (&#8220;DIFC&#8221;)) other than in compliance with the laws of the United Arab Emirates (and the DIFC) governing the issue, offering and sale of securities. Further, this prospectus supplement and
the accompanying prospectus do not constitute a public offer of securities in the United Arab Emirates (including the DIFC) and is not intended to be a public offer. This prospectus supplement and the accompanying prospectus have not been approved
by or filed with the Central Bank of the United Arab Emirates, the Securities and Commodities Authority, Financial Services Regulatory Authority or the Dubai Financial Services Authority. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to Prospective Investors in Saudi Arabia </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This document may not be
distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Rules on the Offer of Securities and Continuing Obligations Regulations as issued by the board of the Saudi Arabian Capital Market Authority
(&#8220;CMA&#8221;), pursuant to resolution number <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">3-123-2017</FONT></FONT> dated 27&nbsp;December 2017, as amended. The CMA does not make any representation as to the accuracy or
completeness of this document and expressly disclaims any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this document. Prospective purchasers of the securities offered hereby should conduct their own due
diligence on the accuracy of the information relating to the securities. If you do not understand the contents of this document, you should consult an authorized financial adviser. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="supptoc159388_13"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The validity of the notes being offered in this prospectus supplement will be passed on by Gibson, Dunn&nbsp;&amp; Crutcher LLP, San Francisco, California. Certain legal
matters in connection with this offering will be passed upon for the underwriters by Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., Boston, Massachusetts and Cooley LLP, San Francisco, California. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="supptoc159388_14"></A>EXPERTS </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The financial statements and
management&#8217;s assessment of the effectiveness of internal control over financial reporting (which is included in Management&#8217;s Report on Internal Control Over Financial Reporting) incorporated in this Prospectus Supplement by reference to
the Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2024 have been so incorporated in reliance on the report of PricewaterhouseCoopers LLP, an independent registered public accounting firm,
given on the authority of said firm as experts in auditing and accounting. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="supptoc159388_15"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company is subject to the informational requirements of the Exchange Act, and in accordance therewith, files annual, quarterly and current reports, proxy statements
and other information with the SEC. The SEC maintains an Internet website that contains reports, proxy statements and other information about registrants, like us, that file electronically with the SEC. The address of that site is www.sec.gov.
Statements contained in this prospectus supplement as to the contents of any contract or other document are not necessarily complete, and in each instance, we refer you to the copy of the contract or document filed as an exhibit to the registration
statement, each such statement being qualified in all respects by such reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="supptoc159388_16"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The SEC allows us to incorporate by reference the information and reports we file with it, which means that we can disclose important information to you by referring you
to these documents. The information incorporated by reference is an important part of this prospectus supplement, and information that we file after the date hereof with the SEC will automatically update and supersede the information already
incorporated by reference. We are incorporating by reference the documents listed below: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001622229/000095017025026115/cogt-20241231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2024 filed with the SEC on February&nbsp;
25, 2025, including the Part III information incorporated by reference from our Definitive Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001622229/000119312525089237/d873012ddef14a.htm">Schedule&nbsp;14A</A> filed with the SEC on April&nbsp;22, 2025; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended March&nbsp;31, 2025 filed
with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001622229/000095017025064005/cogt-20250331.htm">May&nbsp;6, 2025</A>, June&nbsp;
30, 2025 filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001622229/000095017025102440/cogt-20250630.htm">August&nbsp;5, 2025</A>, and September&nbsp;
30, 2025 filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001622229/000119312525272334/cogt-20250930.htm">November&nbsp;7, 2025</A>; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001622229/000119312525135337/d20143d8k.htm">June&nbsp;5,
 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001622229/000119312525138813/d21181d8k.htm">June&nbsp;
11, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001622229/000119312525155811/d156610d8k.htm">July&nbsp;
7, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001622229/000119312525157390/d92808d8k.htm">July&nbsp;
10, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001622229/000119312525201353/d947118d8k.htm">September&nbsp;
11, 2025</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1622229/000119312525273315/d54064d8k.htm">November 10, 2025</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">The description of our common stock contained in <A HREF="http://www.sec.gov/Archives/edgar/data/1622229/000095017025026115/cogt-ex4_1.htm">Exhibit
 4.1</A> to our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2024, as filed with the SEC on February&nbsp;25, 2025, including any amendments or reports filed for the purposes of updating
this description. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">All documents we file with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act shall be deemed
incorporated by reference in this prospectus supplement and to be a part of this prospectus supplement from the date of filing of those documents, with the exception of any portion of any report or document that is not deemed &#8220;filed&#8221;
under such provisions on or after the date of this prospectus supplement, until the earlier of the date on which: (1)&nbsp;all of the securities registered hereunder have been sold; or (2)&nbsp;the registration statement of which this prospectus
supplement is a part has been withdrawn. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under no circumstances will any information filed under current Item 2.02 or Item 7.01 (and exhibits filed pursuant to Item
9.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> that are related to such items) be deemed incorporated herein by reference unless such Form <FONT STYLE="white-space:nowrap">8-K</FONT> expressly provides to the contrary. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon written or oral request, we will provide without charge to each person to whom a copy of the prospectus supplement is delivered a copy of the documents incorporated
by reference herein (other than exhibits to such documents unless such exhibits are specifically incorporated by reference herein). You may request a copy of these filings, at no cost, by writing, calling or emailing us at the contact information
set forth below. We have authorized no one to provide you with any information that differs from that contained in this prospectus supplement. Accordingly, we take no responsibility for any other information that others may give you. You should not
assume that the information in this prospectus supplement is accurate as of any date other than the date of the front cover of this prospectus supplement. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">Cogent Biosciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">275 Wyman Street, 3rd Floor
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">Waltham, Massachusetts 02451 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">Attn: Corporate
Secretary </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">(617) <FONT STYLE="white-space:nowrap">945-5576</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">info@cogentbio.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g159388g99p03.jpg" ALT="LOGO" STYLE="width:2.73333in;height:1.18in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>COMMON STOCK </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>PREFERRED STOCK </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>DEBT
SECURITIES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>WARRANTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>UNITS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may issue, in one or more series or classes, an indeterminate number of shares of our common stock, preferred stock,
debt securities, warrants and/or units, at prices and on terms that we will determine at the time of the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus
provides you with a general description of the securities we may offer. Each time we offer securities, we will provide specific terms of the securities offered in a supplement to this prospectus. We may also authorize one or more free writing
prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. We may not sell any securities under
this prospectus without delivery of the applicable prospectus supplement. If information in any prospectus supplement is inconsistent with the information in this prospectus, then the information in that prospectus supplement will apply and will
supersede the information in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus, the applicable prospectus supplement and any related free
writing prospectus carefully, as well as any documents incorporated by reference, before you invest in any of the securities being offered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our shares of common stock are listed on the Nasdaq Global Select Market under the symbol &#8220;COGT&#8221;. The last reported sale price of
our common stock on the Nasdaq Global Select Market on November&nbsp;6, 2025 was $14.72&nbsp;per share. We recommend that you obtain current market quotations for our common stock prior to making an investment decision. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the
heading</B><B><I> &#8220;</I></B><B><A HREF="#toc159388_4">Risk Factors</A></B><B><I>&#8221;</I></B><B> contained in this prospectus beginning on page 5 and any applicable prospectus supplement, and under similar headings in the other documents that
are incorporated by reference into this prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus dated November&nbsp;7, 2025 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Table of Contents </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc159388_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc159388_2">CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc159388_3">THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc159388_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc159388_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc159388_6">SECURITIES WE MAY OFFER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc159388_7">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc159388_8">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc159388_9">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc159388_10">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc159388_11">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc159388_12">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc159388_13">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc159388_14">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc159388_15">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc159388_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of an automatic shelf registration statement on Form S-3ASR that we filed with the Securities and Exchange Commission
(the &#8220;SEC&#8221; or the &#8220;Commission&#8221;), as a &#8220;well-known seasoned issuer&#8221; as defined in Rule 405 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) utilizing a &#8220;shelf&#8221;
registration process. Under this shelf registration process, we may sell any combination of the securities described in this prospectus from time to time in one or more offerings. This prospectus provides you with a general description of the
securities we may offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each time we sell securities under this prospectus, we will provide a prospectus supplement that will contain
specific information about the terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement and any related
free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in any documents that we have incorporated by reference into this prospectus. You should carefully read
both this prospectus and any prospectus supplement together with additional information under the headings &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation by Reference.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not authorized anyone to provide you with any information other than that contained or incorporated by reference in this prospectus
and any applicable prospectus supplement, along with the information contained in any free writing prospectuses we have authorized for use in connection with a specific offering. We take no responsibility for, and can provide no assurance as to the
reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. This prospectus, any applicable
supplement to this prospectus or any related free writing prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus, any
applicable supplement to this prospectus or any related free writing prospectus constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation
in such jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should not assume that the information contained in this prospectus, any applicable prospectus supplement or
any related free writing prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document
incorporated by reference, even though this prospectus, any applicable prospectus supplement or any related free writing prospectus is delivered, or securities are sold, on a later date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context otherwise requires, we use the terms &#8220;Cogent,&#8221; &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and
&#8220;our&#8221; in this prospectus to refer to Cogent Biosciences, Inc. and, where appropriate, our subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc159388_2"></A>CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus, including the documents that we incorporate by reference, contains forward-looking statements within the meaning of
Section 27A of the Securities Act and Section 21E of the Securities and Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). All statements, other than statements of historical facts contained in this prospectus, including statements
regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plan, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown
risks, uncertainties, and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;should,&#8221;
&#8220;expects,&#8221; &#8220;might,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;could,&#8221; &#8220;intends,&#8221; &#8220;target,&#8221; &#8220;projects,&#8221; &#8220;contemplates,&#8221; &#8220;believes,&#8221;
&#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;seek,&#8221; &#8220;would&#8221; or &#8220;continue,&#8221; or the negative of these terms or other similar expressions. We have based these forward-looking statements
largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Because forward-looking
statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our
forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Some of the key factors that could cause actual results to differ from our expectations
include, but are not limited to, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential impacts of raising additional capital, including dilution to our existing stockholders,
restrictions on our operations or requirements that we relinquish rights to our technologies or product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success, cost, and duration of our product development activities and clinical trials, including the
enrollment rates in our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of our planned regulatory submissions to the U.S. Food and Drug Administration for our bezuclastinib
product candidate and any other product candidates we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain regulatory approval for our bezuclastinib product candidate and any other
product candidates we may develop, and any related restrictions, limitations, and/or warnings in the label of an approved product candidate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential for our identified research priorities to advance our bezuclastinib product candidate or for our
teams to discover and develop additional product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to license additional intellectual property rights relating to our bezuclastinib product candidate or
future product candidates from third parties and to comply with our existing or future license agreements and/or collaboration agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to commercialize our bezuclastinib product candidate and future product candidates in light of the
intellectual property rights of others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain funding for our operations, including funding necessary to complete further discovery,
development and commercialization of our existing and future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scalability and commercial viability of our manufacturing methods and processes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commercialization of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract collaborators with development, regulatory, and commercialization expertise;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future agreements with third parties in connection with the commercialization of our product candidates and any
other approved product; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size and growth potential of the markets for our product candidates, and our ability to serve those markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the pricing and reimbursement of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments in the United States and foreign countries, including pharmaceutical and biological
product marketing regulation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of adverse business and economic conditions including inflationary pressures, general economic
slowdown or a recession, high interest rates, changes in monetary policy, banking institution instability, changes in trade policies, including tariffs or other trade restrictions or the threat of such actions, and the prospect of a, or any then
ongoing, shutdown of the U.S. federal government; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the development and success of competing therapies that are or may be under development in clinical trials or
become available commercially; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain key scientific and management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the accuracy of our estimates regarding expenses, future revenue, capital requirements, and needs for additional
financing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our use of the proceeds from our private placements, sales of our preferred stock and other public offerings of
our common stock from time to time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that interim clinical data may not be indicative of future results; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding our ability to obtain and maintain intellectual property protection for our
bezuclastinib product candidate and future product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These factors should not be construed as exhaustive and
should be read in conjunction with the other cautionary statements that are included in this prospectus, any accompanying prospectus supplement, information incorporated by reference herein or therein, and any related free-writing prospectus. The
forward-looking statements contained in this prospectus are made as of the date of hereof and we undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or
otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc159388_3"></A>THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biotechnology company focused on developing precision therapies for genetically defined diseases. Our approach is to
design rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Our most advanced program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor that is designed to
potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (&#8220;SM&#8221;), a serious and rare disease caused by unchecked
proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (&#8220;GIST&#8221;), a type of cancer with strong dependence on oncogenic KIT signaling. Bezuclastinib is a highly selective and
potent KIT inhibitor with the potential to provide a new treatment option for these patient populations. We are developing bezuclastinib to treat patients living with Non-Advanced Systemic Mastocytosis (&#8220;Non-AdvSM&#8221;), Advanced Systemic
Mastocytosis (&#8220;AdvSM&#8221;) and GIST. We also have an ongoing Phase 1 study of our novel internally developed FGFR2 inhibitor. In addition to bezuclastinib, the Cogent Research Team is developing a portfolio of novel targeted therapies to
help patients fighting serious, genetically driven diseases initially targeting mutations in ErbB2, PI3K, KRAS, and JAK2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For more
information about our business, please see our most recent Annual Report on Form 10-K, as supplemented and updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that we have filed or will file with the SEC, and in
other documents which are incorporated by reference into this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated in March 2014 under the laws of the State of Delaware. We completed our initial public offering in April 2018, and in July
2020 we completed the asset acquisition of Kiq Bio LLC (formerly Kiq LLC) and shifted our development to bezuclastinib, a selective tyrosine kinase inhibitor licensed from Plexxikon, Inc. In October 2020, we changed our name to Cogent Biosciences,
Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive office is located at 275 Wyman Street, 3rd Floor, Waltham, Massachusetts 02451, and our telephone number is
(617)&nbsp;945-5576. Our corporate website address is <I>www.cogentbio.com</I>. The information contained on our website is not incorporated by reference into this prospectus or any accompanying prospectus supplement, and you should not consider any
information contained on, or that can be accessed through, our website as part of this prospectus or any accompanying prospectus supplement in deciding whether to purchase our securities. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc159388_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our securities involves risks. You should carefully consider the risks, uncertainties and other factors described in our most
recent Annual Report on Form 10-K, as supplemented and updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that we have filed or will file with the SEC, and in other documents which are incorporated by reference into
this prospectus, as well as the risk factors and other information contained in or incorporated by reference into any accompanying prospectus supplement before investing in any of our securities. Our business, financial condition, results of
operations, cash flows or prospects could be materially and adversely affected by any of these risks. The risks and uncertainties described in the documents incorporated by reference herein are not the only risks and uncertainties that you may face.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For more information about our SEC filings, please see &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation of
Certain Information by Reference.&#8221; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc159388_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will retain broad discretion over the use of the net proceeds from the sale of the securities offered hereby. Unless otherwise specified in
a prospectus supplement accompanying this prospectus, the net proceeds from the sale by us of the securities to which this prospectus relates will be used for development and regulatory activities relating to bezuclastinib and other product
candidates, the anticipated commercial launch and commercialization of bezuclastinib, as well as for working capital and general corporate purposes. Our expected use of proceeds from the sale of the securities offered hereby represents our current
intentions based on our present plans and business condition. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the proceeds to be received from the sale of the securities offered hereby or the
amounts that we will actually spend on the uses set forth above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending the use of the net proceeds, we may invest the proceeds in
interest-bearing, investment-grade securities, certificates of deposit or government securities. When we offer and sell the securities to which this prospectus relates, the prospectus supplement related to such offering will set forth our intended
use of the proceeds, if any, received from the sale of such securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc159388_6"></A>SECURITIES WE MAY OFFER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains summary descriptions of the securities we may offer from time to time. These summary descriptions are not meant to be
complete descriptions of each security. The particular terms of any security will be described in the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc159388_7"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material terms of our capital stock, as well as other material terms of certain provisions of Delaware law,
our fourth amended and restated certificate of incorporation (as amended from time to time, our &#8220;certificate of incorporation&#8221;), and our amended and restated bylaws (&#8220;bylaws&#8221;), both of which are filed as exhibits to our most
recent Annual Report on Form 10-K, filed with the SEC, and are incorporated by reference herein. This summary does not purport to be complete and is qualified in its entirety by the provisions of our certificate of incorporation and bylaws. For more
information on how you can obtain our certificate of incorporation and bylaws, see the heading &#8220;Where You Can Find More Information.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of 300,000,000 shares of common stock, par value $0.001 per share, and 10,000,000 shares of preferred
stock, par value $0.001 per share, 1,000,000 of which are designated as Series&nbsp;A Non-Voting Convertible Preferred Stock (&#8220;Series A Preferred Stock&#8221;), 20,580 of which are designated as Series B Non-Voting Convertible Preferred Stock
(the &#8220;Series B Preferred Stock&#8221;) and 8,979,420 of which shares of preferred stock are undesignated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The
holders of our common stock do not have any cumulative voting rights. Holders of our common stock are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for that purpose, subject to any
preferential dividend rights of any outstanding preferred stock. Our common stock has no preemptive rights, conversion rights, or other subscription rights or redemption or sinking fund provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of our liquidation, dissolution, or winding up, holders of our common stock will be entitled to share ratably in all assets
remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock. The shares to be issued by us in this offering will be, when issued and paid for, validly issued, fully paid and
non-assessable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All outstanding shares of common stock are validly issued, fully paid and nonassessable, and any issued shares of common
stock will be validly issued, fully paid and nonassessable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Series A Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of Series A Preferred Stock are entitled to receive dividends on shares of Series A Preferred Stock equal to, on an
as-if-converted-to-common-stock basis, and in the same form as dividends actually paid on shares of the common stock. Except as otherwise required by law, the Series A Preferred Stock does not have voting rights. However, as long as any shares of
Series A Preferred Stock are outstanding, we will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred Stock, (a)&nbsp;alter or change adversely the powers, preferences or rights
given to the Series A Preferred Stock, (b)&nbsp;alter or amend the certificate of designations of Series A Preferred Stock (&#8220;Series A Certificate of Designations&#8221;), (c)&nbsp;amend its certificate of incorporation or other charter
documents in any manner that adversely affects any rights of the holders of Series A Preferred Stock, (d)&nbsp;increase the number of authorized shares of Series A Preferred Stock, (e)&nbsp;prior to the stockholder approval of the conversion of the
Series A Preferred Stock into shares of common stock (which stockholder approval has been received) or at any time while at least 40% of the originally issued Series A Preferred Stock remains issued and outstanding, consummate a Fundamental
Transaction (as defined in the Certificate of Designation) or (f)&nbsp;enter into any agreement with respect to any of the foregoing. The Series A Preferred Stock does not have a preference upon any liquidation, dissolution or winding-up of the
Company, and are not be redeemable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of Series A Preferred Stock is convertible into shares of common stock at any time at the
option of the holder thereof, into 250 shares of common stock, subject to certain limitations, including that a holder of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its
affiliates, would beneficially own more than a specified percentage (as established by the holder between 4.9% and 19.9%) of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2025, 95,911 shares of Series A Preferred Stock have been converted to common stock and 67,414 shares of Series A
Preferred Stock were issued and outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Series B Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of Series B Preferred Stock are entitled to receive dividends on shares of Series B Preferred Stock equal to, on an
as-if-converted-to-common stock basis, and in the same form as dividends actually paid on shares of the common stock. Except as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares of
Series B Preferred Stock are outstanding, we will not, without the affirmative vote of each of the holders of the then outstanding shares of the Series B Preferred Stock, (a)&nbsp;alter or change adversely the powers, preferences or rights given to
the Series B Preferred Stock, (b)&nbsp;alter or amend the certificate of designations of Series B Preferred Stock (&#8220;Series B Certificate of Designations&#8221;), or (c)&nbsp;amend its certificate of incorporation or other charter documents in
any manner that adversely affects any rights of the holders of Series B Preferred Stock . The Series B Preferred Stock does not have a preference upon any liquidation, dissolution or winding-up of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of Series B Preferred Stock is convertible into 1,000 shares of common stock, subject to certain limitations, including that a
holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a
specified percentage (to be established by the holder between 0% and 19.9%) of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2025, 13,712 shares of Series B Preferred Stock have been converted to common stock and 6,868 shares of Series B
Preferred Stock were issued and outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has the authority, without further action by our stockholders, to issue up to 8,979,420 additional shares of preferred
stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation
preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect the voting
power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change
in control of the Company or other corporate action. Other than the outstanding Series A Preferred Stock and Series&nbsp;B Preferred Stock, no shares of preferred stock are outstanding, and we have no present plan to issue any shares of preferred
stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Provisions of Delaware Law and Our Certificate of Incorporation and Bylaws </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-Takeover Effects of our Certificate of Incorporation and Bylaws and Delaware Law </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain provisions of the Delaware General Corporation Law and of our certificate of incorporation and by laws could have the effect of
delaying, deferring or discouraging another party from acquiring control of us. These provisions, which are summarized below, are expected to discourage certain types of coercive takeover </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
practices and inadequate takeover bids and, as a consequence, they might also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored
hostile takeover attempts. These provisions are also designed in part to encourage anyone seeking to acquire control of us to first negotiate with our board of directors. These provisions might also have the effect of preventing changes in our
management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders might otherwise deem to be in their best interests. However, we believe that the advantages gained by protecting our ability
to negotiate with any unsolicited and potentially unfriendly acquirer outweigh the disadvantages of discouraging such proposals, including those priced above the then-current market value of our common stock, because, among other reasons, the
negotiation of such proposals could improve their terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;203 of the Delaware General Corporation Law </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the provisions of Section&nbsp;203 of the Delaware General Corporation Law. In general, Section&nbsp;203 prohibits a publicly
held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business
combination is approved in a prescribed manner. Under Section&nbsp;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">before the stockholder became interested, our board of directors approved either the business combination or the
transaction which resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and
also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at or after the time the stockholder became interested, the business combination was approved by our board of
directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 defines a business combination to include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or more of the
assets of the corporation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock
of the corporation to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to exceptions, any transaction involving the corporation that has the effect of increasing the
proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges, or other
financial benefits provided by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines an interested
stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions of our certificate of incorporation and bylaws may delay or discourage transactions involving an actual or potential change in our
control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these
provisions could adversely affect the price of our common stock. Among other things, our certificate of incorporation and bylaws: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">permit our board of directors to issue up to an additional 8,979,420 shares of preferred stock, with any rights,
preferences and privileges as they may designate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that the authorized number of directors may be changed only by resolution adopted by a majority of the
board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that the board of directors or any individual director may only be removed with cause and the affirmative
vote of the holders of at least 66.67% of the voting power of all of our then outstanding common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">divide our board of directors into three classes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges, or other
financial benefits provided by or through the corporation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require that any action to be taken by our stockholders must be effected at a duly called annual or special
meeting of stockholders and not be taken by written consent or electronic transmission; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates
for election as directors at a meeting of stockholders must provide notice in writing in a timely manner and also specify requirements as to the form and content of a stockholder&#8217;s notice; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common
stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that special meetings of our stockholders may be called only by the chairperson of the board, our chief
executive officer, or by the board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors (whether or not there exists any vacancies); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (i)&nbsp;any
derivative action or proceeding brought on our behalf, (ii)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any of our directors or officers to us or our stockholders, (iii)&nbsp;any action asserting a claim against the us
arising pursuant to any provision of the DGCL or our certificate of incorporation or bylaws, or (iv)&nbsp;any action asserting a claim against us governed by the internal affairs doctrine. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amendment of any of these provisions, with the exception of the ability of our board of directors to issue shares of preferred stock and
designate any rights, preferences, and privileges thereto, would require the affirmative vote of the holders of at least 66.67% of the voting power of all of our then outstanding common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Computershare Trust Company, N.A. serves as the transfer agent and registrar for our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc159388_8"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue debt securities under an indenture to be entered into between us and a trustee chosen by us, qualified to act as such under the
Trust Indenture Act of 1939, as amended (the &#8220;Trust Indenture Act&#8221;) and appointed under the indenture. The indenture will consist of a base indenture (the &#8220;base indenture&#8221;) as supplemented by a supplemental indenture or
authorizing resolution setting forth the specific terms of any debt securities we may issue. References below to an &#8220;indenture&#8221; are references to the base indenture, as supplemented, under which a particular series of debt securities is
issued. The indenture will be governed by the Trust Indenture Act unless otherwise specified in the applicable prospectus supplement. We will set forth the terms of any such debt securities in the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the base indenture. It does not restate the base indenture entirely. We urge you to read the indenture. We have
filed the form of base indenture as an exhibit to the registration statement of which this prospectus is a part, and we will file the base indenture we enter into and the supplemental indentures or authorizing resolutions with respect to particular
series of debt securities as exhibits to current or other reports we file with the SEC. See &#8220;Where You Can Find More Information&#8221; for information on how to obtain copies of the base indenture and the supplemental indentures or
authorizing resolutions. You may also inspect copies of the documents for the particular series at the office of the trustee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Terms of the Debt
Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our debt securities will be general obligations of Cogent Biosciences, Inc. We may issue them in one or more series.
Supplemental indentures or authorizing resolutions will set forth the specific terms of each series of debt securities. We will provide a prospectus supplement for each series of debt securities that will describe: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the aggregate principal amount (or any limit on the aggregate principal amount) of the series and, if any
securities of a series are to be issued at a discount from their face amount, or with a premium, the method of computing the accretion of such discount or computing such premium; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the interest rate or method of calculation of the interest rate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date from which interest will accrue; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the record dates for interest payable on securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates when, places where and manner in which principal and interest are payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if there is more than one trustee or a trustee other than the trustee under the base indenture, the identity of
the trustee and, if not the trustee, the identity of each registrar, paying agent or authenticating agent with respect to such securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any mandatory (including any sinking fund requirements) or optional redemption by the company;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any redemption at the option of holders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the permissible denominations in which securities of such series are issuable, if different from minimum
denominations of $2,000 and multiples of $1,000 in excess thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether securities of such series will be issued in registered or bearer form and the terms of any such forms of
securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the securities of the series shall be issued in whole or in part in the form of a global security or
securities, the terms and conditions, if different from those contained in the base indenture, upon which such global security or securities may be exchanged in whole or in part for definitive securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary for such global security or securities; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the form of any legend or legends, if any, to be borne by any such global security or securities in addition to
or in lieu of the legends referred to the base indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency or currencies (including any composite currency) in which principal or interest or both may be paid;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if payments of principal or interest may be made in a currency other than that in which securities of such series
are denominated, the manner for determining such payments, including the time and manner of determining the exchange rate between the currency in which such securities are denominated and the currency in which such securities or any of them may be
paid, and any deletions from or modifications of or additions to the terms of the indenture to provide for or to facilitate the issuance of securities denominated or payable, at the election of the company or a holder thereof or otherwise, in a
foreign currency; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the amount of payments of principal of or any interest on, such securities may be determined with
reference to an index, formula, financial or economic measure or other method or methods (which index, formula, measure or method or methods may be based, without limitation, on one or more currencies, commodities, equity indices or other indices)
and if so, the terms and conditions upon which and the manner in which such amounts shall be determined and paid or be payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provisions for electronic issuance of securities or issuance of securities of such series in uncertificated form;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any events of default, covenants, defined terms and/or other terms in addition to or in lieu of those set forth
in the base indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and upon what terms securities of such series may be defeased or discharged if different from the
provisions set forth in the base indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the form of the securities of such series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any terms that may be required by or advisable under applicable law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the percentage of the principal amount of the securities of such series which is payable if the maturity of the
securities of such series is accelerated in the case of securities issued at a discount from their face amount; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether securities of such series will or will not have the benefit of guarantees and, if applicable, the terms
and conditions upon which such guarantees may be subordinated to other indebtedness of the respective guarantors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the securities of such series are senior or subordinated debt securities, and if subordinated debt
securities, the terms of such subordination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the securities of the series will be convertible into or exchangeable for other securities, common stock,
other securities, cash or property of any kind of the company or another person or persons, and, if so, the terms and conditions upon which such securities will be so convertible or exchangeable, including the initial conversion or exchange price or
rate or the method of calculation, how and when the conversion price or exchange ratio may be adjusted, whether conversion or exchange is mandatory, at the option of the holder or at the company&#8217;s option, the conversion or exchange period, and
any other provision in relation thereto; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms in addition to or different from those contained in the base indenture applicable to such series.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement will also describe any material covenants to which a series of debt securities
will be subject and the applicability of those covenants to any of our subsidiaries to be restricted thereby, which are referred to herein as &#8220;restricted subsidiaries.&#8221; The applicable prospectus supplement will also describe provisions
for restricted subsidiaries to cease to be restricted by those covenants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default and Remedies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise described in the applicable prospectus supplement, an event of default with respect to any series of debt securities will be
defined in the indenture as being: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure to pay interest on any debt security of such series when the same becomes due and payable and the
continuance of any such failure for a period of 30 days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure to pay the principal or premium of any debt security of such series when the same becomes due and
payable at maturity, upon acceleration, redemption or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure to comply with any of our agreements or covenants in, or provisions of, the debt securities of such
series or the indenture (as they relate thereto) and such failure continues for a period of 90 days after our receipt of notice of the default from the trustee or from the holders of at least 25&nbsp;percent in aggregate principal amount of the then
outstanding debt securities of that series; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain events of bankruptcy, insolvency or reorganization occur with respect to us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The base indenture will provide that the trustee shall be protected in withholding notice to the holders of any series of debt securities of
any default, except a default in payment of principal or interest, if any, with respect to such series of debt securities, if the trustee determines that it is in the interest of the holders of such series of debt securities to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The base indenture will provide that if any event of default has occurred and is continuing with respect to any series of debt securities
(other than an event of default resulting from certain events of bankruptcy, insolvency or reorganization), the trustee or the holders of not less than 25% in principal amount of such series of debt securities then outstanding (with a copy to the
trustee if given by the holders) may declare all the debt securities of such series to be due and payable immediately. If an event of default resulting from certain events of bankruptcy, insolvency or reorganization occur, all amounts due and
payable on the debt securities of such series will become and be immediately due and payable without any declaration, notice or other act on the part of the trustee, us or any holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of a majority in principal amount of the debt securities of such series then outstanding by notice to the trustee may waive any
existing default and its consequences with respect to such series of debt securities, other than a default in respect of a covenant or a provision of the indenture that cannot be modified or amended without the consent of all holders of the
applicable series of debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time after such a declaration of acceleration with respect to any series of debt securities
has been made, the holders of a majority in principal amount of the outstanding debt securities of that series, by written notice to the us and the trustee, may rescind and annul such declaration and its consequences, if the rescission would not
conflict with any judgment or decree and if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have paid or deposited with the trustee a sum sufficient to pay all overdue interest on all debt securities of
that series, the principal of (and premium, if any, on) any debt securities of that series which have become due otherwise than by such declaration of acceleration and any interest thereon at the rate or rates prescribed therefor in such debt
securities, to the extent that payment of such interest is lawful, interest upon overdue interest at the rate or rates prescribed therefor in such debt securities, and all sums paid or advanced by the trustee and the reasonable compensation,
expenses, disbursements and advances of the trustee, its agents and counsel; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all events of default with respect to the debt securities of that series, other than the <FONT
STYLE="white-space:nowrap">non-payment</FONT> of the principal and interest, if any, of the debt securities of that series which have become due solely by such declaration of acceleration, have been cured or waived. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of a majority of the outstanding principal amount of the debt securities of any series will have the right to direct the time,
method and place of conducting any proceedings for any remedy available to the trustee with respect to such series, subject to limitations specified in the indenture. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Defeasance, Satisfaction and Discharge </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise described in the applicable prospectus supplement, the indenture will permit us to terminate all our obligations under the
indenture as they relate to any particular series of debt securities (&#8220;legal defeasance&#8221;), other than the right of the holders of the debt securities of such series to receive payments solely from the trust fund described below in
respect of the principal and interest on such debt securities and certain other obligations, at any time by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">depositing in trust with the trustee, under an irrevocable trust agreement, money, government obligations or a
combination thereof in an amount sufficient to pay principal of and interest, if any, on the debt securities of such series to their maturity or redemption; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complying with other conditions, including delivery to the trustee of an opinion of counsel to the effect that
(A)&nbsp;we have received from, or there has been published by, the Internal Revenue Service a ruling, or (B)&nbsp;since the date such series of debt securities were originally issued, there has been a change in the applicable federal income tax
law, in either case to the effect that, and based thereon such opinion of counsel shall state that, holders will not recognize income, gain or loss for federal income tax purposes as a result of our exercise of such right and will be subject to
federal income tax on the same amount and in the same manner and at the same times as would have been the case otherwise. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise described in the applicable prospectus supplement, the indenture will also permit us to terminate all of our obligations
under covenants in the indenture as they relate to any particular series of debt securities, and the debt securities of such series shall thereafter be deemed to be not &#8220;outstanding&#8221; for the purpose of any direction, waiver, consent or
declaration or act of holders of such series in connection with such covenants (&#8220;covenant defeasance&#8221;), at any time by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">depositing in trust with the trustee, under an irrevocable trust agreement, money or government obligations in an
amount sufficient to pay principal and interest, if any, on the debt securities of such series to their maturity or redemption; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complying with other conditions, including delivery to the trustee of an opinion of counsel to the effect that
holders will not recognize income, gain or loss for federal income tax purposes as a result of our exercise of such right and will be subject to federal income tax on the same amount and in the same manner and at the same times as would have been
the case otherwise. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture will be discharged and will cease to be of further effect with respect to a series of
debt securities when either: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all outstanding debt securities of such series, other than any securities that have been destroyed, lost, or
stolen and that have been replaced or paid as provided in the indenture, have been delivered to the trustee for cancellation; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all outstanding debt securities of such series that have not been delivered to the trustee for cancellation have
become due and payable or will become due and payable at maturity within one year or are to be called for redemption within one year under arrangements satisfactory to the trustee for the giving of notice of redemption, and we shall have irrevocably
deposited with the trustee as trust funds the entire amount, in money or governmental obligations, or a combination thereof, sufficient, in the opinion of a nationally recognized firm of independent public accountants, to pay at maturity or upon
redemption of all securities of such series, including principal of and any premium and interest due or to become due to such date of maturity or date fixed for redemption, as the case may be. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In each case, we will also pay all other sums payable by us under the indenture with respect to the securities of such series, deliver
irrevocable instructions to the trustee to apply the deposited money toward the payment of the debt securities of such series at maturity or redemption, as the case may be, and deliver to the trustee an opinion of counsel and an officers&#8217;
certificate, each stating that all conditions precedent to satisfaction and discharge with respect to the securities of such series have been complied with. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer and Exchange </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder will be able to transfer or exchange debt securities only in accordance with the indenture. The registrar may require a holder, among
other things, to furnish appropriate endorsements and transfer documents, and to pay any taxes and fees required by law or permitted by the indenture. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendment, Supplement and Waiver </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Without
notice to or the consent of any holder, we and the trustee may amend or supplement the indenture or the debt securities of a series to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cure any ambiguity or to correct or supplement any provision of the indenture which may be defective or
inconsistent with any other provision in the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">comply with the provisions of the indenture regarding the consolidation, merger, sale, lease, conveyance or other
disposition of all or substantially all of our assets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">create a series and establish its terms; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide for uncertificated debt securities in addition to or in place of certificated debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add to our covenants for the benefit of the holders of all or any series of debt securities or to surrender any
right or power conferred upon us by the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add any additional events of default for the benefit of holders of all or any series of debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add a guarantor in respect of any series of debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">secure any series of debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">comply with requirements of the SEC in order to effect or maintain the qualification of the indenture under the
Trust Indenture Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evidence and provide for the acceptance of appointment of a successor trustee and to add to or change any of the
provisions of the indenture or any supplemental indenture as shall be necessary to provide for or facilitate the administration of the trusts under such indenture or supplemental indenture by more than one trustee pursuant to the requirements set
forth in the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any change that does not adversely affect the rights of any holder in any material respect; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conform the provisions of the indenture to the final offering document in respect of any series of debt
securities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With the exceptions discussed below, we and the trustee may amend or supplement the indenture or the debt
securities of a series with the written consent of the holders of at least a majority in principal amount of the debt securities of each series then outstanding affected by the amendment or supplement (voting as one class). In addition, the holders
of a majority in principal amount of the debt securities of each series then outstanding affected by the waiver (voting as one class) may, without notice to any holder, waive any existing default under, or compliance with, any provision of the debt
securities of each such series or of the indenture relating to each such series. These consents and waivers may be obtained in connection with a purchase of, or tender offer or exchange offer for, debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, without the consent of each holder affected, we and the trustee may not: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change the stated maturity of the principal of, or any installment of principal of or interest thereon, or reduce
the principal amount thereof or the rate of interest thereon or any premium payable upon the redemption thereof, or change the coin or currency in which, such debt securities or any premium or interest thereon is payable, or impair the right to
institute suit for the enforcement of any such payment on or after the stated maturity thereof (or, in the case of redemption, on or after the redemption date); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any change to the provision of the indenture relating to the waiver of past defaults, except to increase the
percentage in principal amount of debt securities of any series the consent of whose holders is required for any waiver or to provide that certain other provisions of the indenture cannot be modified or waived without the consent of the holder of
each outstanding note affected thereby; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">waive a continuing default or event of default in the payment of principal of or interest on the debt securities;
or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the percentage in principal amount of debt securities of any series the consent of whose holders is
required for any amendment, supplement or waiver. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any supplemental indenture which changes or eliminates any covenant
or other provision of the indenture which shall have been included expressly and solely for the benefit of one or more particular series of debt securities, or which modifies the rights of the holders of debt securities of such series with respect
to such covenant or other provision, shall be deemed not to affect the rights of the holders of debt securities of any other series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
right of any holder to participate in any consent required or sought pursuant to any provision of the indenture, and our obligation to obtain any such consent otherwise required from such holder, may be subject to the requirement that such holder
shall have been the holder of record of debt securities with respect to which such consent is required or sought as of a record date fixed by us in accordance with the indenture. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Concerning the Trustee </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture
will contain limitations on the rights of the trustee, should it become our creditor, to obtain payment of claims in specified cases or to realize on property received in respect of any such claim as security or otherwise. The indenture will permit
the trustee to engage in other transactions; however, if it acquires any conflicting interest, it must eliminate such conflict or resign. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture will provide that in case an event of default occurs and is not cured, the trustee will be required, in the exercise of its
power, to use the degree of care of a prudent person in similar circumstances in the conduct of such person&#8217;s own affairs. The trustee shall be under no obligation to exercise any of the rights or powers vested in it by the indenture at the
request or direction of any of the holders pursuant to the indenture, unless such holders shall have offered to the trustee security or indemnity satisfactory to the trustee against the costs, expenses and liabilities which might be incurred by it
in compliance with such request or direction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Repurchases in the Open Market </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We or any of our affiliates may at any time or from time to time repurchase any of the debt securities in the open market or otherwise. Such
debt securities may, at our or the applicable affiliate&#8217;s option, be held, resold or surrendered to the trustee for cancellation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Recourse
against Others </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture will provide that a director, officer, employee or stockholder, as such, of the Company shall not have
any liability for any obligations of the Company under the debt securities or the indenture or for any claim based on, in respect of or by reason of, such obligations or their creation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The laws of the State of
New York will govern the indenture and the debt securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc159388_9"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description, together with the additional information we may include in any applicable prospectus supplements, summarizes the
material terms and provisions of the warrants that we may offer under this prospectus and the related warrant agreements and warrant certificates. While the terms summarized below will apply generally to any warrants that we may offer, we will
describe the particular terms of any series of warrants in more detail in the applicable prospectus supplement. If we indicate in the prospectus supplement, the terms of any warrants offered under that prospectus supplement may differ from the terms
described below. Specific warrant agreements will contain additional important terms and provisions and will be incorporated by reference as an exhibit to the registration statement, which includes this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue warrants for the
purchase of common stock, preferred stock and/or debt securities in one or more series. We may issue warrants independently or together with common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate from
these securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will evidence each series of warrants by warrant certificates that we will issue under a separate warrant agreement.
We will enter into the warrant agreement with a warrant agent. We will indicate the name and address of the warrant agent in the applicable prospectus supplement relating to a particular series of warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will describe in the applicable prospectus supplement the terms of the series of warrants, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the offering price and aggregate number of warrants offered; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency for which the warrants may be purchased; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the designation and terms of the securities with which the warrants are issued and the number of
warrants issued with each such security or each principal amount of such security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date on and after which the warrants and the related securities will be separately
transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon
exercise of one warrant and the price at, and currency in which, this principal amount of debt securities may be purchased upon such exercise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or
preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which these shares may be purchased upon such exercise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreement and
the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any rights to redeem or call the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise
of the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the periods during which, and places at which, the warrants are exercisable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manner of exercise; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which the right to exercise the warrants will commence and expire; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manner in which the warrant agreement and warrants may be modified; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal income tax consequences of holding or exercising the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of the securities issuable upon exercise of the warrants; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of or restrictions on the warrants.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc159388_10"></A>DESCRIPTION OF UNITS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue units comprised of shares of common stock, shares of preferred stock, debt securities and warrants in any combination. We may
issue units in such amounts and in as many distinct series as we wish. This section outlines certain provisions of the units that we may issue. If we issue units, they will be issued under one or more unit agreements to be entered into between us
and a bank or other financial institution, as unit agent. The information described in this section may not be complete in all respects and is qualified entirely by reference to the unit agreement with respect to the units of any particular series.
The specific terms of any series of units offered will be described in the applicable prospectus supplement. If so described in a particular supplement, the specific terms of any series of units may differ from the general description of terms
presented below. We urge you to read any prospectus supplement related to any series of units we may offer, as well as the complete unit agreement and unit certificate that contain the terms of the units. If we issue units, forms of unit agreements
and unit certificates relating to such units will be incorporated by reference as exhibits to the registration statement, which includes this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each unit that we may issue will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the
holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time
or at any time before a specified date. The applicable prospectus supplement may describe: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation and terms of the units and of the securities comprising the units, including whether and under
what circumstances those securities may be held or transferred separately; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions of the governing unit agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices at which such units will be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the applicable United States federal income tax considerations relating to the units; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities
comprising the units; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the units and of the securities comprising the units. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions described in this section, as well as those described under &#8220;Description of Capital Stock,&#8221; &#8220;Description of
Debt Securities&#8221; and &#8220;Description of Warrants&#8221; will apply to the securities included in each unit, to the extent relevant and as may be updated in any prospectus supplements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Issuance in Series </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue units in
such amounts and in as many distinct series as we wish. This section summarizes terms of the units that apply generally to all series. Most of the financial and other specific terms of your series will be described in the applicable prospectus
supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unit Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will
issue the units under one or more unit agreements to be entered into between us and a bank or other financial institution, as unit agent. We may add, replace or terminate unit agents from time to time. We will identify the unit agreement under which
each series of units will be issued and the unit agent under that agreement in the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following provisions will generally apply to all unit agreements unless otherwise stated
in the applicable prospectus supplement: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Modification without Consent </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the applicable unit agent may amend any unit or unit agreement without the consent of any holder: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to cure any ambiguity, including modifying any provisions of the governing unit agreement that differ from those
described below; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to correct or supplement any defective or inconsistent provision; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to make any other change that we believe is necessary or desirable and will not adversely affect the interests of
the affected holders in any material respect. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not need any approval to make changes that affect only units to be
issued after the changes take effect. We may also make changes that do not adversely affect a particular unit in any material respect, even if they adversely affect other units in a material respect. In those cases, we do not need to obtain the
approval of the holder of the unaffected unit; we need only obtain any required approvals from the holders of the affected units. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Modification with
Consent </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not amend any particular unit or a unit agreement with respect to any particular unit unless we obtain the consent
of the holder of that unit, if the amendment would: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impair any right of the holder to exercise or enforce any right under a security included in the unit if the
terms of that security require the consent of the holder to any changes that would impair the exercise or enforcement of that right; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the percentage of outstanding units or any series or class the consent of whose holders is required to
amend that series or class, or the applicable unit agreement with respect to that series or class, as described below. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any other change to a particular unit agreement and the units issued under that agreement would require the following approval: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the change affects only the units of a particular series issued under that agreement, the change must be
approved by the holders of a majority of the outstanding units of that series; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the change affects the units of more than one series issued under that agreement, it must be approved by the
holders of a majority of all outstanding units of all series affected by the change, with the units of all the affected series voting together as one class for this purpose. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions regarding changes with majority approval also apply to changes affecting any securities issued under a unit agreement, as the
governing document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In each case, the required approval must be given by written consent. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unit Agreements Will Not Be Qualified under Trust Indenture Act </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No unit agreement will be qualified as an indenture, and no unit agent will be required to qualify as a trustee, under the Trust Indenture Act.
Therefore, holders of units issued under unit agreements will not have the protections of the Trust Indenture Act with respect to their units. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Mergers and Similar Transactions Permitted; No Restrictive Covenants or Events of Default </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unit agreements will not restrict our ability to merge or consolidate with, or sell our assets to, another corporation or other entity or
to engage in any other transactions. If at any time we merge or consolidate with, or sell our assets substantially as an entirety to, another corporation or other entity, the successor entity will succeed
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to and assume our obligations under the unit agreements. We will then be relieved of any further obligation under these agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unit agreements will not include any restrictions on our ability to put liens on our assets, nor will they restrict our ability to sell
our assets. The unit agreements also will not provide for any events of default or remedies upon the occurrence of any events of default. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Governing
Law </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unit agreements and the units will be governed by Delaware law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Form, Exchange and Transfer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the accompanying prospectus supplement states otherwise, we will issue each unit in global&#8212;i.e., book-entry&#8212;form only. Units
in book-entry form will be represented by a global security registered in the name of a depositary, which will be the holder of all the units represented by the global security. Those who own beneficial interests in a unit will do so through
participants in the depositary&#8217;s system, and the rights of these indirect owners will be governed solely by the applicable procedures of the depositary and its participants. We will describe book-entry securities, and other terms regarding the
issuance and registration of the units in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the accompanying prospectus supplement states
otherwise, each unit and all securities comprising the unit will be issued in the same form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we issue any units in registered,
non-global form, the following will apply to them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The units will be issued in the denominations stated in the applicable prospectus
supplement. Holders may exchange their units for units of smaller denominations or combined into fewer units of larger denominations, as long as the total amount is not changed. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Holders may exchange or transfer their units at the office of the unit agent. Holders may also replace lost,
stolen, destroyed or mutilated units at that office. We may appoint another entity to perform these functions or perform them ourselves. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Holders will not be required to pay a service charge to transfer or exchange their units, but they may be
required to pay for any tax or other governmental charge associated with the transfer or exchange. The transfer or exchange, and any replacement, will be made only if our transfer agent is satisfied with the holder&#8217;s proof of legal ownership.
The transfer agent may also require an indemnity before replacing any units. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we have the right to redeem, accelerate or settle any units before their maturity, and we exercise our right
as to less than all those units or other securities, we may block the exchange or transfer of those units during the period beginning 15 days before the day we mail the notice of exercise and ending on the day of that mailing, in order to freeze the
list of holders to prepare the mailing. We may also refuse to register transfers of or exchange any unit selected for early settlement, except that we will continue to permit transfers and exchanges of the unsettled portion of any unit being
partially settled. We may also block the transfer or exchange of any unit in this manner if the unit includes securities that are or may be selected for early settlement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only the depositary will be entitled to transfer or exchange a unit in global form, since it will be the sole holder of the unit. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Payments and Notices </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In making
payments and giving notices with respect to our units, we will follow the procedures as described in the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc159388_11"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination
of these methods. We may sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers. We may distribute securities from time to time in one or more transactions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price or prices, which may be changed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also sell equity securities covered by this registration statement in an &#8220;at the market offering&#8221; as defined in Rule 415
under the Securities Act. Such offering may be made into an existing trading market for such securities in transactions at other than a fixed price, either: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on or through the facilities of the Nasdaq Global Select Market or any other securities exchange or quotation or
trading service on which such securities may be listed, quoted or traded at the time of sale; and/or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to or through a market maker otherwise than on the Nasdaq Global Select Market or such other securities exchanges
or quotation or trading services. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such at the market offerings, if any, may be conducted by underwriters acting as
principal or agent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus supplement or supplements (and any related free writing prospectus that we may authorize to be provided
to you) will describe the terms of the offering of the securities, including, to the extent applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name or names of any underwriters, dealers or agents, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase price of the securities and the proceeds we will receive from the sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any options under which underwriters may purchase additional securities from us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any agency fees or underwriting discounts and other items constituting agents&#8217; or underwriters&#8217;
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any public offering price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any discounts or concessions allowed or re-allowed or paid to dealers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any securities exchange or market on which the securities may be listed. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only underwriters named in the prospectus supplement are underwriters of the securities offered by the prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time
in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable
underwriting agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain conditions, the underwriters will be obligated to
purchase all of the securities offered by the prospectus supplement. Any public offering price and any discounts or concessions allowed or re-allowed or paid to dealers may change from time to time. We may use underwriters with whom we have a
material relationship. We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell securities directly or through agents we designate from time to time. We will
name any agent involved in the offering and sale of securities, and we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent will act on a best-efforts basis
for the period of its appointment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may authorize agents or underwriters to solicit offers by certain types of institutional investors
to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these
contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may provide agents and
underwriters with indemnification against civil liabilities related to offerings pursuant to this prospectus, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with
respect to these liabilities. Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary course of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All securities we offer, other than our shares of common stock, will be new issues of securities with no established trading market. Any
underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of the trading markets for any securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any underwriter may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids in accordance with
Regulation M under the Exchange Act. Overallotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a
specified maximum. Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer
when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the
underwriters may discontinue any of the activities at any time. These transactions may be effected on any exchange or over-the-counter market or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any underwriters who are qualified market makers on the Nasdaq Global Select Market may engage in passive market making transactions in the
securities on the Nasdaq Global Select Market in accordance with Rule&nbsp;103 of Regulation M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities. Passive market makers must
comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all
independent bids are lowered below the passive market maker&#8217;s bid, however, the passive market maker&#8217;s bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the
securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc159388_12"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain legal matters, including the legality of the securities offered, will be passed upon for us by Gibson, Dunn&nbsp;&amp; Crutcher LLP,
San Francisco, California. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc159388_13"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements and management&#8217;s assessment of the effectiveness of internal control over financial reporting (which is
included in Management&#8217;s Report on Internal Control Over Financial Reporting) incorporated in this prospectus by reference to the Annual Report on Form 10-K for the year ended December&nbsp;31, 2024 have been so incorporated in reliance on the
report of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc159388_14"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC, and we have filed with the SEC a
registration statement on Form S-3 under the Securities Act with respect to the securities offered by this prospectus. This prospectus, which forms part of the registration statement, does not contain all of the information included in the
registration statement, including its exhibits and schedules. For further information about us and the securities described in this prospectus, you should refer to the registration statement, its exhibits and schedules and our reports, proxies,
information statements and other information filed with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our filings are available to the public on the Internet, through a
database maintained by the SEC at <I>http://www.sec.gov</I>. We also maintain a website at<I> www.cogentbio.com</I>. We have included our website address for the information of prospective investors and do not intend it to be an active link to our
website. Information contained on our website does not constitute a part of this prospectus or any applicable prospectus supplement (or any document incorporated by reference herein or therein). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc159388_15"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference much of the information we file with the SEC, which means that we can disclose important
information to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus is considered to be part of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we are incorporating by reference future filings with the SEC, this prospectus is continually updated and those future filings may
modify or supersede some of the information included or incorporated in this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any
document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents listed below and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange
Act (in each case, other than those documents or the portions of those documents not deemed to be filed) following the filing of this prospectus until the offering of the securities under this prospectus is terminated or completed, except that we
are not incorporating by reference any information furnished (and not filed) with the SEC, including any information furnished pursuant to Items 2.02 or 7.01 of Form 8-K or related exhibits furnished pursuant to Item 9.01 of Form&nbsp;8-K: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001622229/000095017025026115/cogt-20241231.htm">Form
 10-K</A> for the year ended December&nbsp;31, 2024 filed with the SEC on February&nbsp;
25, 2025, including the Part III information incorporated by reference from our <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001622229/000119312525089237/d873012ddef14a.htm">Definitive Proxy Statement</A> on
Schedule 14A filed with the SEC on April&nbsp;22, 2025; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form 10-Q for the quarters ended <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1622229/000095017025064005/cogt-20250331.htm">March&nbsp;31,
 2025</A> filed with the SEC on May&nbsp;6, 2025,&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1622229/000095017025102440/cogt-20250630.htm">June&nbsp;30, 2025</A> filed with the SEC on August&nbsp;5,
2025 and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1622229/000119312525272334/cogt-20250930.htm">September&nbsp;30, 2025</A> filed with the SEC on November&nbsp;7, 2025; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form 8-K (other than information furnished rather than filed) filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1622229/000119312525135337/d20143d8k.htm">June&nbsp;5,
 2025</A>,&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1622229/000119312525138813/d21181d8k.htm">June&nbsp;11, 2025</A>,&nbsp;
<A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1622229/000119312525155811/d156610d8k.htm">July&nbsp;7, 2025</A>,&nbsp;
<A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1622229/000119312525157390/d92808d8k.htm">July&nbsp;
10, 2025</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1622229/000119312525201353/d947118d8k.htm">September&nbsp;11, 2025</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock contained in <A HREF="http://www.sec.gov/Archives/edgar/data/1622229/000095017025026115/cogt-ex4_1.htm">Exhibit
 4.1</A> to our Annual Report on Form 10-K for the year ended December&nbsp;31, 2024, as filed with the SEC on February&nbsp;25, 2025, including any amendments or reports filed for the purposes of updating this description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may request a copy of these filings, at no cost, by contacting us, either orally or in writing, at the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cogent Biosciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">275
Wyman Street, 3rd Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Waltham, Massachusetts 02451 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(617)&nbsp;945-5576 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain
a website at<I> www.cogentbio.com</I>. Information about us, including our reports filed with the SEC, is available through that site. Such reports are accessible at no charge through our website and are made available as soon as reasonably
practicable after such material is filed with or furnished to the SEC. Our website and the information contained on that website, or connected to that website, are not incorporated by reference in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may read and copy any materials we file with the SEC at the SEC&#8217;s website mentioned under the heading &#8220;Where You Can Find More
Information.&#8221; The information on the SEC&#8217;s website is not incorporated by reference in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:18pt; font-family:arial" ALIGN="center"><B><I>$200,000,000 </I></B></P> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g159388g01n01.jpg" ALT="LOGO" STYLE="width:1.63459in;height:0.720633in;">
 </P> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial" ALIGN="center"><B><I>1.625% Convertible Senior Notes due 2031
</I></B></P> <P STYLE="margin-top:40pt; margin-bottom:0pt; font-size:24pt; font-family:arial" ALIGN="center"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:40pt; margin-bottom:0pt; font-size:12pt; font-family:arial" ALIGN="center"><I>Joint <FONT
STYLE="white-space:nowrap">Book-Running</FONT> Managers </I></P> <P STYLE="font-size:28pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:16pt">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="52%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:16pt">
<TD VALIGN="bottom"><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>J.P.&nbsp;Morgan</B></TD></TR>
</TABLE> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">November 11, 2025 </P> <P STYLE="font-size:80pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>2
<FILENAME>d159388dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ffd="http://xbrl.sec.gov/ffd/2025">
<head>
<title>EX-FILING FEES</title>
</head>
  <body>
  <div style="display: none"> <ix:header> <ix:hidden> <ix:nonNumeric name="ffd:FormTp" contextRef="rc" id="ixv-356">S-3</ix:nonNumeric> <ix:nonNumeric name="ffd:SubmissnTp" contextRef="rc" id="ixv-357">424B5</ix:nonNumeric> <ix:nonNumeric name="ffd:FeeExhibitTp" contextRef="rc" id="ixv-358">EX-FILING FEES</ix:nonNumeric> <ix:nonNumeric name="ffd:RegnFileNb" contextRef="rc" id="ixv-359">333-291384</ix:nonNumeric> <ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="rc" id="ixv-360">0001622229</ix:nonNumeric> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="rc" id="ixv-361">Cogent Biosciences, Inc.</ix:nonNumeric> <ix:nonNumeric name="ffd:OfferingTableNa" contextRef="rc" id="hiddenrcOfferingTableNa" xsi:nil="true"></ix:nonNumeric> <ix:nonNumeric name="ffd:OffsetTableNa" contextRef="rc" id="hiddenrcOffsetTableNa">N/A</ix:nonNumeric> <ix:nonNumeric name="ffd:CombinedProspectusTableNa" contextRef="rc" id="hiddenrcCombinedProspectusTableNa">N/A</ix:nonNumeric> <ix:nonNumeric name="ffd:FnlPrspctsFlg" contextRef="rc" format="ixt:booleanfalse" id="ixv-365">The prospectus is not a final prospectus for the related offering.</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd" xlink:type="simple"/> </ix:references> <ix:resources> <xbrli:context id="rc"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001622229</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-11-12</xbrli:startDate> <xbrli:endDate>2025-11-12</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="offrl_1"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001622229</xbrli:identifier> <xbrli:segment> <xbrldi:typedMember dimension="ffd:OfferingAxis"> <dei:lineNo>1</dei:lineNo> </xbrldi:typedMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-11-12</xbrli:startDate> <xbrli:endDate>2025-11-12</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="offrl_2"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001622229</xbrli:identifier> <xbrli:segment> <xbrldi:typedMember dimension="ffd:OfferingAxis"> <dei:lineNo>2</dei:lineNo> </xbrldi:typedMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-11-12</xbrli:startDate> <xbrli:endDate>2025-11-12</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:unit id="USD"> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit> <xbrli:unit id="pure"> <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit> <xbrli:unit id="Shares"> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit> </ix:resources> </ix:header> </div> <div>
<table style="width: 99%; font-family: Arial, Helvetica, sans-serif; font-size: 20pt; text-align: center;">
<tr>
<td colspan="4" style="padding-bottom: .5em"> <p> <b>Calculation of Filing Fee Tables</b> </p> </td> </tr>
<tr>
<td style="padding-bottom: .25em"> <p> <b> <ix:nonNumeric name="ffd:FormTp" contextRef="rc" id="ixv-399">S-3</ix:nonNumeric> </b> </p> </td> </tr>
<tr>
<td style="padding-bottom: .25em"> <p> <b> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="rc" id="ixv-400">Cogent Biosciences, Inc.</ix:nonNumeric> </b> </p> </td> </tr> </table> </div> <div style="padding-bottom: 20px;">
<table style="float: center; width: 100%; text-align: left; ">
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
<th style="vertical-align: bottom; text-align: left; word-wrap: break-word"> <b>Table 1: Newly Registered and Carry Forward Securities</b> </th>
<th style="vertical-align: bottom; word-wrap: break-word; text-align: right;"> <span style="-sec-ix-hidden: hiddenrcOfferingTableNa">&#9744;Not Applicable</span> </th> </tr> </table>
<table style="font-family: Arial, Helvetica, sans-serif; float: center; width: 100%; text-align: center; border: 1px solid black; font-size: 16px;">
<tr style="background-color:#9ADAF6">
<th style="width: 12%;">
 </th>
<th style="width: 2%;">
 </th>
<th style="width: 12%;"> <p style="margin: 0pt; text-align: center;"> <b>Security Type</b> </p> </th>
<th style="width: 14%;"> <p style="margin: 0pt; text-align: center;"> <b>Security Class Title </b> </p> </th>
<th style="width: 2%;"> <p style="margin: 0pt; text-align: center;"> <b>Fee Calculation or Carry Forward Rule</b> </p> </th>
<th style="width: 5%;"> <p style="margin: 0pt; text-align: center;"> <b>Amount Registered</b> </p> </th>
<th style="width: 15%;"> <p style="margin: 0pt; text-align: center;"> <b>Proposed Maximum Offering Price Per Unit</b> </p> </th>
<th style="width: 10%;"> <p style="margin: 0pt; text-align: center;"> <b>Maximum Aggregate Offering Price</b> </p> </th>
<th style="width: 5%;"> <p style="margin: 0pt; text-align: center;"> <b>Fee Rate</b> </p> </th>
<th style="width: 6%;"> <p style="margin: 0pt; text-align: center;"> <b>Amount of Registration Fee</b> </p> </th>
<th style="width: 1%;"> <p style="margin: 0pt; text-align: center;"> <b>Carry Forward Form Type</b> </p> </th>
<th style="width: 7%;"> <p style="margin: 0pt; text-align: center;"> <b>Carry Forward File Number</b> </p> </th>
<th style="width: 6%;"> <p style="margin: 0pt; text-align: center;"> <b>Carry Forward Initial Effective Date</b> </p> </th>
<th style="width: 7%;"> <p style="margin: 0pt; text-align: center;"> <b>Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward</b> </p> </th> </tr>
<tr>
<td colspan="14" style="text-align: center"> <b>Newly Registered Securities</b> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> <ix:nonNumeric name="ffd:PrevslyPdFlg" contextRef="offrl_1" format="ixt:booleanfalse" id="ixv-401">Fees to be Paid</ix:nonNumeric> </td>
<td style="text-align: center;"> 1 </td>
<td style="text-align: left;"> <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_1" id="ixv-402">Debt</ix:nonNumeric> </td>
<td style="text-align: left;"> <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_1" id="ixv-403">1.625% Convertible Senior Notes</ix:nonNumeric> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:Rule457rFlg" contextRef="offrl_1" format="ixt:booleantrue" id="ixv-404">457(r)</ix:nonNumeric> </td>
<td style="text-align: right;"> <ix:nonFraction name="ffd:AmtSctiesRegd" unitRef="Shares" decimals="0" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-405">230,000</ix:nonFraction> </td>
<td style="text-align: right;"> <span>$</span> <ix:nonFraction name="ffd:MaxOfferingPricPerScty" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-406">1,000.00</ix:nonFraction> </td>
<td style="text-align: right;"> <span>$</span> <ix:nonFraction name="ffd:MaxAggtOfferingPric" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-407">230,000,000.00</ix:nonFraction> </td>
<td style="text-align: right;"> <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-408">0.0001381</ix:nonFraction> </td>
<td style="text-align: right;"> <span>$</span> <ix:nonFraction name="ffd:FeeAmt" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-409">31,763.00</ix:nonFraction> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> <ix:nonNumeric name="ffd:PrevslyPdFlg" contextRef="offrl_2" format="ixt:booleanfalse" id="ixv-410">Fees to be Paid</ix:nonNumeric> </td>
<td style="text-align: center;"> 2 </td>
<td style="text-align: left;"> <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_2" id="ixv-411">Equity</ix:nonNumeric> </td>
<td style="text-align: left;"> <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_2" id="ixv-412">Common stock, par value $0.001 per share</ix:nonNumeric> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:FeesOthrRuleFlg" contextRef="offrl_2" format="ixt:booleantrue" id="ixv-413">Other</ix:nonNumeric> </td>
<td style="text-align: right;"> <ix:nonFraction name="ffd:AmtSctiesRegd" unitRef="Shares" decimals="0" format="ixt:numdotdecimal" contextRef="offrl_2" id="ixv-414">7,419,340</ix:nonFraction> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> <span>$</span> <ix:nonFraction name="ffd:MaxAggtOfferingPric" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_2" id="ixv-415">0.00</ix:nonFraction> </td>
<td style="text-align: right;"> <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_2" id="ixv-416">0.0001381</ix:nonFraction> </td>
<td style="text-align: right;"> <span>$</span> <ix:nonFraction name="ffd:FeeAmt" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_2" id="ixv-417">0.00</ix:nonFraction> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Fees Previously Paid </td>
<td style="text-align: center;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td> </tr>
<tr>
<td colspan="14" style="text-align: center"> <b>Carry Forward Securities</b> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Carry Forward Securities </td>
<td style="text-align: center;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td> </tr>
<tr>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td colspan="3" style="vertical-align: top"> <p style="margin: 0pt; text-align: right">Total Offering Amounts:</p> </td>
<td>
 </td>
<td style="vertical-align: top; width: 16%;"> <p id="MaxAggtOfferingPrice" style="margin: 0pt; text-align: right"> <span>$</span> <ix:nonFraction name="ffd:TtlOfferingAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-418">230,000,000.00</ix:nonFraction> </p> </td>
<td>
 </td>
<td style="vertical-align: top; border-bottom: 1px black; width: 16%;"> <p id="TotalFeeAmt" style="margin: 0pt; text-align: right"> <span>$</span> <ix:nonFraction name="ffd:TtlFeeAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-419">31,763.00</ix:nonFraction> </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td>
 </td> </tr>
<tr>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td colspan="3" style="vertical-align: top"> <p style="margin: 0pt; text-align: right"> Total Fees Previously Paid: </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td style="vertical-align: top"> <p id="TotalPreviouslyPaidAmt" style="margin: 0pt; text-align: right"> <span>$</span> <ix:nonFraction name="ffd:TtlPrevslyPdAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-420">0.00</ix:nonFraction> </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td>
 </td> </tr>
<tr>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td colspan="3" style="vertical-align: top"> <p style="margin: 0pt; text-align: right"> Total Fee Offsets: </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td style="vertical-align: top"> <p id="TotalOffsetAmt" style="margin: 0pt; text-align: right"> <span>$</span> <ix:nonFraction name="ffd:TtlOffsetAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-421">0.00</ix:nonFraction> </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td>
 </td> </tr>
<tr>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td colspan="3" style="vertical-align: top"> <p style="margin: 0pt; text-align: right"> Net Fee Due: </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td style="vertical-align: top"> <p id="NetFeeAmt" style="margin: 0pt; text-align: right"> <span>$</span> <ix:nonFraction name="ffd:NetFeeAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-422">31,763.00</ix:nonFraction> </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td>
 </td> </tr> </table> </div> <div>
<table style="width: 100%; text-indent: 0px;"> <tbody>
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; vertical-align: top;">
<td> <p style="margin:0pt;text-align:left; margin-bottom: 5px;"> <b>Offering Note</b> </p> </td>
<td/> </tr> </tbody> </table> </div> <div style="padding-bottom: 20px;">
<table style="width: 100%; text-indent: 0px;">
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; vertical-align: top;">
<td style="width:10pt;"> <p style="margin:0pt;text-align:left;"> <sup style="vertical-align:top;line-height:120%;font-size:10px">1</sup> </p> </td>
<td colspan="7" style="white-space: pre-line;"> <ix:nonNumeric name="ffd:OfferingNote" escape="1" contextRef="offrl_1" id="ixv-423">The registration fee is calculated in accordance with Rule 457(r) of the Securities Act of 1933, as amended (the "Securities Act") and represents deferred payment of the registration fees in connection with the Registrant's registration statement on Form S-3ASR (Registration No. 333-291384) paid with the filing of this prospectus supplement</ix:nonNumeric> </td> </tr>
<tr>
<td colspan="7"> <hr style="width:100%;text-align:left;margin-left:0"/> </td> </tr>
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; vertical-align: top;">
<td style="width:10pt;"> <p style="margin:0pt;text-align:left;"> <sup style="vertical-align:top;line-height:120%;font-size:10px">2</sup> </p> </td>
<td colspan="7" style="white-space: pre-line;"> <ix:nonNumeric name="ffd:OfferingNote" escape="1" contextRef="offrl_2" id="ixv-424">(2) Represents the maximum number of shares that may be issued upon conversion of the 1.625% Convertible Senior Notes. (3) Pursuant to Rule 457(i) under the Securities Act, there is no filing fee payable with respect to the shares common stock that may be issuable upon conversion of the 1.625% Convertible Senior Notes because no additional consideration will be received in connection with any conversion.</ix:nonNumeric> </td> </tr>
<tr>
<td colspan="7"> <hr style="width:100%;text-align:left;margin-left:0"/> </td> </tr> </table> </div> <div style="padding-bottom: 20px;">
<table style="float: center; width: 100%; text-align: left; ">
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
<th style="vertical-align: bottom; text-align: left; word-wrap: break-word"> <b>Table 2: Fee Offset Claims and Sources</b> </th>
<th style="vertical-align: bottom; word-wrap: break-word; text-align: right;"> <span style="-sec-ix-hidden: hiddenrcOffsetTableNa">&#9745;Not Applicable</span> </th> </tr> </table>
<table style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; float: center; width: 100%; text-align: center; border: 1px solid black;">
<tr style="background-color:#9ADAF6">
<th style="width: 10%; text-align: left;">
 </th>
<th style="width: 8%; text-align: left;">
 </th>
<th style="width: 16%;"> Registrant or Filer Name </th>
<th style="width: 6%;"> Form or Filing Type </th>
<th style="width: 7%;"> File Number </th>
<th style="width: 6%;"> Initial Filing Date </th>
<th style="width: 6%;"> Filing Date </th>
<th style="width: 6%;"> Fee Offset Claimed </th>
<th style="width: 6%;"> Security Type Associated with Fee Offset Claimed </th>
<th style="width: 8%;"> Security Title Associated with Fee Offset Claimed </th>
<th style="width: 6%;"> Unsold Securities Associated with Fee Offset Claimed </th>
<th style="width: 9%;"> Unsold Aggregate Offering Amount Associated with Fee Offset Claimed </th>
<th style="width: 6%;"> Fee Paid with Fee Offset Source </th> </tr>
<tr>
<td colspan="14" style="text-align: center"> <b>Rules 457(b) and 0-11(a)(2)</b> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Fee Offset Claims </td>
<td> N/A </td>
<td style="text-align: left;"> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: left;"> N/A </td>
<td style="text-align: left;"> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: right;"> N/A </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Fee Offset Sources </td>
<td> N/A </td>
<td style="text-align: left;"> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: left;"> N/A </td>
<td style="text-align: left;"> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: right;"> N/A </td> </tr>
<tr>
<td colspan="14" style="text-align: center"> <b>Rule 457(p)</b> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Fee Offset Claims </td>
<td> N/A </td>
<td style="text-align: left;"> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: left;"> N/A </td>
<td style="text-align: left;"> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: right;"> N/A </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Fee Offset Sources </td>
<td> N/A </td>
<td style="text-align: left;"> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: left;"> N/A </td>
<td style="text-align: left;"> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: right;"> N/A </td> </tr> </table> </div> <div style="padding-bottom: 20px;">
<table style="float: center; width: 100%; text-align: left; ">
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
<th style="vertical-align: bottom; text-align: left; word-wrap: break-word"> <b>Table 3: Combined Prospectuses</b> </th>
<th style="vertical-align: bottom; word-wrap: break-word; text-align: right;"> <span style="-sec-ix-hidden: hiddenrcCombinedProspectusTableNa">&#9745;Not Applicable</span> </th> </tr> </table>
<table style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; float: center; width: 100%; border: 1px solid black;">
<tr style="background-color:#9ADAF6">
<th style="width: 4%">
 </th>
<th style="width: 14%"> <p style="margin: 0pt; text-align: center;"> <b>Security Type</b> </p> </th>
<th style="width: 25%"> <p style="margin: 0pt; text-align: center;"> <b>Security Class Title</b> </p> </th>
<th style="width: 14%"> <p style="margin: 0pt; text-align: center;"> <b>Amount of Securities Previously Registered</b> </p> </th>
<th style="width: 18%"> <p style="margin: 0pt; text-align: center;"> <b>Maximum Aggregate Offering Price of Securities Previously Registered</b> </p> </th>
<th style="width: 6%"> <p style="margin: 0pt; text-align: center;"> <b>Form Type</b> </p> </th>
<th style="width: 10%"> <p style="margin: 0pt; text-align: center;"> <b>File Number</b> </p> </th>
<th style="width: 8%"> <p style="margin: 0pt; text-align: center;"> <b>Initial Effective Date</b> </p> </th> </tr>
<tr style="background-color:#E7E7E2;">
<td style="text-align: center;"> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: center;"> N/A </td>
<td style="text-align: center;"> N/A </td>
<td style="text-align: center;"> N/A </td> </tr> </table> </div> </body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g159388g01n01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g159388g01n01.jpg
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M*"@H*"@H*"@H*"@H*/_  !$( -@!ZP,!(@ "$0$#$0'_Q  <  $  @,! 0$
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M^IP?1O2[F[@])NYQG.<9[L?S4NKNNV-F^/T=UVQLWQ^@B(K"P(B( B(@"(B
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M'XDJE]+"ZHJ8H6#+Y'A@\2<*]U+"VGIHH6##(V!@\ ,(RG$7EL]$1%!M"(B
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MO0>HEH&..<Y([E9[:OQV:W__  A^Q5KV?:ET]8:>L9J#3D5X?*YIB<_=_%@
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g159388g01n44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g159388g01n44.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[0^64&AO=&]S:&]P(#,N,  X0DE-! 0
M    #WD
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_P  +" !F 6<! 1$
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M.K3;,A(OS<TH(88;4XI1-K!()_A'GR;Q/B+BYBE^CX9FU4W#;"BW-S?+0O,
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g159388g02n44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g159388g02n44.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1#$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $*<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M("P@(R8G*2HI&1\M,"TH,"4H*2C_P  +" !N <(! 1$ _\0 '  !  $% 0$
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M?-SE7GN,O$04YE:T8:D5)6ZE)MF RDB_A.H*N\3]2*1(4>GMRE/E&FVF$A"
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M'S3L,5NB/>)Z2J+Y=%]B,B"/F(PL7XMF:%QO7-O2KLQ2I1"6G5I)LDN,MV(
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MI7[B_P#,_3%/OHI0'ZD_\S],/OHI762?^9^F*CC12NDD_P#,_3#[Z*5^XO\
M\1^F*#C12[_J+_S/TQK,0\2\-8BISDA5J4Z[*N:*)))1YCP:'W16E<5*'3Z>
MS),2TTMMH$!2UJ*A<D[E/G&>SQEI*$%'J$Q9.ERHDG_;'I]\])_<7_XC],4'
M&BE?N+_S/TQ7[Z*5^Y/_ #/TQ3[Z*5TDG_F?IA]]%*M^I/\ \1^F*_?12OW%
M_P"9^F*??12K_J3WS/TP^^>E6_4G_P"(_3%?OHI7[B_\S],/OHI1_N+_ ,S]
M,4^^>E?N+]_>?IBOWSTJWZB__$?IBS[YJ5[(D7[?YC],:^N\3\/UV2<DYZGN
MJ8<3E6"201K_ (?./.@\4*%2Y1J4D:=,)99)R%2R;WW_ "](\I+'6%9&MS=5
M9D9A^>F+\UQ:E$HO;P"Z=!H#8:1WN!,>2>+)Z9E9.6<9+#862HG47MV$=I$+
M>DE@Z<K5/IU=I#2GJC2EA2&T@DE-\QL #^R(].'7%ZB/4B2D,0/N4VJ2K2&G
MDS@2R"I*0#;,03J#TC.K/$!=8F!3,%,NS,VM0YLX$YF4)T_.FXVO\H\^)F)?
MT8X?34E-O+F*S,2N1H-@*S.$=!N1X3K:.?\ 1:1*(PI-<QS)5IEY?,;78*"0
MHD:;]^D:#%*WL \>45\2[QIU63D<=0@E*4E2$FYV&B3UB6E\0Y)S$-'I,O+O
MNBHC\%X(NCV"K4@]A';HR+<6D!)MMK&HQ?AP8DH;],<FG)9MY-BML D?.(V1
MP#DQOB*H?Z2(K]PDE>_Z0U#_ $D1(V#<,MX7H#5+:FG)I#2E*#C@ )NHG8>^
M-+Q>PE^EN#'Y&P,PE1=:O>V<-K";_%41?PCX@?H/++PUC9F9D7999;9==;R-
MK0FR0I*E9;@Y38Q(E8XHTAE")>@J<JLXXE7+3)@/)"NF8I)L+G4^^/:DUF9H
M>&G:EB]UMIZ:<+O(0H> *2#87L2008B3@3.LU?B17:[6$+EYY10F6Y@R\Q.1
M:2=>P"=N\;;TBI&<I6)<-8SD$N3:Y-UIE*$)S$6+J^@V_P#,=VKB;29?"4O4
M4*4Y/+"0B658.J62 JR+W(%[^Z-O@S&;&(9N;ITRR96JRI(<86,JK"US8F]K
MJ&MHZ=T_@/9$!Q21?+T,0SAG"U8Q[B)&(<=RX8D)761IX"LH-K*)) 5?,@$:
MG>,_'N"9ZB55O&& TH9GVT@3DHHG*^W=2CT)S%13H+;1*%)F'9N18=FVRV_D
M!4@BVIWWC/+1L0A64E5R1UBO+5S 38VVO%]CV$+'L(I97814 ]A"Q["+%.)2
MJQM;J>@BB702;C*!U.E_=%$OH)T(R]%7T/QBXN!-\U@ +YB=/G'GZPFX!0H$
MFP!&IBQ]?-3D1I=657<1:TT+K4X;O ;G>/>7SEH%6I/?2/0A70"+2X O(!<V
MN;0"P;7&76VND%+"21;7H.IBP3"5+*0DZ)N3;3W>_P H>LMAPH.BN@/7W=X.
MS*&T%2M1L -U'L.YBH?20DVT5_+WQ<A6<'+:+['L(I8]A  ]A )(&@%XM<;S
M-FR$E1&Q.D>")=[*4..9D[@]1Y1[I0HF[EKVMI'HE(3>T5CPFP2V0<F0Z'.F
MXCGIO"&&YQWUB8H-+F'E&Y<5*-FY^*8SI&DTVDJ**=(R,H'-2&9=*,UO<!WB
MV<I5.J:P_.4Z3FW&CE0764KR6]X\S\XK(T60D'E/4^FRDD^L 9FV4I&G^4>9
MBE3IDC/I;^T9*3G)=(\',92HCW7'OB/,8RK,IQ,P&S*--R[)?<"4M)";?@K[
M1*S-T3)0<H%O#IJ?C&3"$6J(23?K%MB;Y@"GL8T55H-"K3BUU.F4^<*!DYCT
MLA938[7(,4IV':-3%H73Z/3I:P(#K4LA)-^EP+QE3M.E)I/*G9)F<N;I0\A*
MTI^!CSEZ+1F7TJEJ;3V9AOJW+)21\0(RIF3DIU :G9>6F6,V9+;C04 ?<1;:
M\0YQFI\A3<38)+<G+RLL'9K.6FTI!)2C+< :ZF+\,.!?I#5IQHA*!(.LNJMH
MITNMG;W1,OA0R<X+:B;;[^<7*0@!38LAL$*0E(MMJ8N.1QM6=(LH>R1<$18D
M$$+58K1IE&@L8S(0A"$(P7E)#BE&Z1FRD*U!\[1&&(N)CHQ,:!A"FNUBHI'B
M(6$I1H219=N@5\HU\UQ=?H;\O3<2T!Z7GW;(;2EQ&5:B;"P%[:F.VQ'B:=I>
M%I:L,49^<06TNNRP<0%)"@+:DVW/\HX7"_&6<Q&T\NA81GYQ,MJZLS+=TC<^
MT1TCHL#\4J/B:KS%*=8>IM5:6H%AU6<D@V.J1;>_7I$B*40E)6!S2;7$9#(M
MF%[ZQ?&%,73G)N$E0NH:$",2H5.2IDDN;GG\DHV!^(JYUV]\1K+<2*EB5;YP
M11)B<0@B\RMU!2--@"01L?E'I0N**I;$K&'<84MZEU-\YFU%:2AR]QLF_5*M
MX[3%=?D<-T!ZL5%U/JS%LB@#=1)]G;J=(CN2XC8GK$G]MTW";YHEN8DJ=;*B
M-[CQ::$=(VG#[B=+8QKK\E3)-YMJ4 5,K<6%!)-Q:W^86B49)LM)6@JO8Z7W
M^)ZQDPA"$(0A%JD!1!/2*A($>*Y>Y<4VLMK605* O>T45+!3H<6HDA-AY><7
MML);(R&R1TBO*-U',;G8VVCGZM@NCU6KRU2GI?F3DOJVO,H938@FP-NIC?LL
MAJP!N!H!VCUA"**3<B_2!!)WTBBD!1%^\4+2"-HM4R%(RJ-['3RBJ6R+762.
MUMX-MY"JQN";V[1K:UA^0K5/>DJDR'F'2"H$D7L;C8]"!&/AS"M-P])K8IC7
M*YAS.JN25FUNI-MAM&V$HD-K;2HA"K:=CWCV*=;WUZ>46%G,!S%%5C?M%W+
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M"$(0A"$(1@/@^L$I*S8W*D[_ .6*IRY@X <R=PKVM=(HL$)L%.>%5PD;@0Y
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>%L2,JTL;*0TE)^8$9=A>]A?O   6 L(0A"$(1__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g159388g40n40.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g159388g40n40.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[0^B4&AO=&]S:&]P(#,N,  X0DE-! 0
M    #X4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M,DC8/(&QC&,*N,>/"YS [+B/ZSY%52-#W'+L2-[8/&5\=XMT=RMLM#(2QLP
M>]G<8.?W*+8^@^E7;L7>YG'M-%C_ .BJ_$+I;_FUT_\ FB_D5=)T.TQ15C*E
MMTN)\,@CQ)HMI/\ [%*GF;$QH\0N9P[W(40_%/520]/8HZ<D-FE+)&>XVDX(
M^Y??\,U#%3=+;=4MXEJ3+OQZ[9I /T*3)O$C\YW%K#AH;^>[T)]U<AF=(_:6
MC. XAO;GW5B[U+:*T7&I>X1%D3GAQ..0TX7+O1W2[>H&K[[?+A+51"223;/
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MYT[C@MD!!X]1R,\*+/BMU)#4S4&G*>?EK_&DV@@C.]O/OV4\:,M]+;](T%%
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MW]*-)EWX#G>=I \+(:PC!=EV2YWIPIBZ0=2J+J!:'0S[8ZV*,[X#G\IVYSM
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g159388g41n41.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g159388g41n41.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[0_04&AO=&]S:&]P(#,N,  X0DE-! 0
M    #[,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*?)<6[IE:Q/H884XIAIQQQ*0A275Y&2>@BU[LN:CT^@3$W.524#:F%I1J>2
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MW7PWE;HNZ1K%0F7#*2K:4B3[VEQ04HZB=0QD*QC!B9MR26&D,--I[ #!0!@
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1_00_"4@ !(P.6W*,P01__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g159388g42n42.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g159388g42n42.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1 D4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $ <
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M$!<4&!@7%!86&ATE'QH;(QP6%B L(",F)RDJ*1D?+3 M*# E*"DH_\  "P@
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MZ>KA(0GPR>I'LDXZ5-?$W3*M5:47;V4M>.7V7$N*3DX2L%7/KT%>PVI&G-+
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M$YSTQ6 2T+<2E;K8=&<L[@5*'GCK\:@7C_PO]?0[JK3>]$MH>(^R@'<KWLJ
M)Z\P, =J]?T?>)#VI[>Y9[VYB[1,!MS RZ,K)!2  ,  5[WI"W_]C<-YJBK8
MY.S$ Z\U(4?_ ,U'W!K2&L+?HQ%PL%Z]2]=42MA45I9.%'!RL$_6)KI&>#,K
M4%W3=-=W]=T7[WJG@)9'4'JVH?$=.]3/:K?&M\"-%B,AIEA ;;0"3@#EWK:"
M$A1(',]:NI2E*4I2F>=44H)&37/735ECMDM3-RNT6,ZDC+2UX5S&1G[O\ZW6
MKO!>@BX-2(ZX1&?$!Z_?]XK9?F,QVP](=0EL].=8%76"EHN*EH\-0Y>U6Q$E
M,R49CN[Q\\ULI'/GUQ5U*4I2K5C*2,XK'@C^S2>M>-=M0V>S>Q<K@Q&)Z%U6
M,_*LENOENND8O09T64RGFI23G%;K$R,Y&,AMULQQD!0/+(Y'_&L2+M!6VIU,
MM 2G_>K/#FQY@)CO!9^!K93[1PH<Q5]*4I2E*4I2E*TWT97[(:\3.0%#ECSJ
M"[CK:%;/2&]5NDIJ+#2T!XZCA 46.0SGN2!TJ7[M=(,.W.3YLMAJ.$[PXHX0
M1Y'X5\]>CQ95W#B%=M0P6BW;&E822,!14E:21CEU!JOI)7EK4.L;/I>-*2IE
M2T%["N27-SB3_@1VKZ*T_#8AV*W1XI #;"4A2>F=HS7HM-G)+B4%?\8%;#7N
M<ZNI2E*4I2E>=>Y3$*&[)F.!N,RA3JUY]T)&<_'IT[U <K5VHN*^IG[%I.4;
M=IZ.2W(G[$KRD*(WA*@D\_9]D*Y9KN+;PCTO'@($J-*E/+.UQQR2[E:B3@\U
M''*HZXF<._V7JBQ-V&3*3;)SBH[D/Q5G:I*"HG<59\NPZ5/6I(4.=9)C-T2H
MQD-E2MBBDC"3W3SKY@X2Z28U;Q-U#$D2):[)"==6RD25C<@.[4C.X'H17I<8
M;%)X5W>V7;3%RDB.ZHE4=Q2E[=I0,96I6<Y/;E7T/P[NJK[I2VW98(<FL(?<
M&?=6H D=O\A735A>6-X;W%*B,],U:L+VX4G>>WM;:O1OVC)VG^'&<??0E0'O
M_P#UJB<HYD[E'K6.2LM,K<"@$I&59["H&U=Q'NFK=4KTCP[24*/LS+@2%!#>
M[8K"%I&?>0<A6:ZNS<'+"S";%X<DW&X*]IQY3SB0HGF?9WD"N'XY<-XUDT^S
M.TDN5$?+J8RV@^M04"%$GFK'8=JF>QVEAC2T&'A2F1'05ME9SDI!4=V<]<FO
MF1O33%XXZR+';)$LVIIX*>;$A?N!Q(/,JST574\:>'[6BK/^\.E9\R$J(1O9
M6^XZ'2I24=5+./>)Z&I5X-:REZNTC#F7).Z?D)<6, *YGG@  =N52-6"82&M
MP'0YSGI\<=_E6FZ\4H20]L[@[=Q5]W:LN4H>4D@@YY<^I_E\JRN*R@Y.XGJG
M.#69C/A#<K<?/&,U?2E*4I2M59425==J\8^%<3+X7Z9FR9CLR*IYV64J*BM>
M1MST.:\-7!733D@+E&<8"?=C&6\KE\]_\J[J/IRW,6)5J@QQ%B$8VH60HC)/
M7KW-<@YP4T8XZIYZ!(=DJ.[QC+=R#_\ *N\TY9XUDMZ84-*PRCW=[A6?Q))K
MU:4I2E*4I2E0)Z6.HWH6GX-CC+6AV>L+)22,I!*2.O0YKL.".FXVGN'5K80A
MHO3V&YC@4D<RXV@D'D.XJ04Y2PD*5N).W(_E6FN(R]+2MR/%6XSS;6MO*TGI
MG/G7)<8;U^[V@KK(4LI+K*XVXGWBM*@*A#@AKNQZ#TDZ]>X4HSICZEA\;/;0
M4H( )Y]037H7.V:GXUW^!.D1#;--QEY;4\"/%&0%="H$Y;..7>OHZP6N/9;?
M'@0ALC1V@TE/+MRSR '2O3W#)&>8ZUK23NW8WE(1NP@\S44W#C.Q N#T-S3%
MY>+1QXC?AX_Q56-/'2,!C]U+]]_A?JJ^/QO8DRF6$:6O:2XM*-RO#P,G&3[5
M2JP\I^,VZV@MJ6 2D]JC/TA]4.::T%)$16R;*PAM62,C>D*Q@@]%5X?HQ:;:
MMFC'+LZWNF3592X0-^TI0<).,]4^=3*E1\'*0D)!YG'^7Q\ZQS(T:9M9F,LO
MH1_:!#B0HDCOSY=Z\[5%RC6O3\N:X?"0VT4HV<N?3'^5?+O!76,#3UVNNI[Y
M&?=<D[F?%3M) .Q6<DY^H>]='JVXZAXRI9@Z9A2(VF"XH+DR/KJ!!.2DD$;D
MC'+O4\Z#T[#TG8(5H@I!#"=OB$#+@R3DD 9/.NH#B"2 H9'6K7"A2%9/)/4^
M7QJ)^*MEU,U*CZKTA<)+TR'E*K<75%EY/N<D#&2 HJ.3V%;%JXK:;F:5>OKT
ME;*HK:BY$=4-_B $I21TWD#ES[UX?#X:HUEK%&K;C*EV^S(YPX*75(0ZV<[5
M.)R0K*5CICF*FUDDM J&T^57;AYU6E*4I2L!2H.%:4X[?,>="#C8$N#ON!J@
M0L<T ?'?S-5#7M9"4X[Y'/[J!LXRG<D#ZN:R- @$D8SVJ^E*4I2E*4I7S-Z6
M[:VM0Z5G*051F$JWGMGQ$D#/W5-^B9;<K0MC?8=20Y 84$H 5LRVDX^ZO>R%
M**!DA&" 1C:?GWK2B72%-N$F'&DI<D,)!>V#(',C;D<L@CYU!OI2W-<B1I[3
M+;GB+G/#=@=#O2!R_P#5YUU.M=%(E<$6;7ZLA4Z# :0A24^UXB4)2>0^^O-]
M%S4'[2T6[9GL%^TJ*<$X*_$<<5Y=L?&I:<N]N:F1X+LAI$R0K"6@YE6<'M]Q
MKT$$N(2E7)1JQ>PA14DX:Y9!//%1%=>+T>#<'XATM+6&U >*EAQ6?^76 \:(
MW/;I.:1Y^K.<_P#EUDB<8F),ME@:4F(+JTH"S'< 3DXS_JZE^(X7F6'-NT8
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MEEXD:?BKD0=0,WB1M#CD0PVV=Q/5(6I9 P>];7!'5=UUD;Q/N($6*A2&V(^
MK!(4%'< /K)ST[UR7&C7&L]!WM#$*Z1WH\GVVFO5$90DE>.9SGDFO6'TO(L:
M9J9\60I2 X&1'82<8SUW5Z'"7BF]J6Y2[!J*,F->(9+3@"@=ZTD)4?92 .>[
MN:ETY"R?JKQ]V*V4^Z,56E6/$I;)2 3Y&O'O;4N7;'6K<\(DM23A10%CI]PK
MYVTGK_B)J;6#]@@SXH#"UH<>,9H[=H41UQUVGO4B/6KB9X3Z8^I8RW3G"?V>
MT,\O,KKS^$NH=:WK5=ZM6JG&G&K26TN)0VVC=O2LI.4_\(\Z]WC#/U/8+([?
M+%=&(C4=H[X[D9#F0 I7O$_ =JT> &MKIK2Q3%WM2"ZRH'<@)&<J5V ^ J5W
M%)2TM9.$I.<XSRJ+N-'$9O1EB"8X2N[R?^[-Y[ @DGD1S3GK7F\/)/$'56D4
M7F7?(T-4E*C&:]1;7N ..9"ACF#U%<CH'6_$#6.KI]B-UC1VH3JFWGA$;.0G
M?CER[H\^]3W/4MK3DI9F!E;;"U)F*1D A).XH[@=<=\5#G#Z[\2=7W>8!=(T
M>Q1I#C*)GJ;1+@22 0C(4,\C]]3_ !BHLI*T;%=T[MV/OK)5JD[B.9 \J; #
MRY51384>9.WRH&PD81[/RJA:"E9421Y4\%."!R!JG@^TDE:CM!'SS7E2M+VB
M7,];D0FG)0/LND>TGY?B?QKUTM  @$\QCY5<@;4@9)QWJM*4JBAD8SBB4@?.
MJ*3D]2/YT\-('(8J@1@8W'YU78,8/2L7JR>0W':"3M[5BN-LB7**N-.80]'7
M[S:NBN6/\B:T;1IBU68*%JBHBA?O!L>\.P->NAL(/L\AC&*OI2K%*(SRJU2U
M)03['XU\F\1%W?AIQH>U,VVX8$IQ 4L).%-80%C. ,G:>]?1^C-4VS5=CC7.
MV2$N-+ 4M(4DJ:44@E*@"<8SBL6@-+,Z3MIAH45J6HJSV'M*/D/XJ@'7,C]]
M?2%@6Y*T^IP'!%?0H\MR'' 3W_B'E4_:EU';-*69R5.DL,!EE7AI<6E*G% <
M@ 2,],5\^<$[1.U-Q6N>K1'=:@*ENR4N["$+*EE6TG!'18/6OJA*DJ1S(./*
MLZ"%)!'0BJGD#6!MY:E_4+>WWDG/.K2KQ6]C@;4KJ0#R'E7@:]O"++HR[7!)
MYQXZU) [$#/G4$>C*]98#E^OEYNUK8<G.)+:'I"4K3A3N<@X_B'G4L0N)$*Z
MZR18M/E%P2TP9#[L<AQ 2%A)VE*CS]H=175P+/%ASI,QMHAR9A3O+F=H.,_+
M-1EQT<-\D671\?<'YS[;RSCF&3XC9\^Y':N1]$]28%]UC:BI 7'6VV@*."O"
MG<X\^E3EK/4T73.G)-SG*2DI2H1VUD!3CNU12@ D9)QT'.OD/BM#N5TO<"7<
MGE/WZY$NH9Z^#'(WMC&-P.TD=QRZU]=B&UIS23L:%AM,1A>SRSS5_.H*]%]C
MUC5NMI*P25O Y3S3GQ'<YKLM=W63JO4C>BM//XA)4%W5Q)R$,9VN- C/,H7G
M! ^=2;8[1%LMD9MT!(:CM-I2A2?>Y #)^>*]IH!+8 3M'E5U*4I2E*4I2E*4
MI2E*4I2E*4K"M1\7;NY%)Y5Y%\O<.R1FW)Q.U1([UJZXTQ;=5VIZW7..VL.(
M(0ZI.2V<$9'3IG.,U\N6V1>."W$A5O<><<M#RU+4R582M@J4$+'O8)VCEU\Z
M^KK_ ')-OTQ.N*E["W&6XDG^+:2*^;>!6EV=<W[4.I+PB04.ON[7&GUM*2Z5
M(43E)!/)1J7T\(K ^\T[=U3K@6CEMM^8\I/7/,%9'XUV\"!%M,1J);K<S&C@
M ;&2$CICF .?0<ZUM4.W=BS/.:>8;DSNC;:E)0,_-7*HU;N7&8-I"M/Q=P'/
M_3HWZ:N_:7&7OIZ*?_?1OTU[&AI?$-Z^*;U1:6(L IR=DEE>.?\ NC-2& "D
M$>R/K#OGM4(>E7J!R#I"-:HRRB5-> 6E)]YM2' <\O,"O9T)PBTM^ZEO-SMZ
MS)<:"U*2^M(.X9Z!6.];7"_AXSH[4=_ELQ?#86ZI,-7B[E>%A!QG).,I/6I1
M0I+>T$<U J.3G'>HBT?XNIN-5^N4I <B6F.Y;V%\L)6EU"P1\<*/_6H^X0.-
MV3C/J%E]Q*&''%N+4H[>B7E5VU@;^E'5#FH;F7/W8M;@]3C+R$/N)(6EXCET
M]I."#\^U<'HN/^^?I!2IKR0Y!M*ULJ1]4( =0D#ITY=!4_\ $1_U?A[J%\$I
M<;M[ZTGR(2:^;N%&H%6/2MQ-G4IS4EW=V1VDCIM<)62<$>XI1YXZ<N=?0>@-
M&Q])6I*) ]:N+HS)FJ_UCR^V>9(& !C..5=DE*24_$#</AV%;#6XMC<<GSJZ
ME*4I2E*4I2E*4I2E*4I2E*5J.)W/+PI(7]7!YXQSJ#?25GW,L66WV*'.E35.
MK*D(;W!0V@@<CGL:ZRS\7],W*S.3+A+_ &:ZCK&E*0VZ#SZ)WGR\^XJ)K^ES
MC'Q.A"U1GTV2$@(>E.(QN *QD%.Y//*>N.M=;Z0.NXK6E)%AM1<=N#BD)(Y$
M)2 ,]%9Z'RKU?1D?ML717[,BK4J6I?K,@';@**&TD<N?4=Q4R)2/$W <ZJEM
M.\K*1OZ9JH;0 0$@ U=BE4"4@8P,5I7B9%ML%R7-<2TRC&Y:B!_G7R3Q'U+"
MUIQ<M2UHD)L45Y$9U: G:0%J)5G)'15?5.F),.?:D>I.I?AI0E""2"K Y<\<
MNU>R&TC&$@8&!7%<2-8V_2L%7KJU)>=:<$="2GVE8'7)'=0Z5Q/HZ75AVQ3$
M/.J3<YDTR9*,CDHH0"//RK@K]H*?J#CS<(D=;S5J*&UOOL9VC^S4H!1VD=1C
M[ZE#7>JK)HK0$NT6Y7^D>K.1XS,;:=BU(5M!&00,^51YZ,EPML)ZZ2;@YLN,
MQPE2<@9YJ/<Y[FI8XYS4P^&M\#@_M)$=QE '<EM>!_A7&^CUPV_=NUL7NX,H
M5<IB0L<CEE!!VE.0,$A6#U^%3?%0 I95CQ,\\=!\JS[$Y!P,CF*JD!(P!@4I
M2E*4I2E*4I2E*4I2E*4I2E4VC.<#/G6)V+'==2ZZPTMQ/NK4@$CY&M%>GK*L
MDKL]N43US&0?Y5M0K;!@@B##C1@>O@M)1G\!6)ZRVM]PN/VV$XX?K+803^)%
M98=M@PB3#A1HY/7PFDHS^ K:I2E*5C?8:D-%M]I#K9ZI6D*!^XUHBP6=.=MI
MMXR<\HR.OX5NQX[,9&R.RVTC^%M(2/\ "LM:LVVP9Q29T.-)*?=\9I*\?+(^
M JD6V0(BBJ+"BL*)R2VTE)/X"LS<9AMU;K;#27%^\M* "KYGO6O(M%MD*S(M
M\-TYSE;*5<_O%6L66UQU[F+9":5YH80D_P" K9EQ(\QOPY<=E]OKM=0%#\#6
61"$-H2E"4I2D8  P /*K@ .E*4K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g159388g43n43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g159388g43n43.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[0_R4&AO=&]S:&]P(#,N,  X0DE-! 0
M    #]4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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C''+^[HV_2,R7E9>6:[.78::;YZ6T!(^ B["$(0A"$(0C_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g159388g99p03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g159388g99p03.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1P.4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &_*^<50X0DE-! 0      !D< 5H  QLE1QP"   "   < E  !41E;'1A
M #A"24T$)0      $)_]]5M,FVC]2'%8$L(%V8@X0DE-!#H      .\    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     8 00!0 $0 +0 R       /<')I;G10
M<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *
M<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M"7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T
M<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !2
M9W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O
M;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M      !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M    4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!
M %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M          !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F-
M60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1"
M;W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P
M4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE-
M ^T      !  E,S,  $  @"4S,P  0 ".$))300F       .
M #^    X0DE-! T       0   !:.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         ".$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!$0      !     "   "0    D      .$))300>       $
M #A"24T$&@     #00    8              6(   ,T    !@!G #D .0!P
M #  ,P    $                          0             #-    6(
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   6(
M    4F=H=&QO;F<   ,T    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$$0       0$ .$))3004       $
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M%=#3Z==IHW-;=E9&[_"?^>ZEM9?^*CIPQ'_8
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ <0$& P$1  (1 0,1 ?_$ !\
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ML5I'[GZ;^E/4QS*\8S&KCW>(Y%1Y/33&JZ'<8_:0KFJE-3_S1K"N/(B2&_\
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MG*B*B]>@$[??I[^E4+=;;!+BTH !)*C @9-,KSGU-O3]US8)595R\T5'L/\
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MAF]9KS.,!),D'HCV.4N^T8[E,*N*1T6%?4MV:L,:RBL%*E5#9U?*>8!&-'Y
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M:DR'/$9:<)3( ,*64F, B#L2(+QCQOJ>DZNK3+)*6PV6@E2T@ATN,H<)!5B
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MJ,2A,R3M@$CT,;DY$8_TT''*HSSD5MCD-D-0&P#I#$JG'<,++CH5D#,]B&L
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ML(>]2(B]B-&S\>YW2ML&<"<=I_@CYU%>-GRSH;P&5.N(;2!N<E2H&YP), D
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MI^'*Q7*U7-_E<J*J?CJ0-*4M 4H*!,$A2>4B0#$29B8F=Y$"*W*22E)*>51
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M*3(WH^PW<-+:=',A8A23D?7['2*JX;<^EWQNURBQLM(<G[7#,5ES"&A8OL/
M09E/J(SWO<D864TN48VZQ&SNP<9)= &0,#4^3,FG52=7/%48VZ28!,C8]/OO
MU@5[P R^ZMRWO2VE:RI+:V^<(!,\O-(DB2"8@]Z5'0'TR>A<*O:^\Y!;MS'=
M (;PG_@_&*$&L<7EE8K?*+<317>3Y/8PG>+WJE;:8V9ZJ-CR.&T@RTA>/L8^
M>\GU/<]:NV? EBPM"KA\OJ!YH" @3[9QB=AG%:S]0CENK.-/"[37#G3--C6O
MH&=Y["N$U_B42)4QXVO=?1)$^3+D5\-@NS+#,YV-&6=)\S6D^#+.4LF1'DD9
M=;49)/4&!T@$"=^Y.^_< 4XO>MK#3$6; ;0I1$-@9Y0E><1U@?$[$9T;Z734
M]F&CY3[OD15;56US@&KZ:<\2=S2L=AW.4Y,$!E5'(QC,BQ5QQL\D5[PJKNXD
M[^O' GKM@](GV&Q$R?I&+P!9N-,W%T4QXG(D&!'*>92HZ[A/K.>]6SYU?#LH
M<FOGQQ2X4P3P2HL@8S D *U6%"816/&416*K"#>US7L<K53LO6.#!G???UKH
MJT)<0I"P"E0@@P9'QD57:Y3_ $X?%S=64W&;:5SG)^.=Q=S9,^?CM32U^::W
M9*D&4QGU.*2[#'[+'V%<\G:#5Y**FC)[;(%1$$WVUN!U0 &,0-@=OE$?OVJ'
MZEP997SBG6GS;+5S& D*3*CT&\2>_7 C%,,?]+1L7W%\>8>&>QYKV5^G;IIO
M%>_9RL9L!X_+\IW1"*B*G9'*GY45H(,!05T)B)'\?Y/<UI$_AZ4R#J *<S#<
M&.\R,_'81ZE4\*^EKQ4$F*?8O+O(KB(B,6=785JJMQV0]?-JD;%NKS,,H&-'
M,1Z,<6@?X/5KE:]&JCJ0ON9^ ^F>HW[=*R6> ;="PI=XM<2"D)Y1\Y)!@C^T
MQ/0BK!O"CA-J3@?IZ3IC3,K,+#'9^23\OM+#.+T%[=6.1V==55<R8XL&LIJR
M$$D.F@,;#K:N)%8\;R>TKR$<[Q2I^&W?X_ZJ9Z7IK&E6@M+<+"$DJE:@I1)Q
M,@#.W0=*B,W]].OJ'D%NS:V\,FY([4K[_:N?9)G5G3U^.8D2#5DR*UD6+:B#
M(DH^02)6 ,.OB%.BF>&.)Y.[U=U6'"( PG,8$Q,P/_N,=LZ"YX.M+J^<O%73
MJ5N++BD0% *4/-V,$[",#$]:L(X3BT#!L-Q/"ZOR^VXCC5'C-?Y-8QWPJ*LB
MU<7NP:-&Q?8BC_D&U&-_W6HC43JV25$D[DS4L8:##+3*3*6FT-@XR$)"1@8
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M2NC0JJH"IK*84LGSAC\8_P C$X/X>7P[;W]]KZTVB'4*:4"K9#@*2"!B5%4
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M%1*K[>Q%.<V-44# R,P>L1/7Z=MMZ\TW6E7B;H7#0:N;-"EN,CNDA/E B9)
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M]I#D#$5(IGMI!'43N=X^';_<#WPM2UNZM-118L,-N%;*%A2UA&2KS"5&)@$
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M+.]E; '47>LY%#@.!T%MF6.T]=+#9Q;H5A06< ;9D:> L%!R/@RQD^,6ZE8
MSDQ'7TS[]]O8C>":GH6HW>HW%RRW;%IU"$)+TE8*4IE2>4X.($@B"<4\;F/Z
M<W*;9O#/@%H/&;BLVWL;CEM+6N1[0RV]R9E..PJ,6QZVK[*= G9"9TZU^(>9
M$@0&2%=9S(,41SB857C'Z%)DY'3)Z[[3T'[UL+O1[I^PTZW*@7+5QM3@2/*
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MI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI7Y<U'?O\ LJ?Z_O\
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BHZ4HZ4HZ4HZ4HZ4HZ4HZ4HZ4HZ4HZ4HZ4HZ4HZ4HZ4K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Submission<br></strong></div></th>
<th class="th"><div>Nov. 12, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissionLineItems', window );"><strong>Submission [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Central Index Key</a></td>
<td class="text">0001622229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">Cogent Biosciences, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_RegnFileNb', window );">Registration File Number</a></td>
<td class="text">333-291384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FormTp', window );">Form Type</a></td>
<td class="text">S-3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissnTp', window );">Submission Type</a></td>
<td class="text">424B5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeExhibitTp', window );">Fee Exhibit Type</a></td>
<td class="text">EX-FILING FEES<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTableNa', window );">Offering Table N/A</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OffsetTableNa', window );">Offset Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CombinedProspectusTableNa', window );">Combined Prospectus Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_CombinedProspectusTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_CombinedProspectusTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeExhibitTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeExhibitTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:feeExhibitTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FormTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FormTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_RegnFileNb">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_RegnFileNb</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissnTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissnTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Offerings<br></strong></div></th>
<th class="th">
<div>Nov. 12, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=1', window );">Offering: 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457rFlg', window );">Rule 457(r)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Debt<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">1.625% Convertible Senior Notes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_AmtSctiesRegd', window );">Amount Registered | shares</a></td>
<td class="nump">230,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxOfferingPricPerScty', window );">Proposed Maximum Offering Price per Unit</a></td>
<td class="nump">1,000.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 230,000,000.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 31,763.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">The registration fee is calculated in accordance with Rule 457(r) of the Securities Act of 1933, as amended (the "Securities Act") and represents deferred payment of the registration fees in connection with the Registrant's registration statement on Form S-3ASR (Registration No. 333-291384) paid with the filing of this prospectus supplement<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=2', window );">Offering: 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesOthrRuleFlg', window );">Other Rule</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_AmtSctiesRegd', window );">Amount Registered | shares</a></td>
<td class="nump">7,419,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">(2) Represents the maximum number of shares that may be issued upon conversion of the 1.625% Convertible Senior Notes. (3) Pursuant to Rule 457(i) under the Securities Act, there is no filing fee payable with respect to the shares common stock that may be issuable upon conversion of the 1.625% Convertible Senior Notes because no additional consideration will be received in connection with any conversion.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_AmtSctiesRegd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of securities being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_AmtSctiesRegd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of registration fee (amount due after offsets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesOthrRuleFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesOthrRuleFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxAggtOfferingPric">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum aggregate offering price for the offering that is being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxAggtOfferingPric</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative100TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxOfferingPricPerScty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum offering price per share/unit being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxOfferingPricPerScty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal4lItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTitl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The title of the class of securities being registered (for each class being registered).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTitl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Type of securities: "Asset-backed Securities", "ADRs/ADSs", "Debt", "Debt Convertible into Equity", "Equity", "Face Amount Certificates", "Limited Partnership Interests", "Mortgage Backed Securities", "Non-Convertible Debt", "Unallocated (Universal) Shelf", "Exchange Traded Vehicle Securities", "Other"</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_PrevslyPdFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_PrevslyPdFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_Rule457rFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 457<br> -Subsection r<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_Rule457rFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fees Summary<br></strong></div></th>
<th class="th">
<div>Nov. 12, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesSummaryLineItems', window );"><strong>Fees Summary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOfferingAmt', window );">Total Offering</a></td>
<td class="nump">$ 230,000,000.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlPrevslyPdAmt', window );">Previously Paid Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlFeeAmt', window );">Total Fee Amount</a></td>
<td class="nump">31,763.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOffsetAmt', window );">Total Offset Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_NetFeeAmt', window );">Net Fee</a></td>
<td class="nump">$ 31,763.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FnlPrspctsFlg', window );">Final Prospectus</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesSummaryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesSummaryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FnlPrspctsFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FnlPrspctsFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_NetFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_NetFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOfferingAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOfferingAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOffsetAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOffsetAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlPrevslyPdAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlPrevslyPdAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>26</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>1</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="d159388dexfilingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995210 - Document - Submission</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/submissionTable</Role>
      <ShortName>Submission</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d159388dexfilingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995211 - Document - Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesOfferingTable</Role>
      <ShortName>Offerings</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d159388dexfilingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995215 - Document - Fees Summary</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesSummaryTable</Role>
      <ShortName>Fees Summary</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="EX-FILING FEES" original="d159388dexfilingfees.htm">d159388dexfilingfees.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="3">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="33">http://xbrl.sec.gov/ffd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>21
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d159388dexfilingfees.htm": {
   "dts": {
    "inline": {
     "local": [
      "d159388dexfilingfees.htm"
     ]
    },
    "schema": {
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/deprecated-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
     ]
    }
   },
   "keyStandard": 26,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 0,
   "hidden": {
    "total": 10,
    "http://xbrl.sec.gov/ffd/2025": 8,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 1,
   "elementCount": 107,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ffd/2025": 33,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/ffd/role/document/submissionTable",
     "longName": "995210 - Document - Submission",
     "shortName": "Submission",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R2": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
     "longName": "995211 - Document - Offerings",
     "shortName": "Offerings",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "offrl_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d159388dexfilingfees.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "offrl_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d159388dexfilingfees.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable",
     "longName": "995215 - Document - Fees Summary",
     "shortName": "Fees Summary",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "3",
     "firstAnchor": {
      "contextRef": "rc",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d159388dexfilingfees.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "rc",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d159388dexfilingfees.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ffd_AggtRedRpPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtRedRpPricPrrFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricPrrFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Prior Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, Prior FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtSalesPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtSalesPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Sales Price, Fiscal Year",
        "terseLabel": "Aggregate Sales Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtRedCdts": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtRedCdts",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Redemption Credits",
        "terseLabel": "Redemption Credits"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtSctiesRcvd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Received",
        "terseLabel": "Amount of Securities Received",
        "documentation": "Amount of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_AmtSctiesRegd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRegd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Registered",
        "terseLabel": "Amount Registered",
        "documentation": "The amount of securities being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CeasedOprsDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CeasedOprsDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ceased Operations Date",
        "terseLabel": "Ceased Operations Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CfwdFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Form Type",
        "terseLabel": "Carry Forward Form Type",
        "documentation": "The Form Type of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrevslyPdFee": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrevslyPdFee",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Previously Paid Fee",
        "terseLabel": "Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward",
        "documentation": "The fee previously paid in connection with the securities being brought forward from the prior shelf registration statement on which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Prior Effective Date",
        "terseLabel": "Carry Forward Initial Effective Date",
        "documentation": "The initial effective date of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward File Number",
        "terseLabel": "Carry Forward File Number",
        "documentation": "The EDGAR File Number of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). If the prior registration statement has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CmbndPrspctsItemAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsItemAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Item [Axis]",
        "terseLabel": "Combined Prospectus",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different references to earlier prospectuses on a single fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Line Items]",
        "terseLabel": "Combined Prospectus:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Table]",
        "terseLabel": "Combined Prospectus Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CombinedProspectusTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CombinedProspectusTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Table [N/A]",
        "terseLabel": "Combined Prospectus Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CshPdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshPdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid by Registrant in Transaction",
        "terseLabel": "Cash Consideration Paid",
        "documentation": "Amount of cash consideration paid by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ffd_CshRcvdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshRcvdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Received by Registrant in Transaction",
        "terseLabel": "Cash Consideration Received",
        "documentation": "Amount of cash consideration received by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "ffd_FeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Amount",
        "terseLabel": "Amount of Registration Fee",
        "documentation": "Total amount of registration fee (amount due after offsets)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeExhibitTp": {
     "xbrltype": "feeExhibitTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeExhibitTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Exhibit Type",
        "terseLabel": "Fee Exhibit Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FeeIntrstAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Interest Amount",
        "terseLabel": "Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note",
        "terseLabel": "Fee Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNoteMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNoteMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note Maximum Aggregate Offering Price",
        "terseLabel": "Fee Note MAOP"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeRate",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Rate",
        "terseLabel": "Fee Rate",
        "documentation": "The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesOthrRuleFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesOthrRuleFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees, Other Rule [Flag]",
        "terseLabel": "Other Rule",
        "documentation": "Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesSummaryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesSummaryLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees Summary [Line Items]",
        "terseLabel": "Fees Summary:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FnlPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FnlPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Final Prospectus [Flag]",
        "terseLabel": "Final Prospectus"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FormTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Form Type",
        "terseLabel": "Form Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_GnlInstrIIhiFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "GnlInstrIIhiFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Instruction II.H,I [Flag]",
        "terseLabel": "General Instruction II.H,I"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrCity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrCity",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, City",
        "terseLabel": "City"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStatOrCtryCd": {
     "xbrltype": "stateOrCountryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStatOrCtryCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, State or Country Code",
        "terseLabel": "State or Country Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt1",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 1",
        "terseLabel": "Street 1"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt2": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt2",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 2",
        "terseLabel": "Street 2"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrZipCd": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrZipCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Zip Code",
        "terseLabel": "Zip Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrNm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Name",
        "terseLabel": "Issuer Name"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_MaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum Aggregate Offering Price",
        "documentation": "The maximum aggregate offering price for the offering that is being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_MaxOfferingPricPerScty": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxOfferingPricPerScty",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Offering Price per Security",
        "terseLabel": "Proposed Maximum Offering Price per Unit",
        "documentation": "The maximum offering price per share/unit being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetFeeAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Fee Amount",
        "terseLabel": "Net Fee"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetSalesAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetSalesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Sales Amount",
        "terseLabel": "Net Sales"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvDsclsr": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvDsclsr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure",
        "terseLabel": "Narrative Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Amount",
        "terseLabel": "Narrative - Max Aggregate Offering Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Price",
        "terseLabel": "Narrative - Max Aggregate Offering Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Axis]",
        "terseLabel": "Offering",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different security offerings on a single fee bearing submission."
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Line Items]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Note",
        "terseLabel": "Offering Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Title",
        "terseLabel": "Security Class Title",
        "documentation": "The title of the class of securities being registered (for each class being registered)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Type",
        "terseLabel": "Security Type",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Table]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Table [N/A]",
        "terseLabel": "Offering Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset [Axis]",
        "terseLabel": "Offset",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different offsets as applied to a fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetClmInitlFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmInitlFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claim Initial Filing Date",
        "terseLabel": "Initial Filing Date",
        "documentation": "The initial filing date of the earlier registration statement with which the earlier (offsetting) fee was paid for a claimed offset. If the offset fee was paid with an amendment, do not provide the amendment date under this element; instead, provide the date of the initial filing (i.e. the \"parent\" filing) ."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Amount",
        "terseLabel": "Fee Offset Claimed",
        "documentation": "The amount of offsetting fees being claimed."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdInd": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdInd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Indicator",
        "terseLabel": "Offset Claimed"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetExpltnForClmdAmt": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetExpltnForClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Explanation for Claimed Amount",
        "terseLabel": "Explanation for Claimed Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetLineItems",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset:",
        "label": "Offset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Note",
        "terseLabel": "Offset Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetPrrFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Fee Amount",
        "terseLabel": "Fee Paid with Fee Offset Source",
        "documentation": "The fee previously paid from which an offset is being derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior File Number",
        "terseLabel": "File Number",
        "documentation": "The EDGAR File Number of the earlier registration statement with which the earlier (offsetting) fee was paid. If the offset filing for the offset has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFilerNm": {
     "xbrltype": "filerNameItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFilerNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Filer Name",
        "terseLabel": "Registrant or Filer Name",
        "documentation": "The name of the registrant that filed the earlier registration statement with which the earlier (offsetting) fee was paid."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Form Type",
        "terseLabel": "Form or Filing Type",
        "documentation": "The Form Type of the offset filing."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrNbOfUnsoldScties": {
     "xbrltype": "nonNegativeIntegerItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrNbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Number of Securities",
        "terseLabel": "Unsold Securities Associated with Fee Offset Claimed",
        "documentation": "The number of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Title",
        "terseLabel": "Security Title Associated with Fee Offset Claimed",
        "documentation": "The title of the class of securities from which offset fees were derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Type",
        "terseLabel": "Security Type Associated with Fee Offset Claimed",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrUnsoldOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrUnsoldOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Offering Amount",
        "terseLabel": "Unsold Aggregate Offering Amount Associated with Fee Offset Claimed",
        "documentation": "The aggregate offering amount of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetSrcFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetSrcFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Source Filing Date",
        "terseLabel": "Filing Date",
        "documentation": "The filing date of the earlier registration statement with which the earlier (offsetting) fee was paid in an offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset Payment:",
        "label": "Offset [Table]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Table [N/A]",
        "terseLabel": "Offset Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_PrevslyPdFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "PrevslyPdFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Previously Paid [Flag]",
        "terseLabel": "Fee Previously Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RegnFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RegnFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration File Number",
        "terseLabel": "Registration File Number"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RptgFsclYrEndDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RptgFsclYrEndDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reporting Fiscal Year End Date",
        "terseLabel": "Reporting FY End Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 0-11 [Flag]",
        "terseLabel": "Rule 0-11"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011a2OffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011a2OffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 0-11(a)(2) Offset",
        "label": "Rule 0-11(a)(2) Offset [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule415a6Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule415a6Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 415(a)(6) [Flag]",
        "terseLabel": "Rule 415(a)(6)",
        "documentation": "Checkbox indicating whether filer is claiming a 415(a)(6) carryforward."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_Rule429AggtOfferingAmt": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429AggtOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Aggregate Offering Amount",
        "terseLabel": "Maximum Aggregate Offering Price of Securities Previously Registered",
        "documentation": "The maximum aggregate offering amount of unsold securities registered on the prior registration statement that are carried forward under Rule 429. Only applicable if 457(o) was used in the fee calculation for the prior registration statement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429CmbndPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429CmbndPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Combined Prospectus [Flag]",
        "terseLabel": "Rule 429",
        "documentation": "Checkbox indicating whether filer is using a combined prospectus under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier File Number",
        "terseLabel": "File Number",
        "documentation": "The Securities Act File Number of the earlier effective registration statement(s) from which securities may be offered and sold using the combined prospectus pursuant to Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier Form Type",
        "terseLabel": "Form Type",
        "documentation": "The Form Type of the earlier registration statement from which unsold securities are carried forward under Rule 429. This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429InitlFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429InitlFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Initial Effective Date",
        "terseLabel": "Initial Effective Date",
        "documentation": "The filing date of the earlier registration statement from which unsold securities are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429NbOfUnsoldScties": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429NbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Number Of Unsold Securities",
        "terseLabel": "Amount of Securities Previously Registered",
        "documentation": "The number of securities registered on the prior registration statement that are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429PrspctsNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429PrspctsNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Prospectus Note",
        "terseLabel": "Combined Prospectus Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Title",
        "terseLabel": "Security Class Title"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Type",
        "terseLabel": "Security Type"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule457aFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457aFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(a) [Flag]",
        "terseLabel": "Rule 457(a)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(a) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ffd_Rule457bOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457bOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(b) Offset [Flag]",
        "terseLabel": "Rule 457(b) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(b) or 0-11(a)(2)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ffd_Rule457fFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457fFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(f) [Flag]",
        "terseLabel": "Rule 457(f)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_Rule457oFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457oFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(o) [Flag]",
        "terseLabel": "Rule 457(o)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ffd_Rule457pOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457pOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(p) Offset [Flag]",
        "terseLabel": "Rule 457(p) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(p)."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ffd_Rule457rFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457rFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(r) [Flag]",
        "terseLabel": "Rule 457(r)"
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ffd_Rule457sFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457sFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(s) Flag",
        "terseLabel": "Rule 457(s)"
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ffd_Rule457uFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457uFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(u) [Flag]",
        "terseLabel": "Rule 457(u)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(u) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ffd_Scties424iAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Axis]",
        "terseLabel": "Securities, 424I"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Line Items]",
        "terseLabel": "Securities, 424I:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Table]",
        "terseLabel": "Securities, 424I Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Securities424iTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Securities424iNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities 424I [N/A]",
        "terseLabel": "Securities 424I N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissionLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission [Line Items]",
        "terseLabel": "Items"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissnTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissnTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission Type",
        "terseLabel": "Submission Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TermntnCmpltnWdrwl": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TermntnCmpltnWdrwl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination / Completion / Withdrawal Statement",
        "terseLabel": "Termination / Withdrawal Statement"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TtlFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee Amount",
        "terseLabel": "Total Fee Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlFeeAndIntrstAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAndIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee and Interest Amount",
        "terseLabel": "Total Fee and Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offering Amount",
        "terseLabel": "Total Offering"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOffsetAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOffsetAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offset Amount",
        "terseLabel": "Total Offset Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlPrevslyPdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlPrevslyPdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Previously Paid Amount",
        "terseLabel": "Previously Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlTxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlTxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Transaction Valuation",
        "terseLabel": "Total Transaction Valuation"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Valuation",
        "terseLabel": "Transaction Valuation"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_ValSctiesRcvd": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received",
        "terseLabel": "Value of Securities Received",
        "documentation": "Value of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_ValSctiesRcvdPerShr": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvdPerShr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received, Per Share",
        "terseLabel": "Value of Securities Received, Per Share",
        "documentation": "Value per share of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form). This is included in the explanation of 457(f) fee calculation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "415",
   "Subsection": "a"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "429"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "f"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "o"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "p"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "r"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "s"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "u"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Subsection": "f",
   "Section": "457"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>22
<FILENAME>0001193125-25-277503-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-277503-xbrl.zip
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MI.!J5U*K9_/\?GHQX1?-LUN EG%X#-B2#%I7IY.].OY>S/[_ 5!+ 0(4 Q0
M   ( %* ;%N>"MXL/0P  &E3   8              "  0    !D,34Y,S@X
G9&5X9FEL:6YG9F5E<RYH=&U02P4&      $  0!&    <PP

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>d159388dexfilingfees_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
      xlink:type="simple"/>
    <context id="rc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001622229</identifier>
        </entity>
        <period>
            <startDate>2025-11-12</startDate>
            <endDate>2025-11-12</endDate>
        </period>
    </context>
    <context id="offrl_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001622229</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-12</startDate>
            <endDate>2025-11-12</endDate>
        </period>
    </context>
    <context id="offrl_2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001622229</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>2</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-12</startDate>
            <endDate>2025-11-12</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <ffd:FormTp contextRef="rc" id="ixv-356">S-3</ffd:FormTp>
    <ffd:SubmissnTp contextRef="rc" id="ixv-357">424B5</ffd:SubmissnTp>
    <ffd:FeeExhibitTp contextRef="rc" id="ixv-358">EX-FILING FEES</ffd:FeeExhibitTp>
    <ffd:RegnFileNb contextRef="rc" id="ixv-359">333-291384</ffd:RegnFileNb>
    <dei:EntityCentralIndexKey contextRef="rc" id="ixv-360">0001622229</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-361">Cogent Biosciences, Inc.</dei:EntityRegistrantName>
    <ffd:OfferingTableNa contextRef="rc" id="hiddenrcOfferingTableNa" xsi:nil="true"/>
    <ffd:OffsetTableNa contextRef="rc" id="hiddenrcOffsetTableNa">N/A</ffd:OffsetTableNa>
    <ffd:CombinedProspectusTableNa contextRef="rc" id="hiddenrcCombinedProspectusTableNa">N/A</ffd:CombinedProspectusTableNa>
    <ffd:FnlPrspctsFlg contextRef="rc" id="ixv-365">false</ffd:FnlPrspctsFlg>
    <ffd:FormTp contextRef="rc" id="ixv-399">S-3</ffd:FormTp>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-400">Cogent Biosciences, Inc.</dei:EntityRegistrantName>
    <ffd:PrevslyPdFlg contextRef="offrl_1" id="ixv-401">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="offrl_1" id="ixv-402">Debt</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_1" id="ixv-403">1.625% Convertible Senior Notes</ffd:OfferingSctyTitl>
    <ffd:Rule457rFlg contextRef="offrl_1" id="ixv-404">true</ffd:Rule457rFlg>
    <ffd:AmtSctiesRegd
      contextRef="offrl_1"
      decimals="0"
      id="ixv-405"
      unitRef="Shares">230000</ffd:AmtSctiesRegd>
    <ffd:MaxOfferingPricPerScty
      contextRef="offrl_1"
      decimals="INF"
      id="ixv-406"
      unitRef="USD">1000.00</ffd:MaxOfferingPricPerScty>
    <ffd:MaxAggtOfferingPric
      contextRef="offrl_1"
      decimals="INF"
      id="ixv-407"
      unitRef="USD">230000000.00</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="offrl_1"
      decimals="INF"
      id="ixv-408"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="offrl_1"
      decimals="INF"
      id="ixv-409"
      unitRef="USD">31763.00</ffd:FeeAmt>
    <ffd:PrevslyPdFlg contextRef="offrl_2" id="ixv-410">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="offrl_2" id="ixv-411">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_2" id="ixv-412">Common stock, par value $0.001 per share</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="offrl_2" id="ixv-413">true</ffd:FeesOthrRuleFlg>
    <ffd:AmtSctiesRegd
      contextRef="offrl_2"
      decimals="0"
      id="ixv-414"
      unitRef="Shares">7419340</ffd:AmtSctiesRegd>
    <ffd:MaxAggtOfferingPric
      contextRef="offrl_2"
      decimals="INF"
      id="ixv-415"
      unitRef="USD">0.00</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="offrl_2"
      decimals="INF"
      id="ixv-416"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="offrl_2"
      decimals="INF"
      id="ixv-417"
      unitRef="USD">0.00</ffd:FeeAmt>
    <ffd:TtlOfferingAmt contextRef="rc" decimals="INF" id="ixv-418" unitRef="USD">230000000.00</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt contextRef="rc" decimals="INF" id="ixv-419" unitRef="USD">31763.00</ffd:TtlFeeAmt>
    <ffd:TtlPrevslyPdAmt contextRef="rc" decimals="INF" id="ixv-420" unitRef="USD">0.00</ffd:TtlPrevslyPdAmt>
    <ffd:TtlOffsetAmt contextRef="rc" decimals="INF" id="ixv-421" unitRef="USD">0.00</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt contextRef="rc" decimals="INF" id="ixv-422" unitRef="USD">31763.00</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="offrl_1" id="ixv-423">The registration fee is calculated in accordance with Rule 457(r) of the Securities Act of 1933, as amended (the "Securities Act") and represents deferred payment of the registration fees in connection with the Registrant's registration statement on Form S-3ASR (Registration No. 333-291384) paid with the filing of this prospectus supplement</ffd:OfferingNote>
    <ffd:OfferingNote contextRef="offrl_2" id="ixv-424">(2) Represents the maximum number of shares that may be issued upon conversion of the 1.625% Convertible Senior Notes. (3) Pursuant to Rule 457(i) under the Securities Act, there is no filing fee payable with respect to the shares common stock that may be issuable upon conversion of the 1.625% Convertible Senior Notes because no additional consideration will be received in connection with any conversion.</ffd:OfferingNote>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
